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ABSTRACT 
 
Schwabe, Anna Louise. A Multifaceted Approach to Address Variation in Cannabis  
sativa. Published Doctor of Philosophy Dissertation, University of Northern 
Colorado, 2019. 
 
For thousands of years, humans have cultivated and dispersed Cannabis sativa L. 
across the globe. Although Cannabis has been largely illegal worldwide for decades, 
public perceptions and attitudes are changing. Increasing interest in potential Cannabis 
usage worldwide and nationwide is leading to less restrictions to make way for an 
expanding and lucrative industry with numerous applications. Although only one species 
is formally recognized in the Cannabis genus, thousands of years of artificial selection 
for diverse phenotypes and uses have resulted in two major usage groups; hemp-types 
which are defined worldwide as having very low levels of THC (< 1.0%), and drug-types 
which exceed a specified level of THC that varies among nations. The drug-type category 
includes three commonly used subcategories including Sativa, Indica and Hybrid types, 
and newly developed high CBD varieties that have more THC than hemp-types but are 
not bred for high THC. The quality of federally produced Cannabis for medical studies in 
the U.S. has recently been brought into question, and we included samples to determine 
the genetic relationship to these groups. 
Phenotypic variation in Cannabis gives rise to commonly referenced categories, 
but sources of variation are unclear and understudied. Phenotypes are observable 
characteristics that results from a combination of both genotype and the environment. 
  iv 
The preferred method of propagation for Cannabis is cloning, and therefore variation 
within varietals should be from differences in environmental factors. Ten microsatellite 
markers were developed de-novo to investigate four aims: (1) genetic variation within 
strains, (2) genetic relationships among the common categories, (3) if genetic variation is 
detectable through olfactory sensation, and (4) how genetic variation is reflected in 
phytochemical levels. This dissertation includes four manuscript chapters representing 
each aim and uses a genetic basis for a multifaceted approach to investigate variation in 
Cannabis sativa. Substantial genetic variation was found within strains from obtained 
from different facilities. Genetic divergence between hemp and drug-types was 
genetically supported, but the Sativa, Indica, and Hybrid subcategories were not 
genetically well defined. The high CBD strains appear to bridge the genetic gap between 
hemp and drug-types, and federally grown research grade marijuana was genetically 
more similar to hemp than Cannabis available through the legal cannabis market. Genetic 
imposters within a strain had measurable aromatic differences, but there was considerable 
variation in aromas among samples with identical genetic identity. Analyses of both 
terpene and cannabinoid profiles among individuals with identical genotypes acquired 
from different sources varied considerably indicating environmental variation has a 
substantial impact on phenotype in Cannabis. 
Together these results show a need for the Cannabis industry to implement 
regulatory checks in the form of genetic testing in order to provide consistency, 
especially for medical applications. These results demonstrate the need for genotyping in 
order for phenotypic consistency to be achieved if standard growing conditions can be 
established. When genetic verification and standard protocols are established, deviations 
  v 
in phenotypic changes can be identified and disclosed to consumers so they are aware 
that there may be abnormal effects. This investigation highlights the need for additional 
research to provide consistent products, which is especially important for medical 
marijuana flower products. In order to provide consumers consistent products, it is 
imperative to understand sources of variation. Consumers deserve to be provided with 
quality consistent products as the industry continues to grow on a global scale. 
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CHAPTER I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
Introduction 
Cannabis sativa L. is one of the most interesting and useful plants with evidence 
of human cultivation dating back as far as 10,000 years (Abel 2013; Clarke and Merlin 
2013; Okazaki et al. 2011; Small 2015a). As humans moved across the globe to various 
continents, they took Cannabis with them for utilitarian purposes such as fiber, food, 
fuel, and also for the plants medicinal and psychoactive properties (Clarke and Merlin 
2013; Small 2015a). Human driven dispersal across the globe may have led to local 
adaptation, contributing to morphological variants. However, cultivation and selective 
breeding over thousands of years has arguably been the driving force behind the wide 
variation of phenotypes observed in modern Cannabis. Generally, two broad categories 
of Cannabis are recognized: hemp-types and drug-types. Hemp-types are grown for fiber, 
seeds, and non-psychoactive phytochemicals produced mainly by the flowers. Drug-types 
produce more of the psychoactive phytochemical precursor Δ9-tetrahydrocannabinolic 
acid (THCA) and are labeled as such when THCA exceeds a predefined threshold of 
percent of dry weight, which varies by country. However, they are labeled as “THC” 
content which is the analyte measured due to decarboxylation during the analysis. While 
the level of THCA produced in the flower is the main distinction between hemp and drug 
types, usage, morphology, and cultivation methods differ between the two types. There is 
a third elusive type, C. ruderalis, which is smaller and flowers as a function of age rather 
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than photoperiod (Clarke and Merlin 2013; Small 2015b) but has been suggested that this 
type may be an escapee from hemp cultivation that has adapted to a weedy lifecycle 
(Clarke and Merlin 2013; Emboden 1974; Schultes et al. 1974). Cultivation and selective 
breeding over several millennia are thought to have altered the evolutionary trajectory of 
Cannabis to such an extent that natural, unaltered ancestral populations no longer exist 
(Small 2017). Cannabis cultivators have successfully bred thousands of varietals, and 
extensive genetic variation has been observed throughout the species (Clarke and Merlin 
2016; Lynch et al. 2016; Pisupati et al. 2018; Soler et al. 2017). Recent legalization for 
medical and recreational consumption has increased access to Cannabis and information 
about Cannabis, leading to changes in the demographics of consumers (Han and Palamar 
2018). The goal of this work is to bring additional awareness and information about the 
products consumers have access to and give more context to the information they are 
provided. 
The Cannabis samples used in this study were collected from dispensaries, 
herbaria, and cultivators. Retail samples were legally purchased from dispensaries located 
in Colorado, Washington, and California. It was important to purchase samples 
anonymously since I wanted flowers that were representative of product supplied to 
customers without bias. Disclosing that the samples would be used in a research study 
could introduce the potential for producers to differentially select samples. The primary 
purpose of this investigation was to examine variation in Cannabis and to determine how 
genetic variation manifests as differences in phenotypic characters. The chapters herein 
address (1) genetic variation within strains, (2) genetic variation among categories, (3) if 
genetic variation is detectable through olfactory sensation, and (4) how genetic variation 
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is reflected in phytochemical levels. Variation in Cannabis can come from multiple 
sources, some of which are explored here to expose and highlight the need for additional 
research to provide consistent products, which is especially important for medical 
marijuana. 
Overview of Cannabis sativa  
Cannabis sativa L. is a member of the Cannabaceae with about 170 species in ten 
small genera including Cannabis, Humulus, and Celtis (McPartland 2018), although 
sources have conflicting information about the current taxonomy (Clarke and Merlin 
2013; Integrated Taxonomic Information System 2014; The Plant List 2013). Although 
the Flora of North America recognizes only Cannabis sativa L. (Small 1997), many 
breeders and botanists support the polytypic taxonomy of Cannabis (Anderson 1980; 
Clarke and Merlin 2013; de Lamarck 1785; Emboden 1974). Whether the genus is 
comprised of one (C. sativa), two (C. sativa and C. indica) or three species (C. sativa, C. 
indica and C. ruderalis) remains a topic of debate. Monotypic Cannabis sativa includes 
narrow and broad leaf drug types, non-drug hemp types, and C. ruderalis, which is 
smaller and flowers as a function of age rather that photoperiod. Drug types are defined 
as any Cannabis sativa plant with total THC (THCA + THC) concentrations above a 
stated limit. Plants of broad and narrow leaf drug types, as well as hybrid variants, are 
commonly referred to as marijuana. Low total THCA defines hemp types with the legal 
limit varying among countries: for example 0.3% by dry weight in the U.S., 0.2% in the 
U.K., and 1.0% in Western Australia (European Monitoring Centre for Drugs and Drug 
Addiction 2018; Parliament of Western Australia 2004; United States Department of 
Agriculture and 113th United States Congress 2018). However, drug types generally have 
  
4 
 
much higher levels of THC compared to hemp, often reported as 12-25% THC in retail 
strains (Jikomes and Zoorob 2018; Potter et al. 2008; Vergara et al. 2017). There are also 
some varieties with relatively low THC that are nonetheless ranked as a drug type due to 
the THC limits defining hemp. Hemp and marijuana are genetically distinct (e.g. Lynch 
et al. 2016; Sawler et al. 2015; Schwabe and McGlaughlin 2018; Soler et al. 2017) and 
are distinguished further by levels of chemical constituents, particularly THC, as well as 
the products that will be made from the plant (Datwyler and Weiblen 2006; de Meijer et 
al. 1992; Lynch et al. 2016; Rustichelli et al. 1998). 
 Terminology to describe Cannabis is convoluted and conflicted among scientists, 
horticulturalists, taxonomists, enthusiasts and consumers. For the purposes of the work 
here, Cannabis and cannabis refer to any variety of Cannabis sativa.  Drug-type and 
marijuana refer to varieties with > 0.3% THC. Hemp-type and hemp refer to varieties 
with low THC (< 0.3% in the U.S.). Sativa is used in the colloquial context to describe 
narrow-leafed strains with uplifting or energizing psychoactivity. Indica is used in the 
colloquial context to describe broad-leafed strains with relaxing and sedating 
psychoactive effects. Hybrid is used to describe varieties with a combination of 
morphologies and/or reported effects from both Sativa and Indica types. Variety is a 
group with distinct and uniform characters (physical, chemical, genetic) that are exhibited 
in all members of the group (Cervantes 2006). The term cultivar refers to a cultivated 
variety that is developed by a plant breeder through cross breeding, which can also be 
called a hybrid (Griess 2016). Plants grown from the seeds of a cultivar often will not 
display characteristics of a single parent since they were produced by crossing two 
distinct varieties (Griess 2016). True-to-type plants have the same genetics as the parent 
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(Griess 2016), and in Cannabis this is most commonly achieved through cloning. 
Although the term “strain” is botanically incorrect when applied to varieties of plants, the 
term is widely used in the cannabis industry to describe selections of cultivars of 
varieties, in part because many strains of Cannabis are not true varieties in that they are 
not genetically stable and do not breed true (Cervantes 2006). According to Cervantes 
(2006), strains in many cases do not have described defining characters and are merely 
hybrids of hybrids that have been given a unique name. Given the recency and 
exponential growth of the number of available strains, it is likely that many strains lack 
genetic stability and are unlikely to be produced consistently.  
Cannabis Breeding System 
Cannabis is predominantly dioecious with separate sex chromosomes, which is 
rare for plants. Male and female flowers develop on separate plants, although 
occasionally hermaphrodites are observed (Moliterni et al. 2004). Male and female plants 
are virtually indistinguishable prior to flowering, although genetic tests for 
Deoxyribonucleic acid (DNA) polymorphisms and sex chromosomes may assist in early 
developmental sexing of Cannabis plants (Mandolino et al. 1999). Hemp types are 
commonly grown for their fibrous stem and seeds that are highly nutritious and rich in 
omega-3 and omega-6 fatty acids (Callaway 2004; Small 2016). Therefore, male and 
female hemp plants are grown together because when female flowers are fertilized, they 
produce large quantities of seed. Drug types are commonly grown for the female 
inflorescence, as it is mainly the female flowers that produce the glandular trichomes 
where the manufacturing of cannabinoids and aromatic terpenes occurs. Specific 
cannabinoid molecules bind to receptors in animals (McPartland et al. 2001) and elicit 
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various effects. Terpenes are produced in many different plants and are the primary 
constituents of essential oils, which are also thought to have therapeutic properties 
(Paduch et al. 2007). The dioecious breeding system is problematic for drug type 
Cannabis breeders because they seek to forego seed production and maximize 
inflorescence growth. Producers of drug type Cannabis remove pollen producing male 
plants from the population to prevent fertilization and seed production (Meier and 
Mediavilla 1998). The preference for production of unfertilized female flowers has led to 
the widely practiced artificial vegetative propagation via cloning of popular Cannabis 
drug type strains.  
In order to produce novel Cannabis varieties, plants are cross- pollinated to 
produce seeds that have characteristics of both the parents (Cervantes 2006). Plants 
grown from seeds of the parental cross are called the first filial (F1) generation and are 
genetic hybrids of the parents (Cervantes 2006). Offspring resulting from the F1 
generation seeds are assessed, and individual plants are selected based on desirable 
phenotypic traits (Cervantes 2006). In order to remove unwanted genetic traits from the 
lineage, it is necessary to continue crossing offspring of each subsequent generation until 
the offspring reliably and consistently exhibit the desired phenotype, and at this point the 
new variety is said to have stable genetics. Other crop and ornamental plants are often 
subjected to inbreeding for several generations to remove genetic variation, but as this is 
time consuming and because breeders are often limited by space, this important technique 
to developing a genetically stable variety may be cursory.  
The legal medical and recreational Cannabis industries aim to produce consistent 
products for consumption and maximum yield, which is generally achieved through 
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vegetative cloning techniques. Female plants are selected based on desirable characters 
and can be used as mother plants for the cloning process. Cloning methods are used to 
reproduce desirable strains that are genetically identical. Some Cannabis strains 
reportedly have stable seed genetics (discussed in Chapter II) and should have little 
variability observed in the phenotype of the offspring. In either case, the genotypes of 
clonal plants or plants from stable seed should be highly similar. Cloning in Cannabis is 
widely practiced in order to produce consistent products from the F1 generations and can 
produce hundreds of genetically identical plants. Therefore, breeders may not be invested 
in creating stable varieties because not only is cloning relatively easy, but also they are 
not provided protection for their novel varieties. This creates a situation where strains 
may be marketed with a specific name, but the genetics of plants with the same strain 
name but from a different source could be quite different. 
Intellectual Property Protection for Plant Varieties 
 In the U.S., intellectual property and commercial exploitation protection for new 
plant cultivars is afforded under the Plant Variety Protection Act (PVPA) of 1970 (United 
States Department of Agriculture 1970). Plant growers and breeders can register 
proprietary varietals with the United States Department of Agriculture (United States 
Department of Agriculture 1970, 2015). In order to obtain a certificate for a novel variety 
from the Plant Variety Protection Office, the cultivar must be “new, distinct, uniform, 
and stable” (United States Department of Agriculture 1970, 2015). The new varietal must 
have a name that does not conflict with existing names of that crop. The distinctness of a 
novel variety may be based on one or more identifiable morphological, physiological, 
genetic, or other characteristics (e.g. baking characteristic for wheat) (United States 
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Department of Agriculture 1970, 2015). However, the ability to describe, distinguish and 
certify new cultivars in crop species does not apply to Cannabis sativa. The USDA lists 
‘Hemp’ as an ineligible commodity (United States Department of Agriculture 1970; 
United States Department of Agriculture 2015) for protection under the PVPA, therefore, 
all Cannabis varietals are excluded from protection.  
There are thousands of described Cannabis varieties, and probably thousands 
more that remain as “backyard” creations. For example, the online database Leafly 
describes more than 2500 strains, but it is far from a comprehensive list (Leafly 2018b). 
Moreover, many of these strains have not been stabilized and will only exist as long as 
there are healthy mothers to produce clones. Because the USDA Plant Variety Protection 
Office lists ‘Hemp’ (Cannabis sativa) as an ineligible commodity (United States 
Department of Agriculture 2015), there is no official or standardized database describing 
the different strains and the characteristics defining each strain. As a result, the cannabis 
industry has no way to verify varieties. Additionally, suppliers are not required to provide 
confirmation that the strain marked for sale as “Blue Dream”, for example, is in fact 
“Blue Dream”. The lack of a verification system for Cannabis strains is more than likely 
contributing to the high potential for misidentification and mislabeling. Consumers report 
that acquiring strains, such as “Blue Dream”, does not always result in the same effects 
each time (Prichard 2014), which reinforces the likelihood that Cannabis strain names are 
not a reliable identifier for plants and flower material at the present time. 
Cannabis Consistency 
Public, scientific, and economic interest in Cannabis and Cannabis products is 
increasing worldwide. Consumers want to have confidence that the products they buy are 
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consistent. Consistency is an issue that researchers and industry are beginning to address. 
Teasing apart some of the elements that could contribute to variation is vital to the 
Cannabis industry, for both recreational and medical consumers. Determining variation 
within and among Cannabis types and how those genetic differences might be reflected 
in physical characteristics such as phytochemical constituents and aromatic profile, 
requires examining genetic differences. The phenotype of any organism is a product of 
genotype and environment. However, environmental variation such as growing 
conditions, harvesting time, soil, nutrient regimes and water levels are examples of 
confounding variables that could contribute to phenotypic differences observed in clonal 
organisms such as commercial Cannabis. Where variation is unexpected, examining the 
genotype to rule out genetic variation, rather than some other variable, is required. 
Unknown genetic differences leading to variation cannot be remedied by standardizing 
growing, harvesting, and storage procedures. However, if a grower has a certified and 
verified variety, any variation among plants can be narrowed down to differences in 
treatment following germination, and presumably be addressed. Occasional recreational 
users may not be concerned with variation in products; however, the growing number of 
medical marijuana patients who seek specific effects from their Cannabis need to be 
provided consistent products. Expecting one set of effects and experiencing another set of 
effects is unacceptable when it comes to medicine.  
Cannabinoids and Terpenes 
 Cannabis sativa is a chemically complex plant with numerous natural 
constituents. To date, 565 constituents have been identified (ElSohly et al. 2016) that are 
classified as cannabinoids or non-cannabinoids (alkaloids, flavonoids, terpenoids, amino 
  
10 
 
acids and others). Varying levels and combinations of the chemical constituents results in 
unique chemical profiles, referred to as a chemotype. Constituents include 120 
phytocannabinoids, which are a group of C21 terpenophenolic molecules with a ring 
structure derived from geranyl pyrophosphate (ElSohly et al. 2017). The main 
psychoactive cannabinoid, and the main reason for Cannabis prohibition, is 9-
tetrahydrocannabinol (THC). Besides being a psychoactive substance, THC has other 
known effects, such as analgesic properties (Rahn and Hohmann 2009). Cannabidiol 
(CBD), the second most abundant cannabinoid, has recently received attention as an 
antiepileptic and is particularly promising for intractable pediatric epilepsy (United States 
Food and Drug Administration 2018). However, the bioactive cannabinoids THC and 
CBD are not produced by the plant. Rather, the acidic forms 9 -tetrahydrocannabinolic 
acid (THCA) and cannabidiolic acid (CBDA) are produced in the plant and are converted 
to their active forms through other mechanisms, such as the addition of heat. Other 
cannabinoids gaining popularity for various reported effects include: 
tetrahydrocannabivarin (THCV), which decreases appetite and increases metabolism 
(Halford and Harrold 2008); cannabichromene (CBC) which has anti-inflammatory, anti-
bacterial, and anti-fungal properties (ElSohly et al. 1982); cannabigerol (CBG), which 
has anti-bacterial properties and reduces blood pressure (Banerjee et al. 1975); and 
cannabinol (CBN), which is an analgesic (Zygmunt et al. 2002), appetite stimulant 
(Farrimond et al. 2012), and an effective but mild sedative (Musty et al. 1976). Aromatic 
terpenes produced in the glandular trichomes of the female flower are a second important 
group of chemical constituents abundantly produced in Cannabis. Terpenes are 
manufactured in varying combinations and levels and produce distinctive characteristic 
  
11 
 
odors. Cannabis strain aroma descriptions include skunk, diesel, fruit, and cheese (see 
Chapter IV). Aromatic profiles give rise to descriptive strain names such as “Island Sweet 
Skunk”, “Sour Diesel”, “Banana Kush”, and “Blue Cheese”. 
 Cannabis types, such as hemp and drug types, are often defined by the level of 
THCA (but reported as THC) produced in the plant, validated methods to measure 
relative amounts of cannabinoids, as well as terpenes, have been developed. Gas 
chromatography (GC) is widely used for detecting the major cannabinoids because it is 
simple, fast and sensitive. However, GC cannot distinguish acidic cannabinoids from 
their decarboxylated forms unless a derivatization is performed. Gas chromatography 
uses high temperature and will decarboxylate the natural acidic forms of several 
cannabinoids such as Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid 
(CBDA) (de Oliveira et al. 2008; ElSohly et al. 2016; Hazekamp et al. 2005; Hillig 2005; 
Pellegrini et al. 2005). Several validated GC cannabinoid and terpene separation methods 
are available (ElSohly et al. 2017; Mariotti et al. 2016; Raharjo and Verpoorte 2004). 
High-performance liquid chromatography (HPLC) is another method to detect Cannabis 
chemical components that does not heat the sample and therefore the natural acidic and 
neutral cannabinoids are unaffected. The limitation of HPLC is that it may not resolve the 
full array of cannabinoids due to the complex composition of the plant extracts. Several 
validated HPLC methods for separation of cannabinoids and terpenes are available 
(Aizpurua-Olaizola et al. 2014; Brighenti et al. 2017; De Backer et al. 2009; Giese et al. 
2015; Gul et al. 2015; Rustichelli et al. 1996; Swift et al. 2013; Xiaoyan et al. 2016). 
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History of Prohibition 
Cannabis has been used for centuries and is notorious for the psychoactive 
properties produced when THCA is activated through heating, for example when it is 
smoked. The Single Convention on Narcotic Drugs of 1961 is an international treaty 
listing specific drugs prohibited worldwide with the exception of medical and research 
purposes (The United Nations 1961). In this treaty, Cannabis drug types, such as hashish 
and marijuana, are listed as both Schedule I and IV drugs (The United Nations 1961). 
Schedule I substances have the strictest controls and Schedule IV substances are 
described as having “particularly dangerous properties” (The United Nations 1961). The 
most dangerous drugs (includes opium, opioids, coca, cocaine, heroin, and fentanyl), are 
listed as Schedule IV and are described as having extremely limited and therapeutic value 
and are thereby subject to the strictest controls under Schedule I (The United Nations 
1961). The treaty explicitly states that Cannabis used for hemp and fiber is not 
considered controlled substances, but rather only the fruiting crowns of the plant and 
derived products are included. The Single Convention requires countries in the treaty to 
establish a government agency to control cultivation of scheduled drugs from plants such 
as Cannabis and opium. In the U.S. the National Institute on Drug Abuse (NIDA) is that 
agency. However, since the treaty was written, the discovery of the endocannabinoid 
system suggests there are therapeutic applications, and mounting evidence suggests a 
wide variety of medical applications for Cannabis. 
The Single Convention united countries worldwide in the prohibition of a 
multitude of substances, but Cannabis bans had been introduced long before 1961. One 
of the first bans was by the Emir of the Joneima in Arabia in 1378 who declared 
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Cannabis ingestion was punishable by removing all the offender’s teeth (Johnson et al. 
2010). King Andrianampoinimerina of Madagascar imposed capital punishment for 
Cannabis use in 1787 (Yates 2015). Napoleon banned Cannabis use and distribution in 
1800 (Booth 2004). Singapore banned Cannabis in 1870 (De Padua et al. 1999). Greece 
banned cultivating, importing, and use in 1890 (Abel 2013). The Ganja Law supported by 
the Council of Evangelical Churches outlawed Cannabis in Jamaica in 1913 (Moyston 
2013). Australia banned Cannabis in 1926 (Wodak and Owens 1996).  
The United States participated in The Single Convention, but already had existing 
legislation in the form of the Marihuana Tax Act of 1937 (75th Congress of the United 
States 1937). The Act did not ban Cannabis outright, but rather placed a hefty sales tax 
on Cannabis and Cannabis products, including hemp, thereby effectively making it 
difficult to engage in Cannabis based business. Cannabis was formally criminalized in 
the United States under the Controlled Substances Act, passed by the 91st United States 
Congress, and signed into Law by President Richard Nixon (United States Congress 
1970).  
Current Status 
 The United States has seen significant changes over the past two decades 
regarding the legal status of Cannabis use for both medical and recreational purposes. 
State-level legislation has side-stepping the federal Cannabis ban, making allowances for 
medical Cannabis use. While Cannabis remains federally illegal, national enforcement of 
Cannabis restrictions has shifted to the responsibility of states. This disconnect between 
federal and state laws creates logistical issues for federally regulated organizations, such 
as research and financial institutions, as well as creating confusion for federal law 
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enforcement agencies such as the United States Marshals Service (USMS), the Federal 
Bureau of Investigation (FBI), and the Drug Enforcement Administration (DEA). 
Moreover, it is impossible to visually distinguish different Cannabis types. Now that 
hemp is legal in all 50 states (United States Department of Agriculture and 113th United 
States Congress 2018), law enforcement has no way to tell if someone is hauling 17,000 
lbs. of hemp flower for CBD, or if they are smuggling 17,000 lbs. of illicit drugs across 
state lines (Konopasek 2019). Some states allow Cannabis treatment in the cases of 
serious or debilitating conditions (ProCon 2016b). Other states are more lenient with 
medical conditions that may appropriately be treated with Cannabis and allow medical 
doctors and authorized healthcare professionals to recommended patients use medical 
marijuana as treatment (National Conference of State Legislatures 2018). The initiation 
of statewide changes began with California passing Proposition 215 in 1996, which 
legalized medical marijuana (National Conference of State Legislatures 2018). From 
1996 to 2012, sixteen states and the District of Columbia passed legislation allowing 
medical marijuana use (Table 1.1). In 2012, Colorado was the first state to legalize 
recreational marijuana use, followed by Washington later that year. Since then, ten more 
states have legalized medical marijuana, and eight states plus the District of Columbia 
legalized recreational use (National Conference of State Legislatures 2018). All in all, the 
current standing in the U.S. is 33 states allow medical marijuana, and of those ten and the 
District of Columbia, also allow recreational use (Table 1.1) (ProCon 2018b). 
While the United States continues to relax legislation, other countries are 
following suit (Table 1.1). Over the last two decades, a wave of decriminalization, re-
classification, and legalization of Cannabis has surged worldwide. Paraguay was one of 
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the first countries to decriminalize possession of small amounts (10 grams) of Cannabis 
in 1988 (Mostyn et al. 2012). Uruguay was the first country in this modern era to fully 
legalize Cannabis, although the legal purchase of Cannabis is limited to registered 
Uruguayan citizens (Gerner 2015). Canada legalized medical use in 2001, and recently 
became the second country to legalize recreational use and establish a nationwide 
marijuana market. There are at least fifteen countries worldwide that have legalized 
medical marijuana use, the majority of which have made changes in the last five years. 
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Table 1.1. Worldwide and U.S. Legalization History. Legalization year of medical and 
recreational Cannabis both worldwide and in the United States (by state). 
Year 
Medical Recreational 
Country  U.S. State Country   U.S. State 
1990 Israel       
1996   California     
1998   Alaska     
    Oregon     
    Washington     
1999   Maine     
2000   Colorado     
    Hawaii     
2001 Canada       
2004 Chile       
2007   Montana     
    New Mexico     
    Rhode Island     
    Vermont     
2008   Michigan     
2009   New Jersey     
2010   Arizona     
    District of Columbia     
2011   Delaware     
2012   Massachusetts   Colorado 
     Connecticut   Washington 
2013 Czech Republic Illinois Uruguay   
  Uruguay New Hampshire     
2014   Minnesota   Alaska 
    New York   District of Columbia 
    Utah   Oregon 
  Maryland   
2015 Columbia Georgia     
  
Croatia  
Italy 
Puerto Rico 
Louisiana 
    
2016 Argentina Florida   California 
  Australia North Dakota   Maine 
  Macedonia Ohio   Massachusetts 
  Turkey Pennsylvania   Nevada 
    Nevada     
  Arkansas   
2017 Germany West Virginia     
  Mexico       
  Philippines       
  
Poland 
Malta 
Peru 
Greece        
2018 Georgia 
New Zealand  
Luxembourg 
Portugal 
Oklahoma 
Missouri 
Canada 
Georgia 
South Africa 
Vermont 
Michigan 
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Medical Applications 
Research on potential medical applications for the treatment of a wide array of 
medical conditions is abundant and ongoing. However, the short and long-term health 
effects of Cannabis consumption remain largely unknown. The National Academies of 
Sciences, Engineering, and Medicine published a comprehensive review of medical 
Cannabis and conclude that the effects of Cannabis are understudied, and limitations 
need to be addressed and prioritized (Cousijn et al. 2018; National Academies of 
Sciences 2017). 
 The recent surge of legalization of medical marijuana in the U.S. and worldwide 
suggests there is enough evidence to support the claims that Cannabis is effective in 
treating certain medical conditions. The U.S. had an estimated 2.2 million registered 
medical marijuana patients in legal medical states in 2016 (Leafly 2018a), and there are a 
wide range of conditions for which Cannabis treatment is being investigated, including 
chronic pain, multiple sclerosis, cancer, and epilepsy. Chronic pain is persistent pain that 
results from injury, disease, or can be a disease in itself (The American Academy of Pain 
Medicine 2019). The American Academy of Pain Medicine estimates there are more than 
100 million Americans suffering from chronic pain with associated costs > $600 billion 
annually (The American Academy of Pain Medicine 2019). Reviews of research on 
Cannabis treatment of chronic pain have found mixed results and suggest further large-
scale clinical trials are necessary (Baron 2018; Hill 2015; Jensen et al. 2015). Recently, a 
large-scale clinical study in Israel administered four strains and reported 93.7% of the 
2,736 elderly patients in the study reported significant pain reductions (Abuhasira et al. 
2018). Cannabinoid agonists found in Cannabis, medicinal isolates such as Sativex, 
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and synthetic cannabinoid receptor agonists such as nabilone, reduce pain by acting on 
CB1 and CB2 receptors located in the central and peripheral nervous systems (Costa et 
al. 2007; Guindon and Hohmann 2008; Pertwee 2001, 2005, 2009). Studies conducted in 
the United Kingdom found convincing evidence that Sativex is an effective treatment 
for tremors and spasticity (Alexander 2016) associated with multiple sclerosis, for 
example. Sativex was also shown to be effective in reducing symptoms related to 
chemotherapy and was well tolerated by patients and resulted in minimal adverse side 
effects (Duran et al. 2010). Anti-tumoral actions are associated with several cannabinoids 
including THC, but CBD has been found to be the most effective cannabinoid in reducing 
tumor cell growth (Ligresti et al. 2006). Additionally, CBD induces apoptosis in human 
myleoblastic cells but has no effect on healthy mononuclear cells (Gallily et al. 2003; 
McKallip et al. 2006; Vaccani et al. 2005). The U.S. Food and Drug Administration 
(FDA) has not approved Cannabis to treat medical conditions but has approved three 
cannabinoids for medical use (United States Food and Drug Administration 2018; United 
States Department of Health and Human Services et al. 2018). These are Epidiolex® 
(CBD) for the treatment of two rare forms of epilepsy, dronabinol (synthetic THC) for 
nausea and weight loss associated with cancer and AIDS, and nabilone (synthetic THC) 
for nausea associated with cancer treatments (United States Food and Drug 
Administration 2018; United States Department of Health and Human Services et al. 
2018).  
Genetic Research 
 Genetic research on Cannabis is complicated because it is primarily dioecious, 
highly heterozygous, considerably variable, and extraordinarily plastic in response to 
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varying environmental conditions (Onofri and Mandolino 2017). Genetic studies on 
Cannabis have focused on evolutionary history (Booth 2004; Clarke and Merlin 2016; 
Hillig 2005; Russo 2007; Small et al. 1976; Sytsma et al. 2002; Yang et al. 2013), 
speciation (Emboden 1981; Hillig 2005; McPartland and Guy 2017; Sawler et al. 2015), 
geographic origins (Alghanim and Almirall 2003; Coyle et al. 2003; Gao et al. 2014; 
Gilmore et al. 2003), distribution (Hillig 2005; Piluzza et al. 2013; Piomelli and Russo 
2016), identification of sex chromosomes (Faux et al. 2014; Faux et al. 2016; Mandolino 
et al. 1999; Moliterni et al. 2004; Peil et al. 2003; Razumova et al. 2016; Techen et al. 
2010), genetic contribution to the variation of chemotypes among varietals (Aizpurua-
Olaizola et al. 2016; de Meijer et al. 2009a; de Meijer et al. 2009b; Desjardins 2008; 
Pacifico et al. 2006; Staginnus et al. 2014; Welling et al. 2016), and analyses to aid law 
enforcement and forensic investigations (Dufresnes et al. 2017; Houston et al. 2016; 
Kojoma et al. 2006; Onofri and Mandolino 2017).   
 Studies with accessions of both hemp and drug types have clearly and consistently 
shown genetic distinction between the two types using clustering analyses such as PCA, 
UPGMA, and STRUCTURE (Datwyler and Weiblen 2006; Gilmore and Peakall 2003; 
Gilmore et al. 2003; Grassa et al. 2018; Hillig 2005; Kojoma et al. 2006; Lynch et al. 
2016; Pacifico et al. 2006; Sawler et al. 2015). Genetic evidence using traditional genetic 
techniques such as allozymes, Random Amplification of Polymorphic DNA (RAPD) and 
Short Tandem Repeat (STR) markers give little support to the differentiation of Sativa 
narrow-leaf drug type and the Indica broad-leaf drug type (Hillig 2005; Knight et al. 
2010; Lynch et al. 2016; Sawler et al. 2015). However, new genetic tools using next-
generation sequencing (NGS) techniques such as single nucleotide polymorphisms 
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(SNPs), whole genome shotgun sequencing (WGS), and Restriction site Associated DNA 
Sequencing (RAD-Seq) create datasets for large portions of the genome compared to 
previous techniques. These tools may be able to better distinguish the genetic difference 
driving the reported Sativa and Indica phenotypic differences. Recent studies using NGS 
have had more success distinguishing the two types (Henry 2015; Lynch et al. 2016; 
Sawler et al. 2015). With the information gathered thus far, it appears that the Sativa and 
Indica types shared a common ancestor that likely diverged via natural selection when 
populations established in regions of India (warm, low, wet) and Afghanistan (cool, high, 
dry) leading to phenotypic and genotypic differences (McPartland 2017). However, the 
human relationship with Cannabis, including cultivation, breeding and selection, has 
blurred the line differentiating what were presumably two distinct species (McPartland 
2017; McPartland and Guy 2017).  
 Entire genomic sequences allow researchers to not only explore relationships 
among different Cannabis types, but also uncover information about genes controlling 
characters of interest, such as cannabinoid and terpene synthesis, as well as flowering 
time, and flower production. The nuclear (van Bakel et al. 2011; Vergara et al. 2016), 
chloroplast (Oh et al. 2015; Vergara et al. 2015), and mitochondrial (White et al. 2016) 
genomes, as well as transcriptomes for “Purple Kush” (drug type) and “Finola” (hemp 
type) (van Bakel et al. 2011) have been published. Despite the full sequencing of the 
nuclear genome, it is complex and highly repetitive, and has yet to be assembled in 
entirety. However, there are several researchers focused on the complete assembly and 
annotation of the entire genome.   Of great interest are the genes responsible for 
synthesizing cannabinoids (Grassa et al. 2018; Laverty et al. 2019). Recently the genes 
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responsible for THCA and CBDA production were found to be located on chromosome 
9, and analyses suggest these genes have been targets for selection by breeding for drug 
type strains (Grassa et al. 2018). However, the genes responsible for controlling the 
relative abundance of cannabinoids have not yet been discovered (Grassa et al. 2018).  
Summary 
Historical criminalization of Cannabis has severely hindered scientific research 
on this prominent plant. Research on Cannabis’ phytochemicals including hundreds of 
cannabinoids and terpenes is growing, but the details of the genetic contribution to the 
abundance and combination of these compounds is in its research infancy. Relatively few 
genetic studies have been conducted and the origins and genetic identities of most 
Cannabis varieties are largely unknown. Additionally, there are few Cannabis studies 
researching genetic and chemical aspects together. While a lack of research on such an 
economically important plant is problematic for the Cannabis industry, it can be argued 
that a larger problem is the lack of a regulation and verification system to accurately 
identify or verify the thousands of strains that have been described. Chemical constituents 
of strains are the dominant focus of the Cannabis industry (Hillig and Mahlberg 2004; 
Pacifico et al. 2006; Fischedick et al. 2010; Hazekamp and Fischedick 2012; Elzinga et 
al. 2015; Aizpurua-Olaizola et al. 2016). However, the cannabinoid and terpenes present 
in the plant, as well as the levels of gene expression can vary widely. Cannabis 
chemotypes are variable (plastic) and are therefore unreliable to identify strains. Research 
on plastic traits such as chemical constituents needs to be juxtaposed with genetic data in 
order to more accurately describe and verify Cannabis strains.  
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The research herein addresses genetic variation in Cannabis and how genetic 
variation relates to phenotype. This dissertation includes: (1) a genetic investigation to 
determine if strains with the same name purchased from Cannabis dispensaries are 
genetically similar (Chapter II), (2) an examination of the genetic relationship among 
various types of Cannabis (Chapter III), (3) an investigation of human perception of 
aromas in four Cannabis strains and if genetic anomalies are detectable through olfaction 
(Chapter IV), and (4) an examination of cannabinoids and terpenes to determine if 
chemical profiles of four Cannabis strains are similar within strains and if genetic 
anomalies are reflected in different cannabinoid levels (Chapter V). Taken together, these 
studies aim to provide valuable information about sources of variation in the recently 
revived and globally expanding Cannabis industry. 
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Abstract 
Unlike other plants, Cannabis sativa is excluded from regulation by the United 
States Department of Agriculture (USDA). Distinctive Cannabis varieties are ostracized 
from registration and therefore nearly impossible to verify. As Cannabis has become 
legal for medical and recreational consumption in many states, consumers have been 
exposed to a wave of novel Cannabis products with many distinctive names. Despite 
more than 2000 named strains being available to consumers, questions about the 
consistency of commercially available strains have not been investigated through 
scientific methodologies. As Cannabis legalization and consumption increases, the need 
to provide consumers with consistent products becomes more pressing. In this research, 
we examined commercially available, drug-type Cannabis strains using genetic methods 
to determine if the commonly referenced distinctions are supported and if samples with 
the same strain name are consistent when obtained from different facilities. We 
developed ten de-novo microsatellite markers using the “Purple Kush” genome to 
investigate potential genetic variation within 30 strains obtained from dispensaries in 
three states. Samples were examined to determine if there is any genetic distinction 
separating the commonly referenced Sativa, Indica and Hybrid types and if there is 
consistent genetic identity found within strain accessions obtained from different 
facilities. Although there was strong statistical support dividing the samples into two 
genetic groups, the groups did not correspond to commonly reported 
Sativa/Hybrid/Indica types. The analyses revealed genetic inconsistencies within strains, 
with most strains containing at least one genetic outlier. However, after the removal of 
obvious outliers, many strains showed considerable genetic stability. We failed to find 
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clear genetic support for common strain descriptions of Sativa, Indica and Hybrid types 
as described in online databases. Significant genetic differences within samples of the 
same strain were observed indicating that consumers could be provided inconsistent 
products. These differences have the potential to lead to phenotypic differences and 
unexpected effects, which could be surprising for the recreational user, but have more 
serious implications for patients relying on strains that alleviate specific medical 
symptoms. 
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Introduction 
Cultivation of Cannabis sativa L. dates back thousands of years (Abel 2013) but 
has been largely illegal worldwide for the best part of the last century. The U.S. Drug 
Enforcement Agency considers Cannabis a Schedule I drug with no “accepted medical 
use in treatment in the United States” (United States Congress 1970), but laws allowing 
Cannabis for use as hemp, medicine, and some adult recreational use are emerging 
(ProCon 2018b). Global restrictions have limited Cannabis related research, and there are 
relatively few genetic studies focused on strains (Lynch et al. 2016; Soler et al. 2017), but 
studies with multiple accessions of a particular strain show variation (Lynch et al. 2016; 
Sawler et al. 2015; Soler et al. 2017).  
Currently, the Cannabis industry has no way to verify strains. Consequently, 
suppliers are unable to provide confirmation of strains, and consumers have to trust the 
printed name on a label matches the product inside the package. Reports of 
inconsistencies, along with the history of underground trading and growing in the 
absence of a verification system, reinforce the likelihood that strain names may be 
unreliable identifiers for Cannabis products at the present time. Without verification 
systems in place, there is the potential for misidentification and mislabeling of plants, 
creating names for plants of unknown origin, and even re-naming or re-labeling plants 
with prominent names for better sale. Cannabis taxonomy is complex (Clarke and Merlin 
2013, 2015, 2016; Emboden 1974; Hillig 2005; Russo 2007; Schultes et al. 1974; Small 
2015b; Small et al. 1976), but given the success of using genetic markers, such as 
microsatellites, to determine varieties in other crops, we suggest that similar genetic 
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based approaches should be used to identify Cannabis strains in medical and recreational 
marketplaces. 
There are an estimated ~3.5 million medical marijuana patients in the United 
States (U.S.) (Leafly 2018a) and various levels of recent legalization in many states has 
led to a surge of new strains (Leafly 2018b; Wikileaf 2018). Breeders are producing new 
Cannabis strains with novel chemical profiles resulting in various psychotropic effects 
and relief for an array of symptoms associated with medical conditions including (but not 
limited to): glaucoma (Tomida et al. 2004), Chron’s Disease (Naftali et al. 2013), 
epilepsy (United States Food and Drug Administration 2018; Maa and Figi 2014), 
chronic pain, depression, anxiety, PTSD, autism, and fibromyalgia (Borgelt et al. 2013; 
Cousijn et al. 2018; Naftali et al. 2013; Ogborne et al. 2000; ProCon 2016a). 
There are primarily two Cannabis usage groups, which are well supported by 
genetic analyses (Dufresnes et al. 2017; Lynch et al. 2016; Sawler et al. 2015; Soler et al. 
2017): hemp defined by a limit of < 0.3% Δ9-tetrahydrocannabinol (THC) in the U.S., 
and marijuana or drug-types with moderate to high THC concentrations (always > 0.3% 
THC). Within the two major groups Cannabis can be further divided into strains 
(varietals), and particularly for the drug types, strains are assigned to one of three 
categories: Sativa which reportedly has uplifting and more psychotropic effects, Indica 
which reportedly has more relaxing and sedative effects, and Hybrid which is the result 
of breeding Sativa and Indica types resulting in intermediate effects. The colloquial terms 
Sativa, Hybrid, and Indica are used throughout this document even though these terms 
do not align with the current formal botanical taxonomy for Cannabis sativa and 
proposed Cannabis indica (McPartland 2017; Piomelli and Russo 2016). We feel the 
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colloquial terminology is 8necessary here as the approach for this study was from a 
consumer view, and these are the terms offered as common descriptors for the general 
public (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf 
2018; Marijuana strains database 2019). Genetic analyses have not provided a clear 
consensus for higher taxonomic distinction among these commonly described Cannabis 
types (Lynch et al. 2016; Sawler et al. 2015), and whether there is a verifiable difference 
between Sativa and Indica type strains is debated. However, both the recreational and 
medical Cannabis communities claim there are distinct differences in effects between 
Sativa and Indica type strains (Smith 2012; Leaf Science 2016; Leafly 2018b; NCSM 
2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database 
2019). 
Female Cannabis plants are selected based on desirable characters (mother plants) 
and are produced through cloning and, in some cases, self-fertilization to produce seeds 
(Green 2005). Cloning allows Cannabis growers to replicate plants, ideally producing 
consistent products. There are an overwhelming number of Cannabis strains that vary 
widely in appearance, taste, smell and psychotropic effects (Leafly 2018b; NCSM 2018; 
PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database 2019). 
Online databases such as Leafly (Leafly 2018b) and Wikileaf (Wikileaf 2018), for 
example, provide consumers with information about strains but lack scientific merit for 
the Cannabis industry to regulate the consistency of strains. Other databases exist 
(NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Marijuana strains database 2019), 
but the method of assignment to the three groups is often undisclosed, confounded, or 
mysterious. Wikileaf reports a numeric percentage of assignment to Sativa and/or Indica 
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(Wikileaf 2018), which is why we chose it as our scale reference scale of ancestry, 
although there is some disagreement among online sources (Table 2.1). To our 
knowledge, there have not been any published scientific studies specifically investigating 
the genetic consistency of strains at multiple points of sale for Cannabis consumers.   
Breeders and growers choose Cannabis plants with desirable characters 
(phenotype) related to flowers, cannabinoid profile, and terpene production. Phenotype is 
a product of genotype and environment. Cannabis is considerably variable and 
extraordinarily plastic in response to varying environmental conditions (Onofri and 
Mandolino 2017). Therefore, determining sources of variation, at the most basic level, 
requires examining genetic differences. Strains propagated through cloning should have 
minimal genetic variation. Eight of the strains examined in this study are reportedly clone 
only strains indicating there should be little to no genetic variation within these strains. 
That being said, it is possible for mutations to accumulate over multiple generations of 
cloning (Gabriel et al. 1993; Hojsgaard and Horandl 2015), but these should not be 
widespread. Self-fertilization and subsequent seed production may also be used to grow a 
particular strain. With most commercial plant products growers go through multiple 
generations of self-fertilization and backcrossing to remove genetic variability within a 
strain and provide a consistent product (Riggs 1988). However, for many Cannabis 
strains, the extent of genetic variability stabilization is uncertain. It has been observed 
that novel Cannabis strains developed through crossing are often phenotypically variable 
(Green 2005), which could be the result of seed producers growing seeds that are not 
stabilized enough to produce a consistent phenotype. Soler et al. (Soler et al. 2017) 
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examined the genetic diversity and structure of Cannabis cultivars grown from seed and 
found considerable variation, suggesting that seed lots are not consistent. 
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Table 2.1. Twelve popular strains and their described assignment of Sativa and Indica according to six online databases of Cannabis strain 
information (Leafly 2018b). 
Strain 
% 
Sativa 
Leafly Strainfinder NCSM PotGuide Seedfinder 
Durban Poison* 100 Pure sativa Sativa dominant Pure Sativa Sativa 
7 breeders: Pure Sativa (4), Mostly Sativa 
(2), Sativa/Indica (1) 
Sour Diesel* 90 
Sativa 
dominant 
Sativa dominant 
(70%) 
Mostly Sativa 
Sativa Dominant 
Hybrid 
19 breeders:  Mostly Sativa (12), 
Sativa/Indica (5), mostly Indica (2) 
Golden Goat*v 65 
Sativa 
dominant 
hybrid 
Not Found 
 Sativa 
Dominant 
Sativa Dominant 
Hybrid 
3 breeders: Mostly Sativa (2), 
Sativa/Indica (1)  
Bruce Banner* 60 Sativa effects 
*Sativa 
dominant (65%) 
Sativa 
Dominant 
(60%) 
*Sativa 
Dominant 
Hybrid 
10 breeders: Mostly Sativa (6), 
Sativa/Indica (1), mostly Indica (3) 
Flo* 60 Hybrid 
Sativa dominant 
(60%) 
Not Found Not Found 1 breeder: Mostly Sativa 
Pineapple Express* 60 
Sativa 
dominant 
hybrid 
Indica dominant 
(70%) 
Sativa 
Dominant 
(60%) 
Not Found 
6 breeders: Mostly Sativa (2), 
Sativa/Indica (1), mostly Indica (1), 
Ruderalis/Sativa/Indica (2) 
OG Kush*v 55 Hybrid 
Indica dominant 
(75%) 
Not Found 
Sativa Dominant 
Hybrid 
25 breeders: Pure Indica (3), mostly Sativa 
(1), mostly Indica (15), Sativa/Indica (6) 
Blue Dream*v 50 
Sativa 
dominant 
hybrid 
Sativa dominant 
(70%) 
Sativa 
Dominant 
(60%) 
Sativa Dominant 
Hybrid 
10 breeders: Mostly Sativa (9), mostly 
Indica (1) 
Chemdawg* 45 Hybrid 
Indica dominant 
(60%) 
Indica dominant 
(55%) 
Sativa Dominant 
Hybrid 
2 breeders: Mostly Sativa (2) (Chem Dog 
and Chemdawg) 
Banana Kush* 40 Hybrid Not Found Not Found 
Indica Dominant 
Hybrid 
3 breeders: Mostly Indica (1), 
Sativa/Indica (2)  
Girl Scout Cookies*v 40 Hybrid 
Indica dominant 
(60%) 
Indica dominant 
(60%) 
Hybrid 
17 breeders: Mostly Sativa (2), 
Sativa/Indica (7), mostly Indica (7), 
Ruderalis/Sativa/Indica (1) 
Purple Kush*v 0 Pure Indica 
Indica dominant 
(75%) 
Pure Indica 
Indica Dominant 
Hybrid 
5 breeders: Mostly Indica (5) 
3
1
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Given the uncertainties surrounding named Cannabis strains, genetic data provide an 
ideal path to examine how widespread genetic inconsistencies might be.  
In the U.S., protection against commercial exploitation, trademarking, and 
recognition of intellectual property for developers of new plant cultivars is provided 
through the United States Department of Agriculture (USDA) and The Plant Variety 
Protection Act of 1970 (United States Department of Agriculture 1970). Traditionally, 
morphological characters were used to define new varieties in crops such as grapes (Vitis 
vinifera L.), olives (Olea europea L.) and apples (Malus domestica Borkh.). With the 
rapid development of new varieties in these types of crops, morphological characters 
have become increasingly difficult to distinguish. Currently, quantitative and/or 
molecular characters are often used to demonstrate uniqueness among varieties. 
Microsatellite genotyping enables growers and breeders of new cultivars to demonstrate 
uniqueness through variable genetic profiles (Rongwen et al. 1995). Microsatellite 
genotyping has been used to distinguish cultivars and hybrid varieties of multiple crop 
varietals within species (Baldoni et al. 2009; Belaj et al. 2004; Cipriani et al. 2002; 
Costantini et al. 2005; Guilford et al. 1997; Hokanson et al. 1998; Muzzalupo et al. 2009; 
Pellerone et al. 2001; Poljuha et al. 2008; Rongwen et al. 1995; Sarri et al. 2006; Stajner 
et al. 2011). Generally, 3-12 microsatellite loci are sufficient to accurately identify 
varietals and detect misidentified individuals (Baldoni et al. 2009; Belaj et al. 2004; 
Cipriani et al. 2002; Muzzalupo et al. 2009; Poljuha et al. 2008; Sarri et al. 2006). 
Cannabis varieties however, are not afforded any legal protections, as the USDA 
considers it an “ineligible commodity” (United States Department of Agriculture 2014) 
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but genetic variety identification systems provide a model by which Cannabis strains 
could be developed, identified, registered, and protected.  
We used a well-established genetic technique to compare commercially available 
C. sativa strains to determine if products with the same name purchased from different 
sources have genetic congruence. This study is highly unique in that we approached 
sample acquisition as a common retail consumer by purchasing flower samples from 
dispensaries based on what was available at the time of purchase. All strains were 
purchased as-is, with no additional information provided by the facility, other than the 
identifying label. This study aimed to determine if: (1) any genetic distinction separates 
the common perception of Sativa, Indica and Hybrid types; (2) consistent genetic identity 
is found within a variety of different strain accessions obtained from different facilities; 
(3) there is evidence of misidentification or mislabeling.  
Methods 
Genetic Material  
Cannabis samples for 30 strains were acquired from 20 dispensaries or donors in three 
states (Table 2.2). All samples used in this study were obtained legally from either retail 
(Colorado and Washington), medical (California) dispensaries, or as a donation from 
legally obtained samples (Greeley 1). DNA was extracted using a modified CTAB 
extraction protocol (Doyle 1987) with 0.035-0.100 grams of dried flower tissue per 
extraction. Although several databases exist with various descriptive Sativa and Indica 
assignments for thousands of strains (Table 2.1 & 2.2), proportions of Sativa and Indica 
phenotypes from Wikileaf (Wikileaf 2018) were used for this study.  Analyses were 
performed on the full 122-sample data set (Table 2.2). The 30 strains were assigned a 
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proportion of Sativa according to online information (Table 2.2). Twelve of the 30 strains 
were designated as ‘popular’ due to higher availability among the dispensaries as well as 
online information reporting the most popular strains (Table 2.3) (Escondido 2014; Rahn 
2016a; Rahn 2016b; Rahn et al. 2016). Results from popular strains are highlighted to 
show levels of variation in strains that are more widely available or that are in higher 
demand. 
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Table 2.2. Cannabis samples (122) from 30 strains. Reported proportion of Sativa from Wikileaf 
(Wikileaf 2018) and the city location and state where each sample was acquired are included. (SLO: 
San Luis Obispo). 
Name Sativa City State Name Sativa City State 
Durban Poison 100 Boulder 1 CO OG Kush 55 Denver 3 CO 
Durban Poison 100 Boulder 3 CO OG Kush 55 Fort Collins 3 CO 
Durban Poison 100 Denver 1 CO OG Kush 55 Garden City 2 CO 
Durban Poison 100 Denver 2 CO OG Kush 55 SLO 1 CA 
Durban Poison 100 Fort Collins 3 CO Blue Dream 50 Boulder 1 CO 
Durban Poison 100 Fort Collins 4 CO Blue Dream 50 Boulder 2 CO 
Durban Poison 100 Garden City 1 CO Blue Dream 50 Boulder 3 CO 
Durban Poison 100 Garden City 2 CO Blue Dream 50 Denver 1 CO 
Durban Poison 100 Union Gap 1 WA Blue Dream 50 Garden City 4 CO 
Hawaiian 90 Boulder 1 CO Blue Dream 50 Garden City 4 CO 
Hawaiian 90 Fort Collins 2 CO Blue Dream 50 SLO 2 CA 
Sour Diesel 90 Boulder 1 CO Blue Dream 50 SLO 3 CA 
Sour Diesel 90 Boulder 3 CO Blue Dream 50 SLO 4 CA 
Sour Diesel 90 Greeley 1 CO Tahoe OG 50 Boulder 1 CO 
Sour Diesel 90 Denver 4 CO Tahoe OG 50 Denver 1 CO 
Sour Diesel 90 Fort Collins 3 CO Tahoe OG 50 Fort Collins 4 CO 
Sour Diesel 90 Garden City 1 CO Tahoe OG 50 SLO 3 CA 
Sour Diesel 90 Garden City 2 CO ChemdawgD* 40 Boulder 1 CO 
Trainwreck 90 Denver 1 CO ChemDawg 45 Boulder 2 CO 
Trainwreck 90 Garden City 1 CO ChemDawg 45 Boulder 3 CO 
Island Sweet Skunk 80 Boulder 1 CO ChemdawgD* 40 Denver 1 CO 
Island Sweet Skunk 80 Garden City 1 CO Chemdawg 91 40 Denver 5 CO 
Island Sweet Skunk 80 Garden City 2 CO Chemdog 1* 40 Garden City 1 CO 
AK-47 65 Boulder 1 CO ChemDawg 45 Garden City 2 CO 
AK-47 65 Denver 3 CO Headband 45 Garden City 1 CO 
AK-47 65 SLO 2 CA Headband 45 Greeley 1 CO 
Golden Goat 65 Boulder 1 CO Banana Kush 40 Denver 1 CO 
Golden Goat 65 Boulder 2 CO Banana Kush 40 Garden City 1 CO 
Golden Goat 65 Boulder 3 CO Banana Kush 40 Garden City 2 CO 
Golden Goat 65 Denver 1 CO Banana Kush 40 Greeley 1 CO 
Golden Goat 65 Garden City 1 CO Girl Scout Cookies 40 Boulder 1 CO 
Golden Goat 65 Garden City 1 CO Girl Scout Cookies 40 Denver 1 CO 
Golden Goat 65 Garden City 2 CO Girl Scout Cookies 40 Fort Collins 2 CO 
Green Crack 65 Fort Collins 2 CO Girl Scout Cookies 40 Garden City 2 CO 
Green Crack 65 Garden City 1 CO Girl Scout Cookies 40 Garden City 3 CO 
Green Crack 65 SLO 2 CA Girl Scout Cookies 40 SLO 3 CA 
Bruce Banner 60 Boulder 1 CO Girl Scout Cookies 40 SLO 4 CA 
Bruce Banner 60 Denver 1 CO Girl Scout Cookies 40 Union Gap 1 WA 
Bruce Banner 60 Denver 4 CO Jack Flash 55 Boulder 1 CO 
Bruce Banner 60 Fort Collins 3 CO Jack Flash 55 Denver 3 CO 
Bruce Banner 60 Fort Collins 4 CO Larry OG 40 Boulder 1 CO 
Bruce Banner 60 Garden City 1 CO Larry OG 40 Denver 4 CO 
Flo 60 Boulder 1 CO Larry OG 40 SLO 3 CA 
Flo 60 Denver 1 CO G-13 30 Boulder 3 CO 
Flo 60 Fort Collins 2 CO G-13 30 Fort Collins 3 CO 
Flo 60 Garden City 1 CO G-13 30 Garden City 2 CO 
Jillybean 60 Garden City 1 CO Lemon Diesel 30 Boulder 1 CO 
Jillybean 60 Garden City 2 CO Lemon Diesel 30 Garden City 2 CO 
Pineapple Express 60 Boulder 1 CO 
Hash Plant 
(Australian) 
20 Garden City 1 CO 
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Table 2.2. continued 
Name Sativa City State Name Sativa City State 
        
Pineapple Express 60 Denver 1 CO Hash Plant 20 Garden City 1 CO 
Pineapple Express 60 Garden City 2 CO Hash Plant 20 Garden City 2 CO 
Pineapple Express 60 Longmont 1 CO Bubba Kush 98 20 Denver 1 CO 
Pineapple Express 60 Union Gap WA Pre-98 Bubba Kush 15 Fort Collins 3 CO 
Purple Haze 60 Denver 4 CO Grape Ape 0 Boulder 1 CO 
Purple Haze 60 Greeley 1 CO Grape Ape 0 Union Gap 1 WA 
Purple Haze 60 Fort Collins 1 CO Purple Kush 0 Denver 1 CO 
Tangerine 60 Denver 1 CO Purple Kush 0 Garden City 3 CO 
Tangerine 60 Garden City 1 CO Purple Kush 0 Garden City 4 CO 
Jack Herer 55 Garden City 3 CO         
Jack Herer 55 SLO 1 CA         
Jack Herer 55 Union Gap 1 WA         
* Strain proportion of “Chemdawg” variants not listed on Wikileaf 
 Strain proportion of “Tangerine” not listed on Wikileaf; proportion listed is of “Tangerine Dream”  
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Table 2.3. Summary of Cannabis samples (122) from 30 strains. The reported proportion of Sativa 
retrieved from Wikileaf (Wikileaf 2018). Abbreviations used for Lynch & Ritland (Lynch and Ritland 
1999) relatedness statistics are included, and the proportions of membership for genotype 1 and genotype 2 
from the STRUCTURE (Fig. 2.1) expressed as a percentage. 
Strain Abbr 
# 
Samples 
Sativa  % 
Genotype 1 
(% average) 
Genotype 2 
(% average) 
Standard 
Deviation 
Durban Poison* DuPo 9 100 86 14 9.9 
Hawaiian Hawa 2 90 61 39 27.58 
Sour Diesel* SoDi 7 90 14 86 53.74 
Trainwreck TrWr 2 90 59 41 21.92 
Island Sweet Skunk ISS 3 80 93 7 9.19 
AK-47 AK47 3 65 55 45 7.07 
Golden Goat* GoGo 7 65 68 32 2.12 
Green Crack GrCr 3 65 60 40 3.54 
Bruce Banner* BrBa 6 60 19 81 28.99 
Flo* Flo 4 60 38 62 15.56 
Jillybean JiBe 3 60 73 27 9.19 
Pineapple Express* PiEx 5 60 62 38 1.41 
Purple Haze PuHa 3 60 77 23 12.02 
Tangerine Tang 2 60 53 47 4.95 
Jack Herer JaHe 3 55 66 34 7.78 
OG Kush* OGKu 4 55 28 72 19.09 
Blue Dream* BlDr 9 50 80 20 21.21 
Tahoe OG TaOG 4 50 26 74 16.97 
Chemdawg* ChDa 7 45 9 91 25.46 
Headband HeBa 2 45 57 43 8.49 
Banana Kush* BaKu 4 40 52 48 8.49 
Girl Scout Cookies* GSC 8 40 25 75 10.61 
Jack Flash JaFl 2 40 96 4 39.6 
Larry OG LaOG 3 40 7 93 23.33 
G-13 G13 3 30 50 50 14.14 
Lemon Diesel LeDi 2 30 85 15 38.89 
Hash Plant HaPl 4 20 37 63 12.02 
Pre98-Bubba Kush PBK 2 15 7 93 5.66 
Grape Ape GrAp 2 0 55 45 38.89 
Purple Kush* PuKu 4 0 29 71 20.51 
* Twelve popular strains  
 Clone only strains (SeedFinder 2018)
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Microsatellite Development 
The Cannabis draft genome from “Purple Kush” (GenBank accession 
AGQN00000000.1) was scanned for microsatellite repeat regions using 
MSATCOMMANDER-1.0.8-beta (Faircloth 2008). Primers were developed de-novo 
flanking microsatellites with 3-6 nucleotide repeat units (Table 2.4). Seven of the 
microsatellites were trinucleotide motifs with >10 repeating units. There was two 
hexanucleotide motifs with 20 and 30 repeating units. Finally, one tetranucleotide motif 
with 10 repeating units was included (Table 2.4). One primer in each pair was tagged 
with a 5’ universal sequence (M13 or T7) so that a matching sequence with a 
fluorochrome tag could be incorporated via Polymerase Chain Reaction (PCR) (Schwabe 
et al. 2015). Ten primer pairs produced consistent peaks within the predicted size range 
and were used for the genetic analyses herein (Table 2.4). 
   
 
 
Table 2.4. Primer information. Includes the multiplex assignment, primer name, microsatellite repeat and number of units repeated in the "Purple Kush" draft genome (National Center for 
Biotechnology Information, accession AGQN00000000.1), forward and reverse sequences (asterisk denotes the sequence to which the tag is attached), the universal tag (sequence revealed at the 
bottom of the table), dye (VIC, FAM, PET), optimized annealing temperature, MgCl uL volume, amplified fragment size range, and the number of alleles in the data set.   
Multiplex Primer Repeat Unit Forward Sequence Reverse Sequence Tag Dye Anneal Temp Magnesium Fragment Size Na 
1 Casa_002 (GGAATT)20 GTTAGACAATGCTGCCGGTG *TTCCGATCCAATCCGCAC M13 FAM 57.4 MgCl 2uL 270-324 8 
1 Casa_022 (AGAT)10 TCCACAGCCAGAGGAGAATC *GGATCATTGGACAGCCATTC T7 VIC 63.0 MgCl 2uL 190-208 6 
1 Casa_027 (GTT)20 CATCTCCCAGCCCTTTCATA *GCTAGGGTTTTTGCCAAC M13 FAM 57.4 MgCl 2uL 184-196 9 
1 Casa_028 (AAT)13 *TGCACATTGCTCTCCTTTTG GAATGTGGTCCAATAAACACTCC M13 PET 55.1 MgCl 2uL 173-190 8 
1 Casa_030 (CAA)19 CAATCCACACAACAGCTCCT *TGCAGCAAGTTTAGGTGGTC M13 VIC 55.1 MgCl 6uL 271-300 8 
2 Casa_006 (TTTCTC)30 *TTCTTCTCTCGACAGAACCC TAGAACCAAGCAAGAAGGGC M13 FAM 55.1 MgCl 1uL 410-422 6 
2 Casa_014 (TAG)13 *ATCGTGTTGCATGTTTGTGG TGTGCTCCCTCTTGTATGATTC M13 FAM 63.0 MgCl 2uL 270-290 8 
2 Casa_018 (ATT)28 *TCATAACCCCAAAAGCAAAG GGGTAAATATAGCTGGCAAAGC T7 VIC 55.1 MgCl 3uL 182-221 10 
2 Casa_026 (CTT)13 *CCATTTCGACCCTTGTAGGT CTGGGGAAGATGAACGAAAG M13 FAM 57.4 MgCl 1uL 201-206 9 
2 Casa_029 (ACC)11 CCCTCTCAGTCCCAAATTCA *GATGGTGATGAGGAGGAGGA M13 PET 55.1 MgCl 2uL 183-192 5 
M13: AGGAAACAGCTATGACCAT                 
T7: GCTAGTTATTGCTCAGCGG 
        
3
9
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Polymerase Chain Reaction 
and Data Scoring 
Microsatellite loci (Table 2.4) were amplified in 12 µL reactions using 1.0 μL 
DNA (10-20 ng/ μL), 0.6 μL fluorescent tag (5 μM; FAM, VIC, or PET), 0.6 μL non-
tagged primer (5 μM), 0.6 μL tagged primer (0.5 μM), 0.7 μL dNTP mix (2.5mM), 2.4 
μL GoTaq Flexi Buffer (Promega, Madison, WI, USA), 0.06 μL GoFlexi taq polymerase 
(Promega), 0.06 μL BSA (Bovine Serum Albumin 100X), 0.5 - 6.0 μL MgCl or MgSO4, 
and 0.48 - 4.98 μL dH2O. An initial 5-minute denaturing step was followed by thirty-five 
amplification cycles with a 1-minute denaturing at 95º C, 1-minute annealing at primer-
specific temperatures and 1-minute extension at 72ºC. Two multiplexes (Table 2.4) based 
on fragment size and fluorescent tag were assembled and 2 μL of each PCR product were 
combined into multiplexes up to a total volume of 10 μL.  From the multiplexed product, 
2 μL was added to Hi-Di formamide and LIZ 500 size standard (Applied Biosystems, 
Foster City, CA, USA) for electrophoresis on a 3730 Genetic Analyzer (Applied 
Biosystems) at the Arizona State University DNA Lab. Fragments were sized using 
GENEIOUS 8.1.8 (Biomatters Ltd).  
Genetic Statistical Analyses  
GENALEX ver. 6.4.1 (Peakall and Smouse 2006; Peakall and Smouse 2012) was 
used to calculate deviation from Hardy–Weinberg equilibrium (HWE) and number of 
alleles for each locus (Table 2.4). Linkage disequilibrium was tested using GENEPOP 
ver. 4.0.10 (Raymond and Rousset 1995; Rousset 2008). Presence of null alleles was 
assessed using MICRO-CHECKER (Van Oosterhout et al. 2004). Genotypes were 
analyzed using the Bayesian cluster analysis program STRUCTURE ver. 2.4.2 (Pritchard 
et al. 2000). Burn-in and run-lengths of 50,000 generations were used with ten 
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independent replicates for each STRUCTURE analysis. STRUCTURE HARVESTER 
(Earl and vonHoldt 2012) was used to determine the K value to best describe the likely 
number of genetic groups for the data set. GENALEX produced a Principal Coordinate 
Analysis (PCoA) to examine variation in the data set. Lynch & Ritland (Lynch and 
Ritland 1999) mean pairwise relatedness (r) statistics were calculated between all 122 
samples resulting in 7381 pairwise r-values showing degrees of relatedness. For all 
strains the r-mean and standard deviation (SD) was calculated averaging among all 
samples. Obvious outliers were determined by calculating the lowest r-mean and 
iteratively removing those samples to determine the relatedness among the remaining 
samples in the subset. A graph was generated for 12 popular strains (Table 2.3) to show 
how the r-mean value change within a strain when outliers were removed. 
Results 
The microsatellite analyses show genetic inconsistencies in Cannabis strains 
acquired from different facilities. While popular strains were widely available, some 
strains were found only at two dispensaries (Table 2.2). Since the aim of the research was 
not to identify specific locations where strain inconsistencies were found, dispensaries are 
coded to protect the identity of businesses. 
 There was no evidence of linkage-disequilibrium when all samples were treated 
as a single population. All loci deviate significantly from HWE, and all but one locus was 
monomorphic in at least two strains. All but one locus had excess homozygosity and 
therefore possibly null alleles. Given the inbred nature and extensive hybridization of 
Cannabis, deviations from neutral expectations are not surprising, and the lack of 
linkage-disequilibrium indicates that the markers are spanning multiple regions of the 
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genome. The number of alleles ranged from 5-10 across the ten loci (Table 2.4). There 
was no evidence of null alleles due to scoring errors.  
STRUCTURE HARVESTER calculated high support (∆K=146.56) for two 
genetic groups, K=2 (Figure 2.1). STRUCTURE assignment is shown in Figure 1 with 
the strains ordered by the purported proportions of Sativa phenotype (Wikileaf 2018).  
 
Figure 2.1. STRUCTURE HARVESTER. Graph indicating K=2 is highly support 
(∆K=146.56) as the number of genetic groups for this data.  
 
A clear genetic distinction between Sativa and Indica types would assign 100% Sativa 
strains (“Durban Poison”) to one genotype and assign 100% Indica strains (“Purple 
Kush”) to the other genotype (Table 2.3, Figure 2.2, and 2.3). Division into two genetic 
groups does not support the commonly described Sativa and Indica phenotypes. “Durban 
Poison” and “Purple Kush” follow what we would expect if there was support for the 
Figure 1. 
STRUCTURE HARVESTER graph indicating K=2 is hi hly supported
(∆K=146.56) as the number of genetic groups for this data. 
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Sativa/Indica division. Seven of nine “Durban Poison” (100% Sativa) samples had 96% 
assignment to genotype 1, and three of four “Purple Kush” (100% Indica) had 89% 
assignment to genotype 2 (Figure 2.2, 2.3). However, samples of “Hawaiian” (90% 
Sativa) and “Grape Ape” (100% Indica) do not show consistent patterns of predominant 
assignment to genotype 1 or 2. Interestingly, two predominantly Sativa strains “Durban 
Poison” (100% Sativa) and “Sour Diesel” (90% Sativa) have 86% and 14% average 
assignment to genotype 1, respectively. Hybrid strains such as “Blue Dream” and “Tahoe 
OG” (50% Sativa) should result in some proportion of shared ancestry, with assignment 
to both genotype 1 and 2. Eight of nine samples of “Blue Dream” show > 80% 
assignment to genotype 1, and three of four samples of “Tahoe OG” show < 7% 
assignment to genotype 1.
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Figure 2.1. STRUCTURE graphs for 122 individuals. Bar plot graphs generated from STRUCTURE analysis for 122 individuals from 30 
strains dividing genotypes into two genetic groups, K=2. Samples were arranged by purported proportions from 100% Sativa to 100% 
Indica and then alphabetically within each strain by city. Each strain includes reported proportion of Sativa in parentheses and each sample 
includes the coded location and city from where it was acquired. Each bar indicates proportion of assignment to genotype 1 (blue) and 
genotype 2 (yellow).  
4
4
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Figure 2.2. Bar plot graphs generated from STRUCTURE analysis for individuals from twelve popular strains (Table 2.3), 
dividing genotypes into two genetic groups, K=2. Each sample includes the coded location and city from where it was acquired. Each 
bar indicates proportion of assignment to genotype 1 (blue) and genotype 2 (yellow). 
4
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A Principal Coordinate Analyses (PCoA) was conducted using GENALEX 
(Figure 2.3). Principal Coordinate Analyses (PCoA) is organized by color from 100% 
Sativa types (red), through all levels of Hybrid types (green 50:50), to 100% Indica types 
(purple; Figure 2.3). Strain types with the same reported proportions are the same color 
but have different symbols. The PCoA of all strains represents 14.90% of the variation in 
the data on coordinate axis 1, 9.56% on axis 2, and 7.07% on axis 3 (not shown).
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Figure 2.3. Principal Coordinates Analysis (PCoA) generated in GENALEX using Nei’s genetic distance matrix. Samples are a color-coded continuum by 
proportion of Sativa (Table 2.2) with the strain name given for each sample: Sativa type (red: 100% Sativa proportion, Hybrid type (dark green: 50% Sativa 
proportion), and Indica type (purple: 0% Sativa proportion). Different symbols are used to indicate different strains within reported phenotype. Coordinate axis 1 
explains 14.29% of the variation, coordinate axis 2 explains 9.56% of the variation, and Coordinate axis 3 (not shown) explains 7.07%.  
4
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Lynch & Ritland (Lynch and Ritland 1999) pairwise genetic relatedness (r) 
between all 122 samples was calculated in GENALEX. The resulting 7381 pairwise r-
values were converted to a heat map using purple to indicate the lowest pairwise 
relatedness value (-1.09) and green to indicate the highest pairwise relatedness value 
(1.00; Figure 2.4). 
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Figure 2.4. A genetic heat map chart of Lynch & Ritland pairwise genetic relatedness (r) values for 122 samples. Purple 
indicates no genetic relatedness (minimum value -1.09) and green indicates a high degree of relatedness (maximum value 1.0). Sample 
strain names and location of origin are indicated along the top and down the left side of the chart. Pairwise genetic relatedness (r) 
values are given in each cell and cell color reflects the degree to which two individuals are related. 
4
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Figure 2.5. Heat maps of six prominent strains (A-F) using Lynch & Ritland (Lynch 
and Ritland 1999) pairwise genetic relatedness (r) values. Purple indicates no genetic 
relatedness (minimum value -1.09) and green indicates a high degree of relatedness 
(maximum value 1.00). Sample strain names and location of origin are indicated along 
the top and down the left side of the chart. Pairwise genetic relatedness (r) values are 
given in each cell and the cell color reflects the degree to which two individuals are 
related. 
 
Comparisons are detailed for six popular strains (Figure 2.5) to illustrate the 
relationship of samples from different sources and the impact of outliers. Values of close 
to 1.00 indicate a high degree of relatedness (Lynch and Ritland 1999), which could be 
indicative of clones or seeds from the same mother (Green 2005; SeedFinder 2018). First 
order relatives (full siblings or mother-daughter) share 50% genetic identity (r-value = 
0.50), second order relatives (half siblings or cousins) share 25% genetic identity (r-value 
= 0.25), and unrelated individuals are expected to have an r-value of 0.00 or lower. 
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Figure 3. 
Heat maps of six prominent strains using Lynch & Ritland [62] pairwise genetic relatedness (r) values: purple indicates no genetic 
relatedness (minimum value -1.09) and green indicates a high degree of relatedness (maximum value 1.0). Sample strain names and 
loc tion of origin are indicated along th  top and down the left side f the chart. Pairwise g netic relat dness (r) values are given in 
each cell and cell color reflects the degree to which two individuals are related. 
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Negative values arise when individuals are less related than expected under normal 
panmictic conditions (Moura et al. 2013; Norman et al. 2017).  
Individual pairwise r-values were averaged within strains to calculate the overall 
r-mean as a measure of genetic similarity within strains which ranged from -0.22 
(“Tangerine”) to 0.68 (“Island Sweet Skunk”) (Table 6). Standard deviations ranged from 
0.04 (“Jack Herer”) to 0.51 (“Bruce Banner”). The strains with higher standard deviation 
values indicate a wide range of genetic relatedness within a strain, while low values 
indicate that samples within a strain share similar levels of genetic relatedness. In order to 
determine how outliers impact the overall relatedness in a strain, the farthest outlier 
(lowest pairwise r-mean value) was removed and the overall r-means and SD values 
within strains were recalculated (Table 2.5). 
 In all strains, the overall r-means increased when outliers were removed. In 
strains with more than three samples, a second outlier was removed, and the overall r-
means and SD values were recalculated. Overall r-means were used to determine degree 
of relatedness as clonal (or from stable seed; overall r-means > 0.9), first or higher order 
relatives (overall r-means 0.46 – 0.89), second order relatives (overall r-means 0.26 - 
0.45), low levels of relatedness (overall r-means 0.00 - 0.25), and not related (overall r-
means <0.00).  Overall r-means are displayed for all 30 strains (Table 2.5), and 
graphically for 12 popular strains (Figure 2.6).
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Table 2.5. Lynch & Ritland (Lynch and Ritland 1999) pairwise relatedness 
comparisons of overall r-means (Mean) and standard deviations (SD) for samples 
of 30 strains. Including r-mean and SD after the first and second (where possible) 
outliers were removed. Outliers were samples with the lowest r-mean. 
Strain 
# 
Samples 
Mean  ± SD  
Mean  ± SD      
(Outlier 1 removed) 
Mean  ± SD     
(Outlier 2 removed) 
Durban Poison* 9 0.31 ± 0.4 0.43 ± 0.37  0.58 ± 0.30 
Hawaiian 2 -0.115 - - 
Sour Diesel* 7 0.44 ± 0.29 0.57 ± 0.22 0.60 ± 0.18 
Trainwreck 2 -0.001 - - 
Island Sweet Skunk 3 0.68 1 - 
AK-47 3 0.16 0.45 - 
Golden Goat* 7 0.25 ± 0.32 0.31 ± 0.36 0.46 ± 0.36 
Green Crack 3 0.38 0.88 - 
Bruce Banner* 6 0.30 ± 0.51 0.51 ± 0.5 0.9 ± 0.05 
Flo* 4 0.29 ± 0.38 0.55 ± 0.39 - 
Jillybean 3 -0.033 0.039 - 
Pineapple Express* 5 0.02 ± 0.16 0.04 ± 0.17 0.13 ± 0.19 
Purple Haze 3 0.041 0.26 - 
Tangerine 2 -0.22 - - 
Jack Herer 3 0.1 0.13 - 
OG Kush* 4 0.13 ± 0.19 0.25 ± 0.22 - 
Blue Dream* 9 0.50 ± 0.39 0.63 ± 0.34 0.76 ± 0.24 
Tahoe OG 4 0.21 0.406 0.539 
Chemdawg* 7 0.42 ± 0.31 0.51 ± 0.31 0.64 ± 0.28 
Headband 2 0.107 - - 
Banana Kush* 4 0.13 ± 0.20 0.24 ± 0.13 - 
Girl Scout Cookies* 8 0.08 ± 0.27 0.13 ± 0.30  0.22 ± 0.32 
Jack Flash 2 0.62 - - 
Larry OG 3 0.32 0.67 - 
G-13 3 0.29 0.562 - 
Lemon Diesel 2 0.1 - - 
Hash Plant 4 0.25 0.25 0.43 
Pre98-Bubba Kush 2 -0.02 - - 
Grape Ape 2 -0.05 - - 
Purple Kush* 4 0.03 ± 0.21 0.16 ± 0.22 - 
* Twelve popular strains  
 Clone only strains (SeedFinder 2018) 
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Figure 2.6. Iterative removal of pairwise genetic relatedness (r) outliers from Table 
2.5. This graph indicates the mean pairwise genetic relatedness (r) initially (light purple), 
and after the removal of one (medium purple) or two (dark purple) outlying samples in 12 
popular strains.  
 
Initial overall r-means indicate only three strains are first or higher order relatives (Table 
2.5). Removing first or second outliers, depending on sample size, revealed that the 
remaining samples for an additional ten strains are first or higher order relatives (0.46 – 
1.00), three strains are second order relatives (r-means 0.26 - 0.45), ten strains show low 
levels of relatedness (r-means 0.00 - 0.25; Table 2.5), and five strains are not related (r-
means <0.00). The impact of outliers can be clearly seen in the heat map for “Durban 
Poison” which shows the relatedness for 36 comparisons (Figure 2.5A), six of which are 
nearly identical (r-value 0.90 - 1.0), while 13 are not related (r-value <0.00). However, 
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removal of two outliers, Denver 1 and Garden City 2, reduces the number of comparisons 
ranked as not related from 13 to zero. 
Discussion 
Cannabis is becoming an ever-increasing topic of discussion, so it is important 
that scientists and the public can discuss Cannabis in a similar manner. Currently, not 
only are Sativa and Indica types disputed (Clarke and Merlin 2013, 2015, 2016; De 
Meijer and Keizer 1996; Emboden 1974; Hillig 2005; McPartland 2017; Piomelli and 
Russo 2016; Russo 2007; Small 2015a), but experts also are at odds about nomenclature 
for Cannabis (Clarke and Merlin 2013, 2015, 2016; De Meijer and Keizer 1996; 
Emboden 1974; Hillig 2005; McPartland 2017; Piomelli and Russo 2016; Russo 2007; 
Small 2015a). We postulated that genetic profiles from samples with the same strain 
identifying name should have identical, or at least, highly similar genotypes no matter the 
source of origin. The multiple genetic analyses used here address paramount questions 
for the medical Cannabis community and bring empirical evidence to support claims that 
inconsistent products are being distributed. An important element for this study is that 
samples were acquired from multiple locations to maximize the potential for variation 
among samples. Maintenance of the genetic integrity through genotyping is possible only 
following evaluation of genetic consistency and continuing to overlook this aspect will 
promote genetic variability and phenotypic variation within Cannabis. Addressing strain 
variability at the molecular level is of the utmost importance while the industry is still 
relatively new. 
Genetic analyses have consistently found genetic distinction between hemp and 
marijuana, but no clear distinction has been shown between the common description of 
Sativa and Indica types (De Meijer and Keizer 1996; Dufresnes et al. 2017; Lynch et al. 
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2016; Sawler et al. 2015; Soler et al. 2017). We found high support for two genetic 
groups in the data (Figure 2.1) but no discernable distinction or pattern between the 
described Sativa and Indica strains. The color-coding of strains in the PCoA for all 122 
samples allows for visualization of clustering among similar phenotypes by color: Sativa 
(red/orange), Indica (blue/purple) and Hybrid (green) type strains (Figure 2.4). If genetic 
differentiation of the commonly perceived Sativa and Indica types previously existed, it 
is no longer detectable in the neutral genetic markers used here. Extensive hybridization 
and selection have presumably created a homogenizing effect and erased evidence of 
potentially divergent historical genotypes.  
Wikileaf maintains that the proportions of Sativa and Indica reported for strains 
are largely based on genetics and lineage (Nelson 2016), although online databases do not 
give scientific evidence for their categorization other than parentage information from 
breeders and expert opinions. This has seemingly become convoluted over time (Clarke 
and Merlin 2013; Russo 2007; Small 2015b; Small 2016). Our results show that 
commonly reported levels of Sativa, Indica and Hybrid type strains are often not reflected 
in the average genotype. For example, two described Sativa type strains “Durban Poison” 
and “Sour Diesel”, have contradicting genetic assignments (Figure 2.1, 2.2 & Table 2.1). 
This analysis indicates strains with similar reported proportions of Sativa or Indica may 
have differing genetic assignments. Further illustrating this point is that “Bruce Banner”, 
“Flo”, “Jillybean”, “Pineapple Express”, “Purple Haze”, and “Tangerine” are all reported 
to be 60/40 Hybrid type strains, but they clearly have differing levels of admixture both 
within and among these reportedly similar strains (Figure 2.1, Table 2.1). From these 
results, we can conclude that reported ratios or differences between Sativa and Indica 
phenotypes are not discernable using these genetic markers. Given the lack of genetic 
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distinction between Indica and Sativa types, it is not surprising that reported ancestry 
proportions are also not supported.  
 To accurately address reported variation within strains, samples were purchased 
from various locations, as a customer, with no information of strains other than publicly 
available online information. Evidence for genetic inconsistencies is apparent within 
many strains and supported by multiple genetic analyses. Soler et al. (Soler et al. 2017) 
found genetic variability among seeds from the same strain supplied from a single source, 
indicating genotypes within strains are variable. When examining the STRUCTURE 
genotype assignments, it is clear that many strains contained one or more divergent 
samples with a difference of > 0.10 genotype assignment (e.g. “Durban Poison” – Denver 
1; Figure 2.1, 2.2, 2.5A). Of the 30 strains examined, only four strains had consistent 
STRUCTURE genotype assignment and admixture among all samples. The number of 
strains with consistent STRUCTURE assignments increased to 11 and 15 when one or 
two samples were ignored, respectively. These results indicate that half of the included 
strains showed relatively stable genetic identity among most samples. Six strains had 
only two samples, both of which were different (e.g., “Trainwreck” and “Headband”). 
The remaining nine strains in the analysis had more than one divergent sample (e.g., 
“Sour Diesel”) or had no consistent genetic pattern among the samples within the strain 
(e.g., “Girl Scout Cookies”; Table 2.5, Figure 2.2, 2.2, 2.5B). It is noteworthy that many 
of the strains used here fell into a range of genetic relatedness indicative of first order 
siblings (see Lynch & Ritland analysis) when samples with high genetic divergence were 
removed from the data set (Table 2.5; Figure 2.6). Eight of the 30 strains examined are 
identified as clone only (Table 2.3). All eight of the strains described as clone only show 
differentiation of at least one sample within the strain (Figure 2.1). For example, one 
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sample of “Blue Dream” is clearly differentiated from the remaining eight, and “Girl 
Scout Cookies” has little genetic cohesiveness among the eight samples (Figure 2.1, 2.2). 
Other genetic studies have similarly found genetic inconsistencies across samples within 
the same strain (Lynch et al. 2016; Sawler et al. 2015; Soler et al. 2017). These results 
lend support to the idea that unstable genetic lines are being used to produce seed.  
A pairwise genetic heat map based on Lynch & Ritland (Lynch and Ritland 1999) 
pairwise genetic relatedness (r-values) was generated to visualize genetic relatedness 
throughout the data set (Figure 2.3). Values of 1.00 (or close to) are assumed to be clones 
or plants from self-fertilized seed. Six examples of within-strain pairwise comparison 
heat maps were examined to illustrate common patterns (Figure 2.4).  The heat map 
shows that many strains contain samples that are first order relatives or higher (r-value > 
0.49). For example, “Sour Diesel” (Figure 2.4) has 12 comparisons of first order or 
above, and six have low/no relationship. There are also values that could be indicative of 
clones or plants from a stable seed source such as “Blue Dream” (Figure 2.2, 2.5F), 
which has 10 nearly identical comparisons (r-value 0.90-1.00), and no comparisons in 
“Blue Dream” have negative values. While “Blue Dream” has an initial overall r-mean 
indicating first order relatedness within the samples (Table 2.5, Figure 2.5F), it still 
contains more variation than would be expected from a clone only strain (SeedFinder 
2018). Other clone-only strains (SeedFinder 2018) e.g., “Girl Scout Cookies” (Table 2.2, 
Figure 2.5B) and “Golden Goat” (Table 3, Figure 6D), have a high degree of genetic 
variation resulting in low overall relatedness values. Outliers were calculated and 
removed iteratively to demonstrate how they affected the overall r- mean within the 12 
popular strains (Table 2.2, Figure 2.6). In all cases, removing outliers increased the mean 
r-value, as illustrated by “Bruce Banner”, which increased substantially, from 0.3 to 0.9 
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when samples with two outlying genotypes were removed. There are unexpected areas in 
the entire data set heat map that indicate high degrees of relatedness between different 
strains (Figure 2.4). For example, comparisons between “Golden Goat” and “Island 
Sweet Skunk” (overall r- mean 0.37) are higher than within samples of “Sour Diesel”. 
Interestingly, “Golden Goat” is reported to be a hybrid descendant of “Island Sweet 
Skunk” (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018; Wikileaf 
2018) which could explain the high genetic relatedness between these strains. However, 
most of the between strain overall r- mean are negative (e.g., “Golden Goat” to “Durban 
Poison” -0.03 and “Chemdawg” to “Durban Poison” -0.22; Figure 2.5), indicative of 
limited recent genetic relationship. 
 While collecting samples from various dispensaries, it was noted that strains of 
“Chemdawg” had various different spellings of the strain name, as well as numbers 
and/or letters attached to the name. Without knowledge of the history of “Chemdawg”, 
the assumption was that these were local variations. These were acquired to include in the 
study to determine if and how these variants were related. Upon investigation of possible 
origins of “Chemdawg”, an interesting history was uncovered, especially in light of the 
results. Legend has it that someone named “Chemdog” (a person) grew the variations 
(“Chem Dog”, “Chem Dog D”, “Chem Dog 4”) from seeds he found in a single bag of 
Cannabis purchased at a Grateful Dead concert (Danko 2016). However, sampling 
suggests dispensaries use variations of the name, and more often the “Chemdawg” form 
of the name is used, albeit incorrectly (Danko 2016). The STRUCTURE analysis 
indicates only one “Chemdawg” individual has > 0.10 genetic divergence compared to 
the other six samples (Figure 2.1, 2.5C). Five of seven “Chemdawg” samples cluster in 
the PCoA (Figure 4), and six of seven “Chemdawg” samples are first order relatives (r-
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value >0.50; Table 2.2, Figure 2.5C). The history of “Chem Dog” is currently 
unverifiable, but the analysis supports that these variations could be from seeds of the 
same plant. This illustrates how Cannabis strains may have come to market in a non-
traditional manner. Genetic analyses can add scientific support to the stories behind 
vintage strains and possibly help clarify the history of specific strains. 
Genetic inconsistencies may come from both suppliers and growers of Cannabis 
clones and stable seed, because currently they can only assume the strains they possess 
are true to name. There is a chain of events from seed to sale that relies heavily on the 
supplier, grower, and dispensary to provide the correct product, but there is currently no 
reliable way to verify Cannabis strains. The possibility exists for errors in plant labeling, 
misplacement, misspelling (e.g., “Chem Dog” vs. “Chemdawg”), and/or relabeling along 
the entire chain of production. Although the expectation is that plants are labeled 
carefully and not re-labeled with a more desirable name for a quick sale, these misgivings 
must be considered. Identification by genetic markers has largely eliminated these types 
of mistakes in other widely cultivated crops such as grapes, olives and apples. Modern 
genetic applications can accurately identify varieties and can clarify ambiguity in closely 
related and hybrid species (Costantini et al. 2005; Guilford et al. 1997; Hokanson et al. 
1998; Sarri et al. 2006; United States Department of Agriculture 2014). 
 Matching genotypes within the same strains were expected, but highly similar 
genotypes between samples of different strains could be the result of mislabeling or 
misidentification, especially when acquired from the same source. The pairwise genetic 
relatedness r-values were examined for incidence of possible mislabeling or re-labeling. 
There were instances in which different strains had r-values = 1.0 (Figure 2.4, 2.5), 
indicating clonal genetic relationships. Two samples with matching genotypes were 
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obtained from the same location (“Larry OG” and “Tahoe OG” from San Luis Obispo 3, 
Figure 2.1). This could be evidence for mislabeling or misidentification because these 
two samples have similar names. It is unlikely that these samples from reportedly 
different strains have identical genotypes, and more likely that these samples were 
mislabeled at some point. Misspelling may also be a source of error, especially when 
facilities are handwriting labels. An example of possible misspelling may have occurred 
in the sample labeled “Chemdog 1” from Garden City 1. “Chemdawg 1”, a described 
strain, could have easily been misspelled, but it is unclear whether this instance is 
evidence for mislabeling or renaming a local variant. Inadvertent mistakes may carry 
through to scientific investigation where strains are spelled or labeled incorrectly. For 
example, Vergara et al. (Vergara et al. 2016) reports genome assemblies for “Chemdog” 
and “Chemdog 91” as they are reported in GenBank (GCA_001509995.1), but neither of 
these labels are recognized strain names. “Chemdawg” and “Chemdawg 91” are 
recognized strains (Leafly 2018b; NCSM 2018; PotGuide.com 2018; Seedfinder 2018; 
Wikileaf 2018; Marijuana strains database 2019), but according to the original source, the 
strain name “Chemdawg” is incorrect, and it should be “Chem Dog” (Danko 2016), but 
the name has clearly evolved among growers since it emerged in 1991 (Danko 2016). 
Another example that may lead to confusion is how information is reported in public 
databases. For example, data are available for the reported monoisolate of “Pineapple 
Banana Bubba Kush” in GenBank (SAMN06546749), and while “Pineapple Kush”, 
“Banana Kush” and “Bubba Kush” are known strains (Leafly 2018b; NCSM 2018; 
PotGuide.com 2018; Seedfinder 2018; Wikileaf 2018; Marijuana strains database 2019), 
the only record we found of “Pineapple Banana Bubba Kush” is in GenBank. This study 
has highlighted several possible sources of error and how genotyping can serve to 
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uncover sources of variation. Although this study was unable to confirm sources of error, 
it is important that producers, growers and consumers are aware that there are errors and 
they should be documented and corrected whenever possible. 
Conclusions 
 Over the last decade, the legal status of Cannabis has shifted and is now legal for 
medical and some recreational adult use, in the majority of the United States as well as 
several other countries that have legalized or decriminalized Cannabis. The recent legal 
changes have led to an unprecedented increase in the number of strains available to 
consumers. There are currently no baseline genotypes for any strains, but steps should be 
taken to ensure products marketed as a particular strain are genetically congruent. 
Although the sampling in this study was not exhaustive, the results are clear: strain 
inconsistency is evident and is not limited to a single source, but rather exists among 
dispensaries across cities in multiple states. Various suggestions for naming the genetic 
variants do not seem to align with the current widespread definitions of Sativa, Indica, 
Hybrid, and Hemp (Clarke and Merlin 2013; Hillig 2005). As our Cannabis knowledge 
base grows, so does the communication gap between scientific researchers and the public. 
Currently, there is no way for Cannabis suppliers, growers or consumers to definitively 
verify strains. Exclusion from USDA protections due to the Federal status of Cannabis as 
a Schedule I drug has created avenues for error and inconsistencies. Presumably, the 
genetic inconsistencies will often manifest as differences in overall effects (Minkin 
2014). Differences in characteristics within a named strain may be surprising for a 
recreational user, but differences may be more serious for a medical patient who relies on 
a particular strain for alleviation of specific symptoms. 
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 This study shows that in neutral genetic markers, there is no consistent genetic 
differentiation between the widely held perceptions of Sativa and Indica Cannabis types. 
Moreover, the genetic analyses do not support the reported proportions of Sativa and 
Indica within each strain, which is expected given the lack of genetic distinction between 
Sativa and Indica. Instances were found where samples within strains are not genetically 
similar, which is unexpected given the manner in which Cannabis plants are propagated. 
Although it is impossible to determine the source of these inconsistencies as they can 
arise at multiple points throughout the chain of events from seed to sale, we theorize 
misidentification, mislabeling, misplacement, misspelling, and/or relabeling are all 
possible. Especially where names are similar, there is the possibility for mislabeling, as 
was shown here. In many cases genetic inconsistencies within strains were limited to one 
or two samples. We feel that there is a reasonable amount of genetic similarity within 
many strains, but currently there is no way to verify the “true” genotype of any strain. 
Although the sampling here includes merely a fragment of the available Cannabis strains, 
our results give scientific merit to previously anecdotal claims that strains can be 
unpredictable. 
  
63 
 
 
 
 
 
 
CHAPTER III 
GENETIC VARIATION PART 2: RESEARCH 
GRADE MARIJUANA SUPPLIED BY THE 
NATIONAL INSTITUTE ON DRUG ABUSE 
IS GENETICALLY DIVERGENT FROM 
COMMERCIALLY AVAILABLE 
CANNABIS 
Contributions of Authors and Co-Authors 
 
Manuscript in Chapter IV 
 
Author: Anna Schwabe  
 
Contributions: Conceived the project, collected samples, conducted DNA extractions, 
designed and optimized microsatellite primers, compiled and analyzed data, and drafted 
manuscript content. 
 
Author: Connor Hansen 
 
Contributions: Conducted DNA extractions, compiled and analyzed data, and prepared 
the first draft of the manuscript. 
 
Author: Dr. Richard Hyslop 
 
Contributions: Provided DNA from NIDA samples, contributed manuscript revisions. 
 
Author: Dr. Mitchell McGlaughlin 
 
Contributions: Directed the project, provided some funding, contributed statistical 
analysis and manuscript revisions.
  
64 
 
Abstract 
Public comfort with Cannabis (marijuana and hemp) has recently increased, 
resulting in revisions of previously strict Cannabis regulations to now allow for hemp 
cultivation, medical use, and in some states, recreational consumption. There is a growing 
interest in the potential medical benefits of the various chemical constituents produced by 
the Cannabis plant. Currently, the University of Mississippi, funded through the National 
Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), is the sole Drug 
Enforcement Agency (DEA) licensed facility to cultivate Cannabis for research purposes. 
Hence, most federally funded research where participants consume Cannabis for 
medicinal purposes relies on NIDA supplied product.  Previous research found that 
cannabinoid levels in research grade marijuana supplied by NIDA did not align with 
commercially available Cannabis from Colorado, Washington and California. Given 
NIDA chemotypes were found to misaligned with commercial Cannabis, we sought to 
investigate where NIDA’s research grade marijuana falls on the genetic spectrum of 
Cannabis groups. NIDA research grade marijuana was found to genetically group with 
Hemp samples along with a small subset of commercial drug-type Cannabis. A majority 
of commercially available drug-type Cannabis was genetically very distinct from NIDA 
samples. These results suggested that subjects consuming NIDA research grade 
marijuana may have different effects than average consumers
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Introduction 
Humans have a long history with Cannabis sativa (marijuana and hemp), with 
evidence of cultivation dating back as far as 10,000 years ago (Abel 2013). The World 
Health Organization proclaims Cannabis as the most widely cultivated, trafficked and 
abused illicit drug, and reports over half of worldwide drug seizures are of Cannabis 
(World Health Organization 2018). Phytochemicals of interest in Cannabis are primarily 
Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), both of which 
require a decarboxylation conversion to the biologically active forms, THC and CBD, 
respectively. The United States is currently experiencing drastic changes in patterns of 
Cannabis use associated with widespread relaxation of laws that previously limited both 
medical and recreational marijuana consumption (Cousijn et al. 2018) and hemp 
cultivation. This has led to a need for extensive research into the basic biology and 
taxonomy of Cannabis sativa (Clarke and Merlin 2013; Hillig 2005; Lynch et al. 2016; 
Small 2017; Vergara et al. 2016), and the possible benefits and threats from Cannabis 
consumption (Baron 2018; Cousijn et al. 2018).  
Although Cannabis sativa is the only described species in the genus Cannabis 
(Cannabaceae), there are several commonly described subcategories of Cannabis that are 
widely recognized. There are two primary Cannabis usage groups, which are well 
supported by genetic analyses (Dufresnes et al. 2017; Lynch et al. 2016; Sawler et al. 
2015; Soler et al. 2017): hemp is defined by a lack of THC (< 0.3% THC in the U.S.), 
and marijuana or drug-types have moderate to high THC concentrations (> 0.3% THC in 
the U.S.). Hemp-type Cannabis tends to have higher concentrations of CBD than drug-
types (de Meijer et al. 1992). Drug-type Cannabis usually contains > 12% THC and 
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averages ~ 10-23% THC in commercially available dispensaries (Jikomes and Zoorob 
2018; Potter et al. 2008; Vergara et al. 2017). Within the two major usage groups, 
Cannabis can be further divided into varietals, which are referred to as strains. The drug-
type strains are commonly categorized further: Sativa strains reportedly have uplifting 
and more psychedelic effects, Indica strains reportedly have more relaxing and sedative 
effects, and Hybrid strains, which result from breeding Sativa and Indica strains, have a 
spectrum of intermediate effects. There is extensive debate among experts surrounding 
the appropriate taxonomic treatment of Cannabis groups, which is confounded by 
colloquial usage of these terms versus what researchers suggest is more appropriate 
nomenclature (Clarke and Merlin 2013, 2015; Emboden 1977, 1981; McPartland 2017; 
McPartland and Guy 2017; Small 2015b; Small 2016; Small et al. 1976). Commercially 
available drug-type strains for medical or recreational consumption are labeled with a 
strain name, as well as the levels of THC and often CBD as a percent of the dry weight. 
Genetic analyses have not shown clear and consistent differentiation among the three 
commonly described drug-type strains (Lynch et al. 2016; Sawler et al. 2015), but both 
the recreational and medical Cannabis communities maintain there are distinct 
differences in effects between Sativa and Indica strains (Smith 2012; Leaf Science 2016; 
Leafly 2018b). 
Although Cannabis has been federally controlled since 1937 (1937), many states 
now allow regulated medical (33 states and the District of Columbia) and recreational use 
(10 states and the District of Columbia) (ProCon 2018b). There were > 3.5 million 
registered medical marijuana patients reported as of May 2018 (ProCon 2018a). 
However, the United States Drug Enforcement Agency (DEA) lists Cannabis sativa as a 
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Schedule 1 Substance (United States Congress 1970), and as such, research on all aspects 
of this plant has been limited. U.S. Surgeon General Jerome Adams recently expressed 
concern that the current scheduling in the most restrictive category is inhibiting research 
on Cannabis as a potentially therapeutic plant (Jaeger 2018). A Schedule 1 substance is 
described as a drug with no accepted medical use and a high potential for abuse (United 
States Congress 1970). The University of Mississippi, funded through the National 
Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), currently holds the 
single license issued by the DEA for the cultivation of Cannabis for research purposes 
(National Institute on Drug Abuse 2018). As such, NIDA serves as the sole legal provider 
of Cannabis for federally funded medical research in the United States. Bulk research 
grade marijuana supplied by NIDA is characterized by the level of THC and CBD. They 
offer Cannabis for research with four levels of THC: low (< 1%), medium (1-5 %), high 
(5-10 %) and very high (>10%), with the additional option of four levels of CBD: low (< 
1%), medium (1-5%), high (5-10%) and very high (> 10%). 
The National Institute on Drug Abuse funds a wide range of research on drug-
type Cannabis, including long and short-term effects on behavior, pain, mental illness, 
brain development, use and abuse, and impacts of policy changes related to marijuana 
(National Institute of Health and National Institute on Drug Abuse 2018a; National 
Institute of Health and National Institute on Drug Abuse 2018b). Additionally, the NIH 
provides support for researching cannabinoids as separate constituents. Funding for CBD 
related research is reported as $36M (2015 - 2017) and projected to be $36M for 2018 - 
2019 (National Institute of Health and National Institute on Drug Abuse 2018b), while 
cannabinoid related research is reported as $366M from 2015 - 2017 and projected to be 
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$292M for 2018 - 2019 (National Institute of Health and National Institute on Drug 
Abuse 2018a). 
Recent research has documented that NIDA provided Cannabis has distinctly 
different cannabinoid profiles than commercially available Cannabis (Vergara et al. 
2017). Specifically, Vergara et al. (2017) found that NIDA samples contained only 27% 
of the amount of THC and 48% of CBD levels of commercially available Cannabis. The 
substantial chemical differences between NIDA and commercially available Cannabis 
raises significant questions about whether research conducted with federal Cannabis is 
indicative of the experience consumers are having.  
Medical research on Cannabis primarily focuses on THC and CBD (Baron 2018; 
Borgelt et al. 2013; Citti et al. 2018; Cousijn et al. 2018; Maa and Figi 2014; Minkin 
2014; National Institute of Health and National Institute on Drug Abuse 2018a, 2018b), 
but there are hundreds of other chemical constituents in Cannabis (ElSohly 2007), 
including cannabinoids and terpenes, which have largely been ignored (Baron 2018). 
There is evidence to suggest that chemical constituents in various combinations and 
abundances work in concert in various ways to create the suite of physiological effects 
reported (Baron 2018). The chemical makeup of each variant of Cannabis is influenced 
by the genetic makeup as well as environmental conditions. Given that previous research 
has determined the cannabinoid levels of research grade marijuana from NIDA is 
significantly different from commercially available Cannabis (Vergara et al. 2017), 
genetic investigations are warranted to determine if NIDA Cannabis is genetical distinct 
from other sources. 
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In the current study we investigated the genetic relationship of NIDA provided 
Cannabis to commercially available drug-type strains, as well as feral and cultivated 
hemp. Ten variable nuclear microsatellite regions were used to examine genetic 
differentiation among our samples. Sampling included NIDA (High THC and High 
THC/CBD), high THC drug-type, low THC/high CBD drug-type, wild growing hemp 
(presumed escapees from cultivation), and commercial hemp. This study aimed to 
investigate where research grade marijuana supplied by NIDA falls on the genetic 
spectrum of Cannabis groups.  
Methods 
Sampling 
A total of 49 Cannabis samples were used in this research (Table 7), including: 
wild hemp (5), cultivated hemp (4), NIDA strains (2), high CBD drug-type strains (3), 
and drug-types strains (35). Drug-type strains were further subdivided into three 
commonly used categories: Sativa (11), Hybrid (14), and Indica (10) based on 
information available online (Leafly 2018b; Wikileaf 2018). The drug-type strains were 
randomly chosen from a much larger pool of samples. Duplicate accessions within strains 
were not included.
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Table 3.1. Sampling Information. Sample names, ID code, accession number/ strain name, and the suppliers name and location 
Name ID Code Accession/ Strain Name Supplier Origin City State 
Wild Hemp 1 1019 Hemp 1019 DBG Herbarium Denver Colorado 
Wild Hemp 2 24845 Hemp 24845 Male DBG Herbarium Denver Colorado 
Wild Hemp 3 25572 Hemp 25572 Male DBG Herbarium Denver Colorado 
Wild Hemp 4 22831M Hemp 22831 Male UNC Herbarium Greeley Colorado 
Wild Hemp 5 28381M Hemp 28381 Male DBG Herbarium Denver Colorado 
Wild Hemp 6 UnkM Hemp Unknown Male Cannabis Genomic Research Initiative Boulder  Colorado 
Wild Hemp 7 Cara#2_4 Hemp Cara#2 Cannabis Genomic Research Initiative Boulder  Colorado 
Wild Hemp 8 Carm Hemp Carmagnola Colorado Seed, Caren Kershner Co. Springs Colorado 
Wild Hemp 9 CoGo Hemp Colorado Gold Colorado Seed, Caren Kershner Co. Springs Colorado 
NIDA THC NIDA_THC NIDA High THC Univ. of Mississippi  Mississippi Colorado 
NIDA THC/CBD NIDA_THC-CBD NIDA THC/CBD Univ. of Mississippi  Mississippi Colorado 
Otto (High CBD) Otto1 Otto (High CBD) Centennial Seeds Co. Springs Colorado 
Juanita La Lagrimosa JLL_2 Juanita La Lagrimosa (High CBD) Nature's Herbs and Wellness Garden City Colorado 
Fuck Cancer FuCa Fuck Cancer Matt Kahl Co. Springs Colorado 
Durban Poison DuPo_19 Durban Poison The Kind Room Denver Colorado 
El Dorado ElDo_1 El Dorado Smokey's 420 Garden City Colorado 
Hawaiian Hawa_9 Hawaiian  Best Colorado Meds Fort Collins Colorado 
Sour Diesel SoDi_2a Sour Diesel  Nature's Herbs and Wellness Garden City Colorado 
Island Sweet Skunk ISS_1 Island Sweet Skunk Smokey's 420 Garden City Colorado 
Agent Orange AgOr_1 Agent Orange  Nature's Herbs and Wellness Garden City Colorado 
Cinderella 99 Cin99_1 Cinderella 99 Smokey's 420 Garden City Colorado 
AK-47 AK47_21 AK-47 Herbal Alternative Denver Colorado 
Gorilla Glue #4 GoGl#4_20 Gorilla Glue #4 Colorado Wellness Denver Colorado 
Golden Goat GoGo_19 Golden Goat The Kind Room Denver Colorado 
Green Crack GrCr_2b Green Crack  Nature's Herbs and Wellness Garden City Colorado 
Bruce Banner BrBa_19 Bruce Banner The Kind Room Denver Colorado 
Flo Flo_9 Flo Best Colorado Meds Fort Collins Colorado 
7
0
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Table 3.1. continued 
Name ID Code Accession/ Strain Name Supplier Origin City State 
Pineapple Express PiEx_2 Pineapple Express Nature's Herbs and Wellness Garden City Colorado 
Purple Haze PuHa_22 Purple Haze Lucy Sky Denver Colorado 
White Widow WhWi_1 White Widow Smokey's 420 Garden City Colorado 
Jack Herer JaHe_12 Jack Herer  The Milkman SLO California 
OG Kush OGKu_21 OG Kush Herbal Alternative Denver Colorado 
Blue Dream BlDr_19 Blue Dream The Kind Room Denver Colorado 
Tahoe OG TaOG_11 Tahoe OG KindCare Fort Collins Colorado 
Chem Dawg ChDa_8 Chem Dawg The Station Boulder Colorado 
Banana Kush BaKu_2 Banana Kush Nature's Herbs and Wellness Garden City Colorado 
Chem Dawg D ChDaD_19 Chem Dawg D The Kind Room Denver Colorado 
Girl Scout Cookie GSC_14 Girl Scout Cookie  Day & Night SLO California 
G13 G13_10 G13 Infinite Wellness Fort Collins Colorado 
Lemon Diesel LeDi_2 Lemon Diesel Nature's Herbs and Wellness Garden City Colorado 
Hash Plant HaPl_1 Hash Plant Smokey's 420 Garden City Colorado 
Australian Hash Plant HaPlAu_1 Australian Hash Plant  Smokey's 420 Garden City Colorado 
Bubba Kush 98 Bub98_19 Bubba Kush The Kind Room Denver Colorado 
Mother of Berries MoBe_2 Mother of Berries Nature's Herbs and Wellness Garden City Colorado 
Northern Lights NoLi_15 Northern Lights CannaExpress SLO California 
Grape Ape GrAp_16 Grape Ape Slow Burn Union Gap Washington 
Purple Kush PuKu_19 Purple Kush The Kind Room Denver Colorado 
Toro Bora  ToBo_4 Toro Bora  Cannabis Genomic Research Initiative Boulder Colorado 
      
7
1
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Deoxyribonucleic Acid Extraction 
Deoxyribonucleic acid was extracted using a modified CTAB extraction protocol 
(Doyle 1987) with 0.035- 0.100 grams of dried flower tissue per extraction. The 
Cannabis draft genome from ‘Purple Kush’ (GenBank accession AGQN00000000.1) was 
scanned for microsatellite repeat regions using MSATCOMMANDER-1.0.8-beta 
(Faircloth 2008). Primers were developed de-novo flanking thirty microsatellites with 3-6 
nucleotide repeat units and optimized for temperature and magnesium concentration. One 
primer in each pair was tagged with a 5’ universal sequence (M13, CAGT or T7) so that a 
matching sequence with a fluorochrome tag could be incorporated via PCR following the 
protocol of Schwabe et al. (2013). Microsatellite primers were optimized (Table 2.4) 
(Schwabe and McGlaughlin 2018), and ten loci were amplified and analyzed using the 
Microsatellite Analysis External Plugin ver. 1.4.5 (Biomatters Ltd.) in GENEIOUS ver. 
8.1.8 (Biomatters Ltd.).  
Statistical Analyses 
GENALEX ver. 6.4.1 (Peakall and Smouse 2006; Peakall and Smouse 2012) was 
used to calculate pairwise genetic differentiation (FST) and Nei’s genetic distance (D) 
between each of the six groups. PCoA eigenvalues calculated in GENALEX were used to 
plot the PCoA in RStudio with the ggplot package (R Studio Team 2015) with 95% 
confidence intervals ellipses. GENALEX was also used to generate a pairwise genetic 
distance square matrix which was then used to generate a hierarchical cluster analysis 
dendrogram with Ward’s method and Euclidean Genetic distance parameters in PC-ORD 
(McCune and Mefford 1999).  
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Genotypes were analyzed using the Bayesian cluster analysis program 
STRUCTURE ver. 2.4.2 (Pritchard et al. 2000). Burn-in and run-lengths of 50,000 
generations were used with ten independent replicates for each STRUCTURE analysis. 
The number of genetic groups for the data set was determined by STRUCTURE 
HARVESTER (Earl and vonHoldt 2012), which implements the Evanno et al. method 
(Evanno et al. 2005).  
Maverick v1.0.5 (Verity and Nichols 2016) was used as an additional verification 
of Bayesian clustering analysis using thermodynamic integration to determine the 
appropriate number of genetic groups. The following parameters were used: admixture 
parameter (alpha) of 0.03 with a standard deviation (alphaPropSD) of 0.008, 10 replicates 
(mainRepeats), 1,000 Burn-in iterations (mainBurnin), 5,000 sample iterations 
(mainRepeats), 100 TI rungs (thermodynamicRungs), 500 TI Burn-in iterations 
(thermodynamicBurnin), and 1,000 TI iterations (thermodynamicSamples).  
EDENetworks ver. 2.18 (Kivela et al. 2015) was used to construct a web of 
genetic relationships using the Linear Manhattan distance measure. Auxiliary data were 
imported to maintain the spatial coordinates and to color individuals by group 
assignment. The automatic percolation threshold was first derived, and threshold was set 
to 8.1. Networks were generated for subsequent iterative threshold intervals of 0.5. 
Increasing the threshold lowers the stringency for genetic relationships, and as the 
threshold increases, more relationships are formed in the network. EDENetworks 
diagrams were constructed for the percolation threshold of 8.1, 8.5, 13.7 and 16.9. These 
are the values that connect: NIDA samples to each other, but not to any other samples in 
the data set (8.5), connect a single NIDA sample to the larger network (13.7), and finally 
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connect all samples in the network (16.9). The size of each node is proportionate to the 
number of relationship connections to other members in the network. The line color and 
width indicated the strength of the relationship between two individuals- lighter thicker 
lines indicate stronger genetic relationships, while the darker thinner lines indicate 
weaker genetic relationships. 
Results 
Our analyses examined the genetic differentiation and structure of samples from 
six groups: 1) NIDA – research grade marijuana samples obtained from NIDA classified 
as High THC or High THC/CBD; 2) Hemp – Cannabis obtained from hemp cultivators 
and feral collected hemp; 3) High CBD – drug-type Cannabis with relatively high levels 
of CBD and low levels of THC; and commercially available drug-type Cannabis 
described as 4) Sativa, 5) Hybrid, or 6) Indica strains. Analyses were also performed on 
samples at the individual level to control for biases that might arise due to the potential 
artificial nature of named groups and varying group sample sizes.   
Genetic Differentiation 
Pairwise genetic differentiation (Fst and Nei’s D) calculated in GENALEX ver. 
6.4.1 (Peakall & Smouse 2006, Peakall & Smouse 2012) found the highest level of 
divergence between hemp and high CBD drug-type strains (Fst = 0.215) and between 
hemp and Sativa drug-type strains (Nei’s D = 0.614) (Table 8). The least divergence was 
observed among the drug-type strains (Fst = 0.023-0.04; Nei’s D = 0.66-0.109) (Table 
3.2).  
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Table 3.2. Genetic Differentiation. Pairwise Fst values (below the diagonal) and 
Nei’s D (above the diagonal) for major Cannabis groups. 
 
NIDA Hemp High CBD Sativa Hybrid Indica 
NIDA 
 
0.519 0.527 0.553 0.48 0.441 
Hemp 0.120 
 
0.489 0.614 0.585 0.459 
High CBD 0.166 0.215 
 
0.329 0.310 0.281 
Sativa 0.114 0.160 0.137 
 
0.098 0.109 
Hybrid 0.117 0.149 0.135 0.04 
 
0.066 
Indica  0.078 0.124 0.121 0.035 0.023 
 
 
Clustering Analysis 
Principal Coordinate Analysis (PCoA) was conducted in GENALEX and plotted 
in R Studio with the ggplot package (R Studio Team 2015) with 95% confidence interval 
ellipses around the major groups (Figure 8). No confidence intervals were drawn for 
NIDA (n = 2) or High CBD (n = 3) due to small sample size. Coordinate 1 explains 
13.26% of the genetic variation and an additional 11.39% of the genetic variation is 
explained by coordinate 2. The drug-type strains (Indica, Sativa, Hybrid, and High CBD) 
all occupy the same character space. There is clear separation of hemp samples from the 
drug-types, with NIDA samples clustering within the hemp confidence interval.  
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Figure 3.1. Principal Coordinates Analysis. 95% confidence intervals are around the 
major groups (hemp = yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid = 
green, Indica = purple). Approximately 25% of the genetic variation in these groups is 
shown (coordinate 1= 13.26% and coordinate 2 = 11.39%). No confidence intervals were 
drawn for NIDA or High CBD samples due to the small sample size (n = 2 and n = 3, 
respectively).  
 
PC-Ord version 6 (McCune and Mefford 1999) was used to generate a 
dendrogram with Ward’s method and Euclidean Genetic distance parameters based on 
pairwise genetic distance values generated in GENALEX (Figure 3.2). The initial 
branching split the samples into two clusters, A and B. Cluster A contains all but one 
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hemp sample (88%), as well as the NIDA samples (100%) and two drug-type samples 
(5%). Cluster B contains the remaining drug-type samples (95%) and one hemp sample 
(12%). Cluster B further branches into three clusters (C, D, and E), where Sativa, Hybrid 
and Indica drug type strains are dispersed throughout. 
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Figure 3.2. PC-Ord group linkage dendrogram. Samples are color-coded (Hemp = 
yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid = green, Indica = 
purple).  
A
B
D
E
C
Wild Hemp 4
Wild Hemp 1
NIDA THC
NIDA THC/CBD
Colorado Gold
Wild Hemp 5
Durban Poison
Hash Plant
Wild Hemp 2
Wild Hemp 3
Unknown Male Hemp
Carmagnola
C. ruderalis
Juanita La Lagrimosa
Fuck Cancer
Bruce Banner
OG Kush
Grape Ape
Hawaiian
Otto
Jack Herer
Pineapple Express
Mother of Berries
Purple Haze
Australian Hash Plant
Cinderella 99
Green Crack
Golden Goat
Island Sweet Skunk
Blue Dream
Jilly Bean
Flo
G13
Agent Orange
Lemon Diesel
Northern Lights
AK-47
White Widow
Sour Diesel
Chem Dawg D
Gorilla Glue #4
Eldorado
Girl Scout Cookies
Banana Kush
Tahoe OG
Bubba Kush 98
Chem Dawg
Purple Kush
Tora Bora
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STRUCTURE ver. 2.4.2 (Pritchard et al. 2000) was used to examine sample 
assignment to genetic groups while allowing admixture. The appropriate number of 
STRUCTURE groups was validated using STRUCTURE HARVESTER (Earl and 
vonHoldt 2012), which had high support two genetic groups (K = 2, ∆K = 67.68) and 
weak support for three genetic groups (K = 2, ∆K = 4.48) (Figure 3.3).  
 
Figure 3.3. STRUCTURE HARVESTER graph showing high support for two 
genetic groups (K = 2, ∆K = 67.68). There is weak support for three genetic groups (K = 
2, ∆K = 4.48). 
 
Additionally, MavericK 1.0.5 (Verity and Nichols 2016) was used to independently test 
group assignments, which also had strong support for two genetic groups (K = 2, 
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probability 0.901) and weaker support for three genetic groups (K = 3, probability 0.097) 
(Figure 3.4), with the sample assignments matching STRUCTURE.  
 
Figure 3.4. MavericK 1.0.5 thermodynamic integration evidence estimates 
normalized to a sum of 1.0.  
 
The two genetic group STRUCTURE analyses (Figure 3.5) show consistent 
differentiation between hemp and drug-type strains.  All hemp samples were assigned to 
genetic group 1 (yellow) with a proportion of inferred ancestry (Q) greater than 0.82 
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(hemp mean group 1, Q = 0.94). Drug-type samples showed some admixture with the 
majority of the genetic signal of 31 samples (82%) being assigned to genetic group 2 
(drug-type mean group 2, Q = 0.72). NIDA samples were assigned to genetic group 1 
(NIDA mean group 1, Q = 0.97), demonstrating a strong association with hemp. 
Although not strongly supported, the three genetic group analysis shows some additional 
genetic structure among drug-type strains.  
 
   
Figure 3.5. Bayesian clustering analysis from STRUCTURE. The proportion of 
inferred ancestry for two genetic groups (K = 2, top), and for three genetic groups (K = 3, 
bottom). 
 
 
 
K=2
K=3
  
82 
 
Genetic Relatedness Network 
EDENetwork ver. 2.18 (Kivela et al. 2015) was used to generate a web of genetic 
relationship based on pairwise linkages (Figure 3.6). The automatically selected 
percolation threshold was 8.1 (Figure 3.6A), although not all individuals were connected 
at this level. The threshold was raised iteratively to connect more divergent samples and 
explore larger patterns of genetic relationships. The two NIDA samples were united at a 
threshold of 8.5 (Figure 3.6B). When the threshold was raised to 13.7 (Figure 13C) the 
NIDA samples become connected to the network via the drug-type sample Eldorado. At a 
threshold level of 16.9 (Figure 3.6D) all samples in the data set are included in the 
relationship network.
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Figure 3.6. EDENetworks genetic relationship network with incrementally decreasing stringency of required genetic relatedness among samples in the 
data set. (A) Threshold 8.1: the percolation threshold determined by the analysis. (B) Threshold 8.5: the threshold required to connect NIDA samples to each 
other, but not to any other samples in the data set. (C) Threshold 13.7: the threshold necessary to connect the NIDA sample to the larger network with the 
connection via the drug-type strain Eldorado. (D) Threshold 16.9: the required threshold to connect all samples in the network. Nodes are colored to indicate 
group designation (Hemp = yellow, NIDA = blue, High CBD = orange, Sativa = red, Hybrid = green, Indica = purple). Node size is proportionate to the number 
of connections to that individual within the network. Lines thinner and lighter in color indicate weak genetic relationships, while thicker darker lines indicate 
stronger relationships. 
8
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Discussion 
The purpose of this study was to examine the genetic relationship of Cannabis 
samples from the National Institute on Drug Abuse (NIDA) to hemp and drug-type 
samples. Our results clearly demonstrate that NIDA Cannabis samples are substantially 
different from most commercially available drug-type strains, sharing a genetic affinity 
with hemp samples in most analyses. Previous research has found that medical and 
recreational Cannabis from California, Colorado and Washington, differs significantly in 
cannabinoid levels from the research grade marijuana supplied by NIDA (Vergara et al. 
2017). Our genetic investigation adds to this previous research, indicating that the genetic 
makeup of NIDA Cannabis is also distinctive from commercially available medical and 
recreational Cannabis.  
The genetic data collected in this study indicates that two major genetic groups 
exist within Cannabis sativa. The first group contained a majority of hemp (88 - 100%, 
depending on analysis) and both NIDA samples (100%), while the second group 
contained a majority of drug-type samples (82 - 95%). These results contribute to the 
growing consensus that hemp and drug-type Cannabis can be consistently differentiated 
(Datwyler and Weiblen 2006; Dufresnes et al. 2017; Forapani et al. 2001; Hakki et al. 
2007; Lynch et al. 2016; McPartland 2006; Sawler et al. 2015; Soler et al. 2017). This is 
the first genetic study to include research grade marijuana from NIDA, and its placement 
with hemp samples was unexpected. However, it is important to note that some drug-type 
samples (e.g. Durban Poison, Figure 3.2, 3.4) are also placed in the hemp group. 
Although the sample size of NIDA samples could impact their placement in group-based 
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analyses such as genetic distances (Table 3.2), all other analyses were carried out at an 
individual level (Figure 3.1, 3.2, 3.4, 3.5) to avoid this issue.  
According to the University of Mississippi National Center for Natural Products 
Research (NCNPR), which produces research grade marijuana for NIDA, the first 
experimental plots of Cannabis were planted in 1968 with seeds from “Mexico, Panama, 
Southeast Asia, Korea, India, Afghanistan, Iran, Pakistan, and Lebanon” (Khan 2018; 
University of Mississippi 2017). Over the next decade, cultivation techniques were 
standardized, with over 100 varieties planted in 1976 (University of Mississippi 2017). 
Between the late 1970’s and today, the University of Mississippi has continued to be the 
sole producer of research grade marijuana for NIDA, and it has refined cultivation 
techniques and extraction procedures, particularly for THC and CBD (Mississippi 2017). 
The program does not provide variety or strain information when filling Cannabis orders, 
so it is unclear what is currently grown by NCNPR for federally funded marijuana 
research. The NCNPR director recently stated that “The marijuana project currently 
stocks 27 plant varieties with different cannabinoid profiles, various CBG potencies, and 
a wide range of THC levels” (Khan 2018). However, the NCNPR website states that only 
three Cannabis varieties were grown in 2014 (University of Mississippi 2017). Our data 
suggest that the NIDA Cannabis analyzed in this study was sourced from a single strain 
or two very closely related strains within the NCNPR stock. Without additional 
information about NCNPR Cannabis production, it is difficult to know how many strains 
are being used in research 
This study indicates the need for additional research and refinement of our 
understanding of Cannabis genetic structure and how those difference might impact 
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Cannabis consumers. Although medicinal research on Cannabis has predominantly 
focused on THC and CBD (Baron 2018; Borgelt et al. 2013; Citti et al. 2018; Cousijn et 
al. 2018; Maa and Figi 2014; Minkin 2014; National Institute of Health and National 
Institute on Drug Abuse 2018a, 2018b), it is becoming apparent that other chemical 
constituents in various combinations and abundances likely have important effects (Baron 
2018). If researchers are solely interested in the effects of THC and CBD at know 
concentrations, then NIDA Cannabis could serve as a representative source, although in 
these cases, isolates of these molecules may be more appropriate. However, given the 
genetic distinction between NIDA and commercially available Cannabis, patients in 
federally funded Cannabis research are likely experiencing effects that are specific to the 
plant material provided by NIDA. As the interest for medical Cannabis increases, it is 
important that research examining the threats and benefits of Cannabis use accurately 
reflect the experiences of the general public.  
Given the rapidly changing landscape of Cannabis regulations and consumption 
(ProCon 2018b), it is not surprising that commercially available Cannabis contains a 
diversity of genetic types. Commercially available Cannabis has come to market through 
non-traditional means leading to many inconsistencies. We have previously documented 
(Schwabe and McGlaughlin 2018) that there is substantial genetic divergence among 
samples within named strains, which only exacerbates questions about the impacts of 
Cannabis consumption. This calls to increase regulation and consistency within the 
Cannabis marketplace, and the need for research grade Cannabis to accurately represent 
what consumers have access to. 
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Conclusion 
In conclusion, this study highlights the genetic difference between research grade 
marijuana provided by NIDA and commercial Cannabis available to medical and 
recreational users. This finding highlights that research conducted with NIDA Cannabis 
may not be indicative of the effects that consumers are experiencing. Additionally, 
research has found that Cannabis distributed by NIDA has lower levels of the principal 
medicinal cannabinoids (THC and CBD) and higher levels of degradation byproducts of 
cannabinoids (cannabinol, CBN) (Vergara et al. 2017). Taken together, these results 
demonstrate the need for there to be greater diversity of Cannabis available for medical 
research and that the genetic provenance of those samples to be established to fully 
understand the implications of results. 
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Abstract 
 
 There are thousands of Cannabis varietals (strains) which are generally described 
based on psychotropic effects and phytochemical profile. Recent research has found that 
aroma profiles are distinctive among strains, but also that multiple accessions of the same 
strain from different sources show genetic inconsistencies. Genetic variation may lead to 
differences in consumer-relevant phenotypic traits such as terpene content, and therefore 
differences in aroma. By combining molecular genotyping and olfactory phenotyping 
techniques, we sought to determine whether genetically inconsistent samples within a 
commercial strain display inconsistent aroma profiles. We genotyped 42 samples from 
five strains to determine the consensus genotype as well as genetic outliers (if any) based 
on 10 variable microsatellite regions. Results were used to select four strains (15 
samples) for olfactory testing: “Blue Dream” (5), “OG Kush” (4), “Mob Boss” (3), and 
“Durban Poison” (3). A genetic outlier sample was included for each strain except 
“Durban Poison”, which served as a control where all samples had an identical genetic 
profile. Aroma profiles were produced by 55 untrained sniff panelists (33 men, 22 
women) using check-all-that-apply ballots with 40 previously validated odor descriptors. 
The sensory aroma profile for the “Mob Boss” genetic outlier was at odds with the 
consensus samples as well as the strain’s previously observed aroma profile. All “OG 
Kush” samples displayed the strain-typical aroma profile previously described, but the 
genetic outlier expressed a high-scoring yet atypical “cheese” note. The pungent, 
chemical, and skunk descriptors were reported far more often in the “Blue Dream” 
genetic outlier than the for the consensus samples. Although all three samples of “Durban 
Poison” were genetically identical, the scent profiles do not seem to follow a particular 
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pattern, which could be due to different growing, curing, storing or age differences 
among dispensaries. It appears that within-strain differences identified by microsatellite 
genotyping are associated with differences in aroma profile. 
Introduction 
 Cannabis has been domesticated and cultivated for millennia for fiber, seed and 
the psychotropic qualities of Δ9-tetrahydrocannabinol (THC) from the female flower 
(Clarke and Merlin 2015; Small 2015a; Small 2016, 2017).  Recent legalization in many 
states (National Conference of State Legislatures 2018) and a handful of countries 
worldwide has created a flourishing retail industry. Marijuana Business Daily estimates 
retail Cannabis sales in the U.S. may reach as high as $7.3 billion in 2019 (Marijuana 
Business Daily 2017). Currently, there are thousands of described strains (Leafly 2018b; 
NCSM 2018; PotGuide.com 2018; Wikileaf 2018) sold as dried flower “buds” that vary 
in levels of psychotropic cannabinoids and also emit characteristic aromas. The aroma of 
Cannabis is striking and quite unique, and, while some find the odor quite overwhelming 
and noxious, many people enjoy the aroma and appreciate the subtle nuances among 
strains. The subtleties underlying the characteristic earthy skunky odor of Cannabis often 
contribute to the multitude of creative strain names. “Sour Diesel” as one can imagine is 
pungent and possesses a characteristic diesel aroma. Strains with names such as “Cherry 
Pie”, “Lemon Haze”, “Lavender” and “Banana Kush” lend a suggestion as to their scent.  
Aromatic terpene molecules in various combinations and abundances are 
responsible for creating unique odors associated with Cannabis. The terpene profile of 
each plant is the result of genotype and environmental conditions (Elzinga et al. 2015), is 
variable over time as the plant matures (Aizpurua-Olaizola et al. 2016) and is also 
  
91 
 
presumably impacted by differences in curing (drying) techniques, and time in storage. 
Chemical profile, including terpene profile, has been suggested as a possible mechanism 
of identification for Cannabis cultivars (Casano et al. 2011). Presumably, like other 
plants such as grapes (de Boubee et al. 2000; Jackson and Lombard 1993) and hops 
(Patzak et al. 2010; Pavlovic et al. 2012; Sharp et al. 2014), phytochemical production in 
Cannabis is influenced by soil, nutrients, temperature, carbon dioxide, and light, among 
other environmental factors (Figueiredo et al. 2008). Since chemical profiles change over 
time, and there are no standard growing conditions yet defined for the Cannabis industry, 
it is unclear if differences in aromatic profiles are due to changes in terpenes over time 
and/or differences in growing conditions, or perhaps a reflection of genetic variation, or a 
combination of variables. Steep Hill (Steep Hill Analytics and Research, Berkeley CA) 
has produced “strain fingerprints” for multiple strains, which are chemical profiles that 
reportedly characterize ranges of cannabinoids and terpenes specific to strains. The strain 
fingerprints were initially published on the online strain database Leafly providing details 
about the levels of seven cannabinoids (THC,CBD, CBN, CBG, THCV, CBC, and CBL) 
and five terpenes (linalool, -myrcene, a-pinene, D-limonene, and -caryophyllene), but 
they have since been replaced with a set of three icons that describe the dominant flavors 
of the strain (Leafly 2018b). For example, “Green Crack” flavors are described as earthy, 
citrus and sweet (Leafly 2018b). 
With the legalization of marijuana in many jurisdictions, expert cultivators and 
connoisseurs are emerging. Cultivators are crossing strains and creating a wide diversity 
of new strains with an array of aromas and taste profiles. Competitions, such as the 
Cannabis Cup, allow cultivators to present and connoisseurs to judge aromas, effects, and 
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quality of novel strains. Retail experts, such as behind-the-counter personnel referred to 
as “budtenders”, ideally have knowledge about strains and their unique characteristics, 
especially those in high demand. Scent profiles within a strain should be highly similar, 
as they are labeled as the same product, presumably with similar genotypes. Several 
recent genetic studies (Lynch et al. 2016; Sawler et al. 2015; Schwabe and McGlaughlin 
2018; Soler et al. 2017) have found genetic differences among samples within Cannabis 
strains, which is interesting as Cannabis strains are often produced through cloning 
methods. Cloning propagation in the legal Cannabis industry is often preferred over seed 
germination for several reasons, arguably the most important being the ability to produce 
consistent products for consumers. Although genetic variation can result in phenotypic 
variation, the extent to which genetics might play a role in Cannabis strain aroma was 
previously unknown. Similarities in phenotype, including scent profile, may be a factor 
leading to misidentification and could be one reason why variation in genetic profiles has 
been found within strains.  
Previous work has identified two dominant aroma groups among a small number 
of retail strains (Gilbert and DiVerdi 2018). These two groups were described as Cluster 
A with earthy, woody and herbal aromas, and Cluster B with citrus, lemon, sweet and 
pungent aromas (Gilbert and DiVerdi 2018). This study included duplicate samples of 
two strains, “Durban Poison” and “G13”, and both accessions of “G13” fell within 
Cluster A, while both accessions of “Durban Poison” fell in Cluster B. The “Durban 
Poison” samples were purchased from different dispensaries and were separated from one 
another in the cluster. The two “G13” samples were purchased from the same dispensary 
and had the same harvest date. These samples grouped together as having highly similar 
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profiles in Cluster A. The researchers were investigating olfactory lexicons to 
characterize Cannabis strains available in the recreational market, but the results raised 
some interesting questions in light of recent genetic research. 
We wondered if genetically anomalous samples labeled as the same strain would 
have different detectable odors from those that were genetically cohesive. We 
purposefully identified genetic outliers in a set of otherwise genetically cohesive samples 
obtained from multiple sources to determine if genetic anomalies are detected through 
validated sensory methods. In order to assess if genetic anomalies within a strain have 
different aromas, molecular genotyping and olfactory phenotyping techniques were 
combined in a two-part study. Based on previous research (Schwabe and McGlaughlin 
2018), we determined that in order to maximize our chances of capturing both a 
consensus and outlying genetic profile, 6-10 samples needed to be collected from 
different retail facilities. Five strains were chosen based on reported availability at 
dispensaries and aromatic profile clusters previously described by Gilbert and DiVerdi 
(2018). Forty-two samples from five strains were genotyped using ten previously 
published variable short repeating regions of DNA (microsatellites) (Schwabe and 
McGlaughlin 2018) to determine the consensus genotype and find genetic outliers (if 
any). For the sensory portion, we predetermined that 15 samples were needed in order to 
obtain reliable results and not present too many samples in a single setting. These two 
combined studies aim to demonstrate whether or not genetic anomalies within strains 
have different odors from samples with a highly similar genotype.  
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Methods 
Genetic Methods 
Strain selection. Recreational dispensary strain information was researched 
online (Weedmaps 2018) to determine which strains were most likely to be available 
from multiple sources. Online scent profiles (Leafly 2018b) were examined to select a 
subset of strains with reportedly unique scent profiles in order to minimize aromatic 
similarity of the strains to include in the olfactory analysis. Fifteen strains were cross-
referenced with the results from Gilbert and DiVerdi (2018), and five strains were chosen 
based on reported availability at dispensaries and aromatic profile (Table 4.1). “Durban 
Poison” was selected as having an aromatic profile representative of the citrus, lemon, 
sweet, pungent group (Cluster B) (Gilbert and DiVerdi 2018). “OG Kush” is reportedly 
unique in both genetic and aromatic profiles (Elzinga et al. 2015; Gilbert and DiVerdi 
2018; Leafly 2018b) and was selected as having an aromatic profile representative of the 
earthy, woody, herbal group (Cluster A) (Gilbert and DiVerdi 2018). “Sour Diesel” was 
chosen as it was previously observed to have aromatic properties of both groups (Clusters 
A and B) (Gilbert and DiVerdi 2018) and is described online as earthy, pungent, and 
diesel (Leafly 2018b). “Blue Dream” had not previously been analyzed for aromatic 
profile. However, because the online odor descriptors of berry, blueberry, and sweet 
(Leafly 2018b) indicated this strain might be unique compared to the others, it was 
chosen for inclusion in the olfactory perception analysis. During sample acquisition, 
“Mob Boss” was available at many locations, so it was collected in addition to the 
previously chosen strains. Gilbert and DiVerdi (2018) placed “Mob Boss” in the earthy, 
woody, herbal group (Cluster A) (Gilbert and DiVerdi 2018). Both “Mob Boss” and “OG 
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Kush” have the same earthy, pine, and woody descriptors described online (Leafly 
2018b). 
Table 4.1. The number of samples of five selected Cannabis strains. The 
Scent Cluster assignment (Gilbert & DiVerdi 2018), and the Leafly database 
scent profile (Leafly 2018b). 
Strain Sample number Scent Cluster  Leafly 
Durban Poison 8 B earthy, pine, sweet 
OG Kush 8 A earthy, woody, pine 
Sour Diesel 10 A/B diesel, pungent, earthy 
Blue Dream 10 unknown sweet, berry, blueberry 
Mob Boss 6 A pine, pungent, sweet 
(A) earthy, woody, herbal (B) citrus, lemon, sweet, pungent  
 
Genetic material. A total of 42 retail Cannabis samples were purchased from 25 
recreational Cannabis dispensaries in six Colorado cities (Table 4.2). The names for each 
dispensary have been withheld to protect the identity of businesses where genotypes may 
deviate from the norm. The locations of the dispensaries in this experiment were chosen 
based solely on the availability of strains. A minimum of six samples of each strain were 
collected. All samples were purchased legally over-the-counter. The dispensary weighed 
2 grams of each sample, and these samples are labeled as ‘SN’, indicating eligibility for 
the scent analysis in the olfactory portion of this study. Additional samples were added to 
the genetic study, labeled as ‘GN’, in order to capture the variation contained in a strain, 
without the intention of using them in the olfactory portion of this study. Purchase 
receipts and original packaging labels were retained for reference.  
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Table 4.2. Information for all samples included in the genetic portion of this 
study. 
Strain Location Date Acquired Sample ID 
Durban Poison Denver Aug 7 2018 DuPo_1SN 
 Denver Aug 7 2018 DuPo_2SN 
 Denver Aug 7 2018 DuPo_3SN 
 Denver Aug 7 2018 DuPo_4SN 
 Fort Collins Aug 6 2018 DuPo_5SN 
 Garden City Aug 7 2018 DuPo_6SN 
 Breckenridge May 9 2018 DuPo_7GN 
  Garden City April 28 2018 DuPo_8GN 
OG Kush Denver Aug 7 2018 OGKu_1SN* 
 Denver Aug 7 2018 OGKu_2SN 
 Fort Collins Aug 6 2018 OGKu_3SN 
 Denver Aug 7 2018 OGKu_4SN* 
 Denver Aug 9 2018 OGKu_5SN* 
 Denver Aug 9 2018 OGKu_6SN 
 Denver Aug 9 2018 OGKu_7SN 
  Denver Aug 7 2018 OGKu_8GN 
Sour Diesel Denver Aug 7 2018 SoDi_1SN 
 Denver Aug 7 2018 SoDi_2SN 
 Denver Aug 7 2018 SoDi_3SN 
 Fort Collins Aug 6 2018 SoDi_4SN 
 Garden City Aug 6 2018 SoDi_5SN 
 Garden City Aug 7 2018 SoDi_6SN 
 Denver Aug 7 2018 SoDi_7SN 
 Frisco May 9 2018 SoDi_8GN 
 Breckenridge May 9 2018 SoDi_9GN 
  Frisco May 9 2018 SoDi_10SN 
Blue Dream Denver Aug 7 2018 BlDr_1SN 
 Denver Aug 7 2018 BlDr_2SN 
 Denver Aug 7 2018 BlDr_3SN 
 Denver Aug 7 2018 BlDr_4SN 
 Fort Collins Aug 6 2018 BlDr_5SN 
 Garden City Aug 6 2018 BlDr_6SN 
 Denver Aug 9 2018 BlDr_7SN 
 Breckenridge May 9 2018 BlDr_8GN 
 Frisco May 9 2018 BlDr_9GN 
  Breckenridge May 9 2018 BlDr_10GN 
Mob Boss Denver Aug 7 2018 MoBo_1SN 
 Denver Aug 7 2018 MoBo_2SN 
 Denver Aug 7 2018 MoBo_3SN 
 Denver Aug 7 2018 MoBo_4SN 
 Fort Collins Aug 7 2018 MoBo_5SN 
  Boulder Aug 8 2018 MoBo_6SN 
*Labeled with the same grower and same lot number 
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Deoxyribonucleic acid extraction, Polymerase Chain Reaction and fragment 
analysis. Deoxyribonucleic acid was extracted using a modified CTAB extraction 
protocol (Doyle 1999) with 0.035-0.100 g of dried flower tissue per extraction. Ten 
primers developed de-novo from the ‘Purple Kush’ genome were used to amplify DNA 
fragments containing variable microsatellite regions as described in Chapter II (Schwabe 
and McGlaughlin 2018).  
Genetic statistical analysis. GENALEX ver. 6.4.1 (Peakall and Smouse 2006; 
Peakall and Smouse 2012) was used to calculate Lynch & Ritland (Lynch and Ritland 
1999) mean pairwise genetic relatedness (r) within each strain. A genetic pairwise 
relatedness heat map for each strain was generated in Microsoft EXCEL. Samples with 
identical genotypes share 100% genetic identity (r-value = 1.00), first order relatives (full 
siblings or mother-daughter) share 50% genetic identity (r-value = 0.50), second order 
relatives (half siblings or cousins) share 25% genetic identity (r-value = 0.25), and 
unrelated individuals are expected to have an r-value of 0.00 or lower.  PCoA 
eigenvalues were calculated in GENALEX and plotted in RStudio (R Studio Team 2015) 
with the ggplot package (Wickham 2016) with 95% confidence interval ellipses. 
GENALEX was also used to generate a pairwise genetic distance square matrix to 
generate a hierarchical cluster analysis dendrogram with Ward’s method and Euclidean 
Genetic distance parameters in PC-ORD (McCune and Mefford 1999). Genotypes were 
analyzed using the Bayesian cluster analysis program STRUCTURE ver. 2.4.2 (Pritchard 
et al. 2000). Burn-in and run-lengths of 100,000 generations were used with ten 
independent replicates for each STRUCTURE analysis. STRUCTURE HARVESTER 
(Earl and vonHoldt 2012), which implements the Evanno et al. (2005) method, was used 
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to determine the K value that best describes the number of genetic groups for the data set. 
Missing data for seven of ten “Blue Dream” samples at one locus did not change the 
results when removed, therefore all analyses in GENALEX and STRUCTURE were 
conducted using ten loci. 
Sample selection. The samples included in the sensory portion of this study were 
chosen based on the results of the genetic analysis (see Genetic Results section). The 
“Sour Diesel” samples obtained for this study did not have enough genetic variation in 
any of the samples to be considered for the sensory portion. The selected samples were 
assigned a random identification number for the double-blind olfactory study (Table 4.3). 
Neither the study conductor nor the participant was provided information to disclose the 
name of the strain. 
Table 4.3. Samples used in the olfactory study. The Sample ID is included with 
genetic outliers identified with and asterisk and the random Sample Code.  
Strain Sample ID Sample Code 
Durban Poison DuPo_1SN 245 
 DuPo_4SN 351 
  DuPo_5SN 403 
OG Kush OGKu_1SN* 584 
 OGKu_2SN 752 
 OGKu_3SN 781 
  OGKu_4SN 437 
Blue Dream BlDr_1SN 925 
 BlDr_3SN* 116 
 BlDr_4SN 700 
 BlDr_5SN 307 
  BlDr_6SN 312 
Mob Boss MoBo_1SN 187 
 MoBo_3SN 482 
  MoBo_5SN* 659 
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Sensory Methods 
Odor Stimuli  
Odor stimuli consisted of 15 cannabis samples drawn from four strains: “Durban 
Poison” (3), “OG Kush” (4), “Blue Dream” (5), “Mob Boss” (3). Each stimulus (1 g of 
dried cannabis flower) was presented in a wide mouth 118 mL (4 oz) amber glass bottle 
labeled with a three-digit code (Figure 4.1). Samples were kept in a freezer at -2° C and 
thawed at room temperature for two hours before testing. The stimuli were exchanged for 
fresh samples midway through the study. Our use of strain designations provided by the 
retail dispensaries was a matter of convenience; it does not imply a position regarding the 
taxonomic validity or botanical derivation of these strains. Our goal was to characterize 
olfactory variation in commercially available offerings. 
 
Figure 4.1. Samples (1 gram) of dried Cannabis flower. Samples were presented to 
participants in wide mouth 118 mL (4 oz) amber glass bottles labeled with a three-digit 
code. 
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Odor Descriptors  
 
Forty odor descriptors were chosen from online sources that describe 
characteristic scents for strains (Gilbert and DiVerdi 2018; Leafly 2018b) (Table 4.4). 
Due to the wide variety of strains and descriptive scent characters, the selection aimed to 
include the majority of previously detected odors in a variety of Cannabis strains (Gilbert 
and DiVerdi 2018). 
 
Table 4.4. The 40 odor descriptors used to characterize the samples in this study in 
alphabetical order. 
 
Ammonia Diesel Mango Rose 
Apricot Earthy Menthol Sage 
Berry Flowery Mint Skunk 
Blue cheese Grape Nutty Spicy 
Butter Grapefruit Orange Sweet 
Cheese Herbal Peach Tea 
Chemical Honey Pepper Tobacco 
Chestnut Lavender Pine Tropical fruit 
Citrus Lemon Pineapple Violet 
Coffee Lime Pungent Woody 
 
 
Rating Scales and Presentation 
Participants rated each sample using a Check All That Apply (CATA) ballot with 
40 descriptors, presented in alphabetical order on a single screen of a touch-screen device 
(Apple iPad 2). Data were automatically entered into a spreadsheet; scale presentation 
and data collection were designed using free online services (Google Forms and Google 
Sheets). 
Ethics Statement  
This study protocol was approved by the Western Institutional Review Board 
(Puyallup, Washington) (WIRB Protocol #20170080). All participants provided informed 
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written consent using a form approved by WIRB. At no time did participants come into 
direct contact with the Cannabis samples. Retail sale of marijuana for recreational use to 
adults 21 years of age and older has been legal in the state of Colorado since January 1, 
2014. 
Participants  
Test participants were recruited from Fort Collins and vicinity. Participants from a 
previous study (Gilbert and DiVerdi 2018) who indicated a willingness to participate in 
further research were re-contacted. A notice (text approved by WIRB) was posted to an 
online bulletin board for the local community. Printed text emphasized “current, former, 
and non-users all welcome” and that only sniffing was required (“no touching, no 
smoking, no eating”). All participants were at least 21 years of age, residents of 
Colorado, and had a self-reported normal sense of smell. Exclusion criteria included self-
reported pregnancy, active nasal allergy, and current head cold. Subjects were paid 
$20.00 for their participation. 
Sensory Statistical Analyses  
A Friedman’s nonparametric repeated-measures ANOVA was performed on the 
summed frequencies for each odor descriptor across all samples within a given strain 
using SPSS Statistics v. 24 (IBM Corp. 2016). A Wilcoxon signed-rank test on all 
pairwise combinations of samples within each strain (analogous to post-hoc t-tests in 
ANOVA) was conducted using SPSS Statistics v. 24 (IBM Corp. 2016). Calculations for 
histograms and tables were conducted using Microsoft Excel.  
Within strain scent profiling was analyzed using two measures: Perceived Shared 
Character Category and Cannabis Lexicon Category. For the Perceived Shared Character 
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Category analyses aroma descriptors were assigned to one of five categories by A. 
Schwabe. The five Perceived Shared Character Categories were: “Earthy” which 
included soil, buttery, nutty or roasted aromas, “Spicy” which included spices and dried 
leafy scents, “Sweet” which included scents associated with fruits, “Floral” scents as 
fresh plants/flowers, and “Pungent” which included sharp and/or unpleasant aromas 
(Table 4.5).  
Table 4.5. Perceived Shared Character categories. Each of the 40 odor descriptors 
assigned to one of five categories. The total number of descriptors is in parentheses. 
Earthy (7) Spicy (6) Sweet (14)  Floral (6)  Pungent (7) 
Earthy Herbal Apricot Flowery Ammonia 
Butter Sage Berry Lavender Skunk 
Coffee Pepper Citrus Rose Cheese 
Pine Spicy Grape Violet Chemical 
Woody Tea Grapefruit Mint Blue cheese 
Nutty Tobacco Lemon Menthol Pungent 
Chestnut  Lime  Diesel 
  Mango   
  Orange   
  Peach   
  Pineapple   
  Citrus   
  Sweet   
  Tropical fruit   
    Honey     
 
For the Cannabis Lexicon Category analyses, aroma descriptors were assigned to four 
categories by combining characters of two Cannabis lexicons, the Terpene Flavor Wheel 
© (The Holden Company and Western Cultured 2016) and The Flavor Wheel TM  (Green 
House Seed Company 2018). The wheels are similar, but a combination of the two was 
used to capture all 40 scent descriptors used in this study. The four categories in 
Cannabis Lexicon Categories were “Sweet”, “Sour”, “Spicy” and “Bitter” (Table 4.6).  
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Table 4.6. Cannabis Lexicon Categories. Each of the 40 odor descriptors 
assigned to one of four categories. The total number of descriptors is in 
parentheses. 
Sweet (12) Sour (8) Spicy (9) Bitter (11) 
Apricot Blue cheese Herbal Ammonia 
Berry Butter Lavender Chemical 
Flowery Cheese Menthol Chestnut 
Grape Citrus Mint Coffee 
Honey Grapefruit Pepper Diesel 
Mango Lemon Pine Earthy 
Peach Lime Sage Nutty 
Pineapple Orange Spicy Pungent 
Rose  Woody Skunk 
Sweet   Tea 
Tropical fruit   Tobacco 
Violet       
 
The Perceived Shared Character Category and Cannabis Lexicon Category data 
were analyzed separately for the genetically cohesive samples and for the genetic outlier 
sample. A frequency of detection scale was calculated for each sample by dividing the 
total number of positive detections by the number of descriptors in the category 
multiplied by the number of samples in the strain group, multiplied by 55 (the number of 
possible positive detections) (Equation 1).  
∑positive detections 
55 (n descriptor x n strain samples) 
 
The frequency of detection metric normalizes the data and allows for comparisons across 
categories with different numbers of scents, as well as across strain groups with different 
numbers of samples. The range of the frequency of detection scale is 0.00-1.00, where 
zero means no participants detected any scents in that category, and 1.00 means every 
participant detected every scent in the category. Given the subjective and personal nature 
of olfactory ratings, we would not expect to see a value of 1.00. Histograms for the 
Equation 1. 
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frequencies were generated in Excel to compare differences in the mean frequencies of 
the genetic consensus sequences compared and the genetic outlier. As these are 
frequencies of detection, the data were normalized to demonstrate the scent profile of 
consensus versus outlier samples in each strain. 
Genetic Results 
Genetic Relatedness 
Lynch & Ritland (Lynch and Ritland 1999) pairwise genetic relatedness within 
each strain was calculated in GENELEX (Figure 4.2). Values of r = 1.00 are indicative of 
identical individuals as observed in clones. Values of r < 0 between two individuals 
indicate the individuals have a very low level of relatedness. Samples 1SN, 4SN and 5SN 
in “Durban Poison” were identical (r = 1.00) and 8GN was a genetic anomaly compared 
to the other samples (r = -0.18; Figure 4.2C). Samples 2SN and 3SN, and 6SN and 8GN 
in “OG Kush” had a high level of genetic relatedness (r = 1.00 and r = 0.91, 
respectively), and other pairwise relatedness between samples were low to moderate (r 
=0.06 – 0.75; Figure 4.2D). Samples 1SN, 4SN, 7SN and 10GN in “Sour Diesel” had a 
high level of genetic relatedness (r =0.91 - 1.00), and the remaining samples had 
moderate to low genetic relatedness (r =-0.19 - 0.72; Figure 4.2B). Samples 1SN, 2SN, 
4SN, 5SN, 6SN, and 8GN in “Blue Dream” were genetically identical (r = 1.00), and 
3SN had a very low level of relatedness to all identical samples in the set (r = - 0.21; 
Figure 4.2A). Samples 1SN and 3SN in “Mob Boss” were identical (r = 1.00) and 5SN 
had a very low level of relatedness to all identical samples in the set (r = -0.29 – 0.05; 
Figure 4.2E). 
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Figure 4.2. Lynch & Ritland pairwise genetic relatedness within each strain. Values 
of r = 0.50 are indicative identical as observed in clones, r < 0 indicates a low level of 
genetic relatedness. “OG Kush” samples 1SN, 4SN and 5SN (asterisk) were labeled with 
the same Retail Marijuana Cultivation Facility and the same lot number even though they 
were purchased from different dispensaries.  
 
Clustering Analyses 
 Principal Coordinates Analysis (Figure 4.3) was conducted in GENALEX and 
plotted using the ggplot package in R Studio with 95% confidence interval ellipses 
around the major groups (Figure 4.3) (R Studio Team 2015). The samples that fell 
outside the confidence intervals, “OG Kush” 1 SN, “Blue Dream” 3SN, and “Mob Boss” 
5SN were considered genetic outliers (Figure 4.3). 
1SN 2SN 3SN 4SN 5SN 6SN 7SN 8GN 9GN
2SN 1.00
3SN -0.21 -0.21
4SN 1.00 1.00 -0.21
5SN 1.00 1.00 -0.21 1.00
6SN 1.00 1.00 -0.21 1.00 1.00
7SN 0.58 0.58 -0.10 0.58 0.58 0.58
8GN 1.00 1.00 -0.21 1.00 1.00 1.00 0.58
9GN 1.00 1.00 -0.17 1.00 1.00 1.00 0.58 1.00
10GN 0.40 0.40 -0.07 0.40 0.40 0.40 0.15 0.40 0.55
Blue Dream
A
1SN 2SN 3SN 4SN 5SN 6SN 7SN 8GN 9GN
2SN 0.49
3SN 0.16 0.00
4SN 0.95 0.35 0.23
5SN 0.52 0.18 -0.08 0.53
6SN 0.39 0.11 -0.02 0.37 0.13
7SN 0.91 0.55 0.01 0.72 0.44 0.33
8GN 0.15 0.21 -0.08 0.08 0.40 0.01 0.21
9GN -0.19 -0.07 -0.07 -0.17 -0.13 -0.06 -0.13 -0.05
10GN 0.91 0.55 0.01 0.72 0.44 0.33 1.00 0.21 -0.13
B
Sour Diesel
1SN 2SN 3SN 4SN 5SN 6SN 7SN
2SN -0.03
3SN 0.17 0.17
4SN 1.00 -0.03 0.17
5SN 1.00 -0.03 0.17 1.00
6SN 0.19 0.51 0.15 0.19 0.19
7SN 0.00 -0.14 -0.02 0.00 0.00 0.01
8GN -0.18 0.08 -0.02 -0.18 -0.18 -0.03 -0.09
Durban Poison
C
*1SN 2SN 3SN *4SN *5SN 6SN 7SN
2SN 0.12
3SN 0.12 1.00
*4SN 0.15 0.44 0.44
*5SN 0.12 0.71 0.71 0.29
6SN 0.06 0.40 0.40 0.28 0.29
7SN 0.43 0.75 0.75 0.44 0.51 0.40
8GN -0.28 0.39 0.39 0.17 0.30 0.91 0.14
OG Kush
D
1SN 2SN 3SN 4SN 5SN
2SN 0.79
3SN 1.00 0.79
4SN 0.84 0.51 0.77
5SN -0.22 -0.29 -0.17 -0.17
6SN 0.38 0.56 0.83 0.36 0.05
Mob Boss
E
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Figure 4.3. Principal Coordinate Analysis generated using ggplot in R Studio (R 
Studio Team 2015). The samples are colored by strain name, and 95% confidence 
interval ellipses are drawn around each cluster.  
 
STRUCTURE ver. 2.4.2 (Pritchard et al. 2000) was used to examine individual 
assignment to genetic groups. STRUCTURE HARVESTER (Earl and vonHoldt 2012) 
calculated the appropriate number of STRUCTURE groups using the Evanno method 
(Evanno et al. 2005). This data set had extremely high support for three genetic groups 
(K = 3, ∆K = 216.07) and weak support for two or six genetic groups (Figure 4.4).  
  
107 
 
 
Figure 4.4. STRUCTURE HARVESTER output as calculated using the Evanno 
method, showing robust support for three genetic groups (K = 3) in this data set ( K = 
216.07). 
 
The three groups represented in STRUCTURE are color coded as blue (group 1), 
green (group 2) and yellow (group 3) (Figure 4.5). All but one sample of “OG Kush” was 
comprised largely of group 1 genetic assignment (blue, 87.1- 98.9 %); sample 1SN had 
only 20.5 % group 1 genetic assignment and 78.1 % assignment to group 3 (yellow). All 
but one sample of “Blue Dream” was largely assigned to group 2 (green, 91.2 - 98.6 %); 
sample 3SN had a 98 % assignment to group 3 (yellow). The remaining samples from 
“Durban Poison”, “Mob Boss”, and “Sour Diesel” were assigned to group 3 (66.8 – 98.8 
%). “Durban Poison” 8GN was assigned to group 2 (green, 74.8 %), but there was not 
enough sample for the sensory study. However, “Durban Poison” 2SN and “Mob Boss” 
5SN had relatively low assignment to group 3 (66.8 % and 69.5 % respectively) and were 
considered in this analysis to be comparative outliers. All samples of “Sour Diesel” were 
assigned to group 3 (yellow, > 95%).  
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Figure 4.5. STRUCTURE graph with the proportion of genetic assignment to each 
of the three genetic groups as indicated by the proportion of each color in each bar 
representing an individual. “OG Kush” samples 1SN, 4SN and 5SN (asterisk) were 
labeled with the same Retail Marijuana Cultivation Facility and the same lot number even 
though they were purchased from different dispensaries.  
 
Two dendrograms were created based on pairwise genetic distance values labeled 
with the sample names and color coded by strain (Figures 4.6, 4.7). The analysis of all 42 
samples (Figure 4.6) showed an initial split of “OG Kush” from the remaining samples. 
Within the remaining strains there was clear groups consisting of seven “Blue Dream”, 
four “Mob Boss”, three “Durban Poison”, and six “Sour Diesel” samples. 
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Figure 4.6. PC-Ord hierarchical genetic cluster analysis based on genetic distance 
color coded by strain. Clear genetic outliers assigned to a conflicting cluster are 
indicated by the arrows. “Durban Poison” and “Sour Diesel” samples span several 
clusters therefore no clear genetic outlier is indicated. “Blue Dream” (BlDr) samples are 
blue, “Mob Boss” (MoBo) samples are green, “Sour Diesel” (SoDi) are red, “OG Kush” 
(OGKu) samples are purple, and “Durban Poison” (DuPo) samples are yellow. 
 
Blue Dream (BlDr)
Mob Boss (MoBo)
Durban Poison (DuPo)
OG Kush (OGKu)
Sour Diesel (SoDi)
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Sample Selection for the  
Sensory Study 
Genetic relatedness, PCoA clustering, genetic structure, and hierarchical 
clustering based on genetic distance clearly identified genetic outliers and consensus 
samples within strains, with the exception of “Sour Diesel” which was omitted from the 
sensory study. The genetic outliers “Durban Poison” 8GN, “OG Kush” 1SN, “Blue 
Dream” 3SN, and “Mob Boss” 5SN consistently showed differentiation from the other 
samples in the strain, but there was insufficient sample of “Durban Poison” 8GN to be 
included in the study. Three identical “Durban Poison” samples were included to 
examine scent variation among samples with identical genotypes. The remaining 12 
samples selected for the sensory study had either identical or an extremely high degree of 
genetic similarity (Table 4.2). Samples from the sensory selection were included in a 
second dendrogram to confirm clustering and genetic outliers (Figure 4.7). 
 
Figure 4.7. Hierarchical genetic cluster analysis of the cannabis samples. Arrows 
indicates genetic outliers. “Blue Dream” (BlDr) samples are red, “Mob Boss” (MoBo) 
samples are green, “OG Kush” (OGKu) samples are purple, and “Durban Poison” (DuPo) 
samples are yellow.  
*
*
*
Blue Dream (BlDr)
Mob Boss (MoBo)
Durban Poison (DuPo)
OG Kush (OGKu)
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Sensory Results 
 
Subject Demographics 
Fifty-five people (33 men, 22 women; mean age 29.5 ± 7.8 years) were tested. Of 
these, all but eight had purchased Cannabis since January 1, 2014, and all but five 
subjects had smoked it. The high rates of purchase (85.5%) and use (90.9%) among study 
participants occurred despite efforts to recruit former and non-users as well. Seven 
subjects (12.7%) had taken part in previous cannabis sniff studies (Gilbert & DiVerdi 
2018; Gilbert & DiVerdi, submitted). 
Hierarchical Cluster Analysis 
 
Hierarchical cluster analysis (HCA) yielded a configuration consisting of two 
large clusters, designated as Cluster A’ and Cluster B’ (Figure 21). Previous sensory 
research examining scent profiles in Cannabis found two clusters and designated them as 
Cluster A and Cluster B (Gilbert and DiVerdi 2018). To avoid confusion between the 
previous work and the present study, we designated the two main clusters from this work 
as Cluster A’ and Cluster B’ (Figure 4.8). We feel that Gilbert and DiVerdi’s (2018) 
Cluster A and Cluster B largely correspond to the current Cluster A’ and Cluster B’, but 
there are some minor discrepancies. Cluster A’ contains “OG Kush”, as it was previously 
assigned to Cluster A and described as citrus, lemon, sweet and pungent  (Gilbert and 
DiVerdi 2018). Cluster A’ contained all four samples of “OG Kush”, which scored high 
on earthy, woody, and herbal descriptors, which is consistent with previous aromatic 
profiling and descriptions online (Gilbert and DiVerdi 2018; Leafly 2018b). Cluster B’ 
contains “Durban Poison”, as it was previously assigned to Cluster B, and described as 
citrus, lemon, sweet, pungent (Gilbert and DiVerdi 2018). However, in this analysis two 
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samples of “Durban Poison” were described as sweet, citrus, flowery, lemon, and the 
third was described as herbal, woody, flowery, and earthy, differing from Gilbert and 
DiVerdi (2018). This is the first study to provide olfactory analysis of the “Blue Dream” 
strain, and the results are ambiguous; three samples were assigned to Cluster B’, while 
two samples, including the genetic outlier, were assigned to Cluster A’. “Mob Boss” was 
previously grouped with strains in Cluster A (earthy, woody, herbal) (Gilbert and 
DiVerdi 2018). In this study, only one sample of “Mob Boss” was characterized this way 
(MoBo_3SN), with the other two samples, including the genetic outlier, assigned to 
Cluster B’. 
 
Figure 4.8. Hierarchical cluster analysis (HCA) for 15 samples included in the sensory study 
containing two large clusters, Cluster B’ and Cluster A’. Strains are color coded and arrows 
indicate the genetic outlier for each if the strains. All “Durban Poison” samples were genetically 
identical. “Blue Dream” (BlDr) samples are blue, “Mob Boss” (MoBo) samples are green, “OG 
Kush” (OGKu) samples are purple, and “Durban Poison” (DuPo) samples are yellow. 
B’ 
A’ 
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Within Strain Descriptor Profiles 
The aim of this study was to assess if the aroma profile of an anomalous genetic 
sample differed from those of the consensus samples. As a first effort, a Friedman’s 
nonparametric repeated-measures ANOVA was performed on the summed frequencies 
for each odor descriptor across all samples within a given strain. All four strains returned 
significant chi-square values (Table 4.7). Thus, for example, aroma profiles of the five 
samples of “Blue Dream” differ significantly. 
 
Table 4.7. Results of Friedman’s test on the summed frequencies for each odor 
descriptor across all samples within a given strain for each Cannabis strain. The 
number of samples (N) in each strain, along with the Chi-square value, degrees of 
freedom (df) and asymptotic significance (Asymp. Sig). 
  Blue Dream  Mob Boss OG Kush Durban Poison 
N 5 3 4 3 
Chi-Square 117.668 69.398 107.223 91.776 
df 39 39 39 39 
Asymp. Sig. 0.000 0.002 0.000 0.000 
 
This analysis, however, does not address differences between specific samples 
within a strain, and in particular, if an anomalous sample differed from consensus 
samples. A Wilcoxon signed-rank test on all pairwise combinations of samples within 
each strain (analogous to post-hoc t-tests in ANOVA) was conducted. None of these 
pairwise comparisons yielded a statistically significant difference. We are not the first to 
note that this is a paradoxical result, given the significant results of the overall Friedman 
tests (Zimmerman and Zumbo 1993).  
In order to assess the question of within strain aromatic differences with special 
interest to the genetic outlier, characterization of within-strain aroma differences was 
analyzed using the number of times particular odor descriptors were reported among the 
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participants. The five most frequently endorsed odor descriptors for each sample were 
identified and pooled within each strain. This resulted in 12 pooled descriptors for both 
“Blue Dream” and “Durban Poison”, nine for “Mob Boss”, and eight for “OG Kush”. 
Frequency counts for each descriptor were averaged across a strain’s consensus samples 
and compared to the counts for the genetic outlier sample (Figures 4.8 – 4.11).  
The results for “Durban Poison” were interesting and somewhat unexpected. 
Although three samples were genetically identical, all three differed across the 12 pooled 
descriptors (Figure 4.9, Table 4.8). However, when examining the pooled five most 
frequently endorsed odor descriptors of the consensus samples of “Blue Dream”, “Mob 
Boss” and “OG Kush” (Figure 4.10, Table 4.8) there is also evidence of inconsistency in 
the aromas of the genetically cohesive samples of all strains. In order to examine the 
aroma consistency of “Durban Poison” we calculated the mean, standard deviation, and 
average standard deviation of the top descriptors for the consensus samples for each 
strain (Table 4.7). Since the strains have different aromas, we focused on the range of 
standard deviations and the average standard deviation: “Durban Poison” standard 
deviation range = 2.08-7.64, average standard deviation = 4.29; “OG Kush” standard 
deviation range = 1-7.57, average standard deviation = 4.37; “Blue Dream” standard 
deviation range = 2-7.18, average standard deviation = 5.12; and “Mob Boss” standard 
deviation range = 0.71-8.49, average standard deviation = 3.22.  
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Figure 4.9. Detection frequency of top-rated odor descriptors for “Durban Poison”. 
 
 
Figure 4.10. Detection frequency of top-rated descriptors for consensus samples of 
“Blue Dream”, “Mob Boss” and “OG Kush” and the mean for each descriptor.
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Table 4.8. Frequencies plus mean and standard deviation of the top five pooled odor descriptors for the genetic consensus samples of 
"Durban Poison", "OG Kush", "Blue Dream" and "Mob Boss". 
 
 
  Flowery Herbal Citrus Sweet Earthy Woody Lemon Lavender Pungent Sage Tea Pine 
DuPo_1SN 15 15 19 20 19 13 11 12 13 11 9 8 
DuPo_4SN 23 19 22 16 11 6 21 14 11 12 4 6 
DuPo_5SN 19 21 12 15 17 21 6 9 7 8 16 13 
Mean 19.00 18.33 17.67 17.00 15.67 13.33 12.67 11.67 10.33 10.33 9.67 9.00 
SD 4.00 3.06 5.13 2.65 4.16 7.51 7.64 2.52 3.06 2.08 6.03 3.61 
             
  Earthy Herbal Woody Pungent Pine Chemical Diesel Tea Sweet Flowery Nutty   
OGKu_2SN 25 19 17 17 13 13 13 11 11 9 3  
OGKu_3SN 27 27 19 5 6 3 4 21 9 15 15  
OGKu_4SN 22 21 18 19 11 13 11 9 9 7 3  
Mean 24.67 22.33 18.00 13.67 10.00 9.67 9.33 13.67 9.67 10.33 7.00  
SD 2.52 4.16 1.00 7.57 3.61 5.77 4.73 6.43 1.15 4.16 6.93  
             
  Herbal Earthy Flowery Sweet Citrus Woody Tea Nutty Pungent Berry    
BlDr_1SN 20 17 17 15 15 14 12 12 10 9   
BlDr_4SN 20 17 15 14 12 17 12 8 15 10   
BlDr_5SN 20 13 17 21 11 9 11 5 7 12   
BlDr_6SN 24 28 8 6 5 25 26 17 4 2   
Mean 21.00 18.75 14.25 14.00 10.75 16.25 15.25 10.50 9.00 8.25    
SD 2.00 6.45 4.27 6.16 4.19 6.70 7.18 5.20 4.69 4.35    
             
  Earthy Woody Chemical Citrus Herbal Flowery Sweet Tea Pungent      
MoBo_1SN 16 17 16 16 15 14 13 9 11    
MoBo_3SN 28 21 18 12 19 11 6 13 12    
Mean 22.00 19.00 17.00 14.00 17.00 12.50 9.50 11.00 11.50      
SD 8.49 2.83 1.41 2.83 2.83 2.12 4.95 2.83 0.71      
1
1
6
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The results for “OG Kush” (Figure 4.11) show that the genetic outlier sample was 
far more cheesy and less pungent and tea-like, than the mean of the consensus samples. 
“OG Kush” was characterized by Gilbert and DiVerdi (Gilbert and DiVerdi 2018) as 
having the earthy/woody/herbal aroma profile characteristic of Cluster A. All the “OG 
Kush” samples in the present study, including the genetic outlier, were rated highly on 
these three descriptors, confirming the earlier results. The fact that cheese was a 
relatively frequently endorsed descriptor for the anomalous genetic sample is noteworthy: 
cheese was not a highly ranked descriptor for any of the 11 strains tested previously 
(Gilbert and DiVerdi 2018). The blue cheese descriptor was also reported more than 
twice the frequency for the outlier than the consensus samples. Although blue cheese was 
not in the five most frequently endorsed odor descriptors, it lends more evidence for the 
unusual scent profile of the genetic outlier in the set. Thus, the “OG Kush” genetic outlier 
was distinctive from both the strain-typical profile, as well as the consensus samples. 
 
 
Figure 4.11. Detection frequency of top-rated odor descriptors for “OG Kush” 
samples; error bars indicate standard deviation from the mean of the consensus samples. 
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The results for “Blue Dream” (Figure 4.12) show that the genetic outlier was far 
more pungent, chemical, and skunk-like than the mean of the four consensus samples. 
HCA configuration (above) indicates that two “Blue Dream” samples align with Cluster 
A’, and three with Cluster B’. Despite this anomalous result, within-strain comparison 
shows the genetic outlier sample to have unique and marked differences from the other 
samples. 
 
 
Figure 4.12. Detection frequency of top-rated odor descriptors for “Blue Dream” 
samples; error bars indicate standard deviation from the mean of the consensus samples. 
 
  
The results for “Mob Boss” (Figure 4.13) show that the genetic outlier was 
strikingly more flowery, sweet, and berry-like, and less woody and chemical than the 
consensus samples. Gilbert & DiVerdi (Gilbert and DiVerdi 2018) found that “Mob 
Boss” has an earthy/woody/herbal aroma profile typical of Cluster A strains. The 
consensus genetic samples of “Mob Boss” tested here fit the Cluster A profile: they were 
described as earthy/woody/herbal/chemical and woody/earthy/citrus/chemical, 
respectively. In contrast, the description of the genetic outlier sample (MoBo_5SN) as 
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flowery/sweet/herbal/berry was at odds with both the consensus samples and the 
previously established Cluster A profile. 
 
 
 Figure 4.13. Detection frequency of top-rated odor descriptors for “Mob Boss” 
samples; error bars indicate standard deviation from the mean of the consensus samples. 
 
Additional Within-Strain  
Scent Profiling Analyses 
 In order to lend a more holistic analysis of the aroma profiles, the 40 odor 
descriptors (Table 4.4) were broken down into smaller subsets which included categories 
of scents based on broad characters common to the scents included in each category. 
These categories were then used to determine if there were differences in overall 
characteristic aromas between the samples within strains that were identified as 
genetically cohesive and the sample identified as the genetic outlier (Table 4.3).  
Within Strain Scent Profiling:  
Perceived Shared Character 
Categories 
 
The Perceived Shared Character Category analyses was used to determine if 
genetics consensus and outlier samples differ when organized by categories including all 
scents. The “OG Kush” outlier was identified as pungent and earthy, but less sweet than 
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the consensus samples (Figure 4.14C). The genetic outlier of Blue Dream” was far more 
pungent than the consensus samples (Figure 4.14A). The genetic outlier of “Mob Boss” 
has unique and marked differences from the other samples in that it was identified as 
floral and sweet, and less pungent (Figure 4.14B). “Durban Poison” was not included in 
this analysis as all the samples were genetically identical. 
 
Table 4.9. Shared Character Category Frequency of Detection. Scores for each 
scent category (Pungent, Sweet, Floral, Earthy, Spicy) for the genetic consensus 
samples and the genetic outlier. 
    Pungent Sweet Floral Earthy Spicy 
Blue Dream Consensus Mean 0.074 0.084 0.081 0.139 0.141 
 Outlier 0.239 0.074 0.085 0.135 0.142 
Mob Boss Consensus Mean 0.117 0.070 0.068 0.111 0.099 
 Outlier 0.068 0.157 0.194 0.099 0.124 
OG Kush Consensus Mean 0.087 0.123 0.049 0.149 0.152 
 Outlier 0.133 0.058 0.091 0.210 0.148 
 
 
 
Figure 4.14. Shared Character Category Histograms. Frequency of Detection Scores 
of Pungent, Sweet, Floral, Earthy, Spicy detected among the samples by the 55 
participants for “Blue Dream” (A), “Mob Boss” (B) and “OG Kush” (C). 
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Within Strain Scent Profiling:  
Cannabis Lexicon Categories  
A second analysis looking at the impact of grouping scents used Cannabis 
Lexicon Categories. With these groupings, the “OG Kush” outlier identified far more 
similarly to the consensus samples but was less bitter (Figure 4.15C). The genetic outlier 
of Blue Dream” was far more bitter than the consensus samples (Figure 4.15A). The 
genetic outlier of “Mob Boss” was identified as sweet, with less spicy and bitter notes 
(Figure 4.15B). “Durban Poison” was not included in this analysis as all the samples were 
genetically identical.  
Table 4.10.  The Frequency of Detection Scores. Scores for each Cannabis Lexicon 
Category for the genetic consensus samples and the genetic outlier. 
    Sweet Sour  Spicy Bitter 
Blue Dream Consensus Mean 0.105 0.158 0.158 0.130 
 Outlier 0.063 0.139 0.139 0.195 
Mob Boss Consensus Mean 0.079 0.155 0.155 0.170 
 Outlier 0.202 0.129 0.129 0.074 
OG Kush Consensus Mean 0.068 0.162 0.162 0.170 
  Outlier 0.068 0.162 0.162 0.132 
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Figure 4.15. Histograms for Frequency of Detection Scores of each Cannabis 
Lexicon category (Sweet, Sour, Spicy and Bitter). Frequency of categorical scents 
detected among the samples by the 55 participants for “Blue Dream” (A), “Mob Boss” 
(B) and “OG Kush” (C). 
 
Discussion 
In the present study we purposefully targeted Cannabis strains with different 
scent profiles and sought to evaluate if genetic variation manifests as discrepant aromatic 
characterization. Using the combination of previously published genotyping methods and 
olfactory phenotyping techniques, a two-part study was designed to uncover the 
relationship between genotype and phenotype in Cannabis. First, samples were collected 
and genotyped to identify cohesive samples and genetic outliers in five strains. Then, a 
sensory study was conducted using non-expert participants to determine if participant 
descriptors aligned with the genetic results.   
Genetic analyses were conducted on multiple samples of targeted strains to 
identify genetically cohesive and outlier samples. Previous research (Schwabe and 
McGlaughlin 2018) (Chapter II) found genetic variability in “Durban Poison”, “OG 
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Kush”, “Sour Diesel” and “Blue Dream”, and although “Mob Boss” had not been 
genotyped, all strains analyzed showed variation. The genetic results were clear and 
robust with support for three genetic groups (Figures 4.4 and 4.5). Relatedness statistics 
and clustering analyses revealed four of five strains had a cohesive genetic signal in the 
majority of the samples, and one clear genetic outlier. The requirement for samples 
selection for the sensory portion were that the genetically cohesive and outlying samples 
were supported in each of the analyses conducted. Two strains, “OG Kush” and “Blue 
Dream”, had consistent consensus genotypes with a clear outlier, fitting the requirements 
for inclusion in the sensory study. The outlier for “Mob Boss” was not as divergent but 
fulfilled the requirements for sensory inclusion. “Sour Diesel” had no consistent genetic 
outlier, and therefore was not included in the sensory study, even though this strain 
reportedly has a unique aromatic profile (Gilbert and DiVerdi 2018; Leafly 2018b). 
“Durban Poison” had a clear outlier, but there was not enough sample tissue to be 
included in the sensory portion. However, three identical “Durban Poison” samples were 
chosen to serve as a control to examine scent variation among samples with identical 
genotypes.  
Fifteen samples from four strains were selected for inclusion in the sensory study: 
“Durban Poison” (3), “OG Kush” (4), “Blue Dream” (5), and “Mob Boss” (3) (Table 
4.3). Clustering analysis of the sensory data was at odds with the clustering analysis of 
the genetic data (Figure 4.7 and 4.8). Three “Durban Poison” were assigned to Cluster A’ 
indicating a degree of aroma similarity. Four “OG Kush” samples were assigned to 
Cluster B’. Genetic consensus samples of “Blue Dream” were assigned to both Cluster A’ 
(1) and Cluster B’ (3), indicating some dissimilarity between those genetic consensus 
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samples. One genetic consensus sample of “Mob Boss” was assigned each to Cluster A’ 
and B’, indicating some dissimilarity between those genetic consensus samples. The 
genetic outliers for “OG Kush”, “Blue Dream”, and “Mob Boss” clustered with at least 
one genetic consensus sample.  
Analysis of variance (ANOVA) revealed samples within strains differed 
significantly from one another (Table 4.7). This is evident in “Durban Poison” where 
frequently endorsed odor descriptors show a high degree of variation, even though the 
genotypes are identical (Figure 4.9). “Blue Dream” and “Mob Boss” with identical 
genotypes, and “OG Kush” (4SN) with difference at one locus, all had a high degree of 
variation in the frequently endorsed odor descriptors (Figure 4.10). Due to this variation, 
a method to uncover within strain aromatic differences with special interest to the genetic 
outlier was needed. As this type of study combining genetic and sensory data had not 
previously been published, a novel approach was required. The first approach was to pool 
the five most frequently reported strain descriptors for the genetic consensus samples for 
each strain. The mean frequency for each descriptor for the genetic consensus samples 
was compared to the number of reports for the descriptor for the genetic outlier. This 
analysis revealed substantial differences in the aromatic profiles of the outliers in each 
strain (Figures 4.10 - 4.12). The second approach used categories of scents to calculate 
frequencies of detection in each category to compare aroma profiles of the genetic 
consensus samples to the genetic outlier. Two different scent category profiles were 
created, one from perceived shared characters (Shared Characteristics Category) and one 
from Cannabis flavor lexicons (Cannabis Lexicon Category). Both the profiles returned 
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at least one category in which the genetic outlier was considerably different than those of 
the genetic consensus samples (Figures 4.14 and 4.15). 
 “OG Kush” is reportedly a clone only strain (Chapter II) described online as 
woody, pine and earthy (Leafly 2018b) and is assigned to Gilbert and DiVerdi’s (2018) 
earthy, woody and herbal Cluster A. Hierarchical Cluster Analysis of the scent data 
grouped all “OG Kush” samples, including the genetic outlier, in Cluster A’ with the 
genetic outlier nested with consensus samples (Figure 4.8). Analyses using frequently 
endorsed odor descriptors (Figure 4.11) indicate the “OG Kush” outlier had less of a tea 
scent and a distinctive cheese aroma when compared to the consensus samples. The 
standard deviation from the mean of the consensus samples of the 11 pooled descriptors 
ranged from 1.0 (woody) to 7.57 (pungent) (Figure 4.10, Table 4.8). Analysis of 
frequencies in scent categories show the genetic outlier in “OG Kush” is less sweet and 
more earthy according to Shared Character Category (Figure 4.14C) and more bitter 
according to Cannabis Lexicon Category (Figure 4.15C) relative to consensus samples. 
The odor descriptors reported for all “OG Kush” samples align with consumer 
expectations as earthy, woody and herbal (Figure 4.11), however the outlier has some 
unique aromatic qualities that separate it from the consensus samples (Figure 4.11, 4.14C 
and 4.15C) indicating the genetic outlier could be identified using sensory perception 
methods. 
“Blue Dream” is reportedly a clone-only strain (Chapter II) described as having 
blueberry, berry and sweet flavors (Leafly 2018b) but has not been previously described 
using validated sensory methods (Gilbert and DiVerdi 2018). Hierarchical Cluster 
Analysis of the scent data split the “Blue Dream” samples over the two major scent 
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clusters with two samples, including the genetic outlier, in a cluster A’, and the remaining 
three samples in Cluster B’ (Figure 4.8). HCA was unable to differentiate the “Blue 
Dream” outlier. Further analyses using frequently endorsed odor descriptors (Figure 4.12) 
indicate the “Blue Dream” outlier was less herbal and tea, but far more pungent, chemical 
and skunk aromas were detected compared to the consensus samples. The standard 
deviation from the mean of the consensus samples of the 10 pooled descriptors ranged 
from 2.0 (herbal) to 7.18 (tea) (Figure 4.10, Table 4.8). Analysis of frequencies in scent 
categories show that the genetic outlier in “Blue Dream” is overwhelmingly more 
pungent according to Shared Character Category (Figure 4.14A) and bitter according to 
Cannabis Lexicon Category (Figure 4.15A) than consensus samples. The odor 
descriptors reported for the outlier do not align with consumer expectations as a 
blueberry, berry and sweet strain, indicating the genetic outlier could be identified using 
sensory perception methods. 
“Mob Boss” is described online as woody, pine and earthy (Leafly 2018b) and is 
assigned to Gilbert and DiVerdi’s (2018) earthy, woody and herbal Cluster A. 
Hierarchical Cluster Analysis of the scent data split the “Mob Boss” samples over the two 
major scent clusters with two samples, including the genetic outlier, in Cluster B’ and one 
consensus sample in Cluster A’ (Figure 4.8). Analyses using frequently endorsed odor 
descriptors (Figure 4.13) indicate the “Mob Boss” outlier was less earthy, woody and 
chemical, but extensive flowery, sweet, and berry aromas were detected compared to the 
consensus samples. The standard deviation from the mean of the consensus samples of 
the 10 pooled descriptors ranged from 0.71 (pungent) to 8.49 (earthy) (Figure 4.10, Table 
4.8). Analysis of frequencies in scent categories show the genetic outlier in “Mob Boss” 
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overwhelmingly more floral (Figure 4.14B) and sweet (Figure 4.14B and 4.15B) 
according to Shared Character Category, and less pungent (Figure 4.14B) and bitter 
(Figure 4.15B) according to Cannabis Lexicon Category than the consensus samples. The 
odor descriptors reported for the outlier do not align with consumer expectations as a 
woody, pine and earthy strain. Floral, sweet, and berry (Figures 4.9, 4.14B, and 4.15B), 
and are uncharacteristic of aromas associated with “Mob Boss”, indicating the genetic 
outlier was identified using sensory perception methods.   
“Durban Poison” is described online as earthy, pine and sweet (Leafly 2018b) 
which is quite different from Gilbert and DiVerdi’s (2018) assignment to the citrus, 
lemon, sweet, and pungent Cluster B. Three genetically identical “Durban Poison” 
samples were selected for the sensory study (Table 4.3, Figures 4.2, 4.3, 4.5 - 4.7) to 
determine variation in the scent profile of samples from different origins with no genetic 
variation. The HCA assigned the three samples in to the Cluster B’ (Figure 4.8) 
indicating a similar major aromatic profile among the three. The frequency of detection 
for 12 descriptors (Figure 4.13) indicated there was variation in scent detection by the 
participants. As these three samples were genetically identical, it would stand to reason 
that they should have similar aroma profiles. This expectation was not met in “Durban 
Poison” as all samples deviated from one another across the most frequently reported 
odor descriptors. Moreover, there was not a single sample that consistently deviated from 
the others. There was variation in scent detection by the participants in the genetic 
consensus samples in all four strains. (Figure 4.13 and 4.14; Table 4.8). Additionally, 
“Durban Poison” and “Blue Dream” had higher average standard deviations (4.37 and 
5.12 respectively) than “Durban Poison” and “Mob Boss” (4.29 and 3.22 respectively). 
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From this analysis it is clear that genetic identity alone does not control aroma profiles 
and that differences were observed among consensus samples for all strains.  
 The utility of combining genetic and sensory methods to determine if genetic 
anomalies are detectable through sensory perception was confirmed for the samples used 
here. However, several challenges and limitations need to be addressed. It is unclear from 
the results of this study how much variation in aromatic profiles is standard within 
strains, as all the consensus sequences have scent profile variation (Figure 4.9, 4.10; 
Table 4.8). Participants for sensory studies such as this are limited by sensory overload to 
a maximum of 15 samples per sitting, resulting in a forced small samples size, but the 
number of participants in the study give strong support for the results herein. We are 
aware that sensory perception is personal and subjective, but the aim of the study was not 
to identify samples, but rather to determine if genetic outliers have a different aroma 
profile from genetically cohesive samples, which was achieved in the three strains with 
an outlier. We are also aware that an untrained consumer panel such as that used here 
tends to show greater variation in descriptor use than a highly trained expert panel. Thus, 
some participants may be very lax in reporting the odors they detect, while others may be 
more conservative, and of course there is everything in between. However, we feel that 
the number of participants in this study well represent consumer perceptions. The data 
were difficult to analyze because each 55 participants have the option to detect 40 aromas 
in 15 samples, and both presence and absence of scents are considered character states. 
Standard statistical analyses methods detected differences among all samples, and within 
strains, but given the variation seen among genetically cohesive samples of the same 
strain, standard statistical analyses were not appropriate. For this reason, the data analysis 
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required a novel approach. Grouping scents into categories is novel, and not necessarily a 
validated method for analyzing sensory data such as these, but this approach did reveal 
differences between genetically anomalous samples and those with cohesive genotypes. 
 Terpenes are aromatic phytochemicals produced in many plants that contribute to 
the multitude of aromas associated with leaves, flowers, and fruits, including those of 
Cannabis. Previous research has found terpenes vary in concentration over time 
(Aizpurua-Olaizola et al. 2016). As there are no standard growing conditions or harvest 
protocols in place for the Cannabis industry, scent variation in genetically identical 
samples could be due to differences in growing conditions (nutrients, light, etc.), harvest 
time and/or post-harvest flower processing (Cervantes 2006) among different grow 
facilities. In drug-type Cannabis strains, terpenes in flowers increase in concentration 
from day 122 until about day 165 of the growth cycle when levels began to decrease 
(Aizpurua-Olaizola et al. 2016). However, there is no standard time to harvest Cannabis 
flowers. Maturity varies among plants, and different strains reportedly mature at different 
times, ranging from 3-6 months (Leafly 2018b). Growers harvest flowers by examining 
the color of the stamens and the cloudiness of the trichomes under a magnifying glass. 
Growers aim to harvest at the height of THC production, which is when the stamens have 
dried and turned amber and trichomes have developed a spherical head and have clear or 
a creamy appearance (Figure 4.16) (Cervantes 2006). Although there have been studies 
analyzing cannabinoid and terpene production over time in plants grown under 
standardized conditions (Aizpurua-Olaizola et al. 2014), harvesting and processing 
information are not provided to consumers, and may well be beyond what consumers are 
willing to take into account when purchasing Cannabis. Our results suggest there can be 
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significant variation in terpenes, as seen through aroma descriptors, even when samples 
are genetically identical (Table 4.8), which could be surprising for those expecting certain 
characteristics in a strain. Although this study included a relatively small sampling of 
Cannabis strains, it demonstrates genetic variation is reflected in aromatic profile 
differences. However, in order to determine what is a reasonable amount of variation in 
scent profiles of Cannabis, more in-depth studies examining other factors known to 
influence terpene production are needed.  
 
Figure 4.16. The glandular trichomes of the female flower of Cannabis sativa at 40X 
magnification.  
Conclusion 
The purpose of this study was to investigate if genetic inconsistencies are 
reflected in aroma profiles. Strains were selected based on availability, previous 
genotyping (Schwabe and McGlaughlin 2018) (Chapter II), and sensory research (Gilbert 
and DiVerdi 2018). We found that the tested strains provided additional evidence that 
samples of the same strain from different origins can have unexpected genetic and aroma 
variation, but consensus samples seem to align with previous sensory analysis profiles 
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(clusters A and B; Gilbert and DiVerdi 2018), as well as online descriptions (Gilbert and 
DiVerdi 2018; Leafly 2018b). Comparison of top-rated odor descriptors revealed that, 
compared to consensus samples, genetic outliers have distinctive aroma profiles. Broader 
scent categories, Shared Character Category and Cannabis Lexicon Category revealed 
genetic variants have different scent profiles than those of the consensus samples. In 
samples with identical genotypes there were notable differences in reported aroma 
descriptors, which could be attributed to differences in growing and curing processes 
among different grow facilities. We believe genetic variation in the samples included 
here were adequately reflected in differences in aromas, but aroma variation in samples 
with highly similar genotypes is substantial, which could be the result of different 
cultivation practices among different Cannabis grow facilities. These results show not 
only that genetic imposters within a strain can be detected and result in aromatic 
differences, but also that there is considerable variation in aromas among samples with 
identical genetic identity. 
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Abstract 
 
This research investigates how genetic variation in neutral genetic markers is 
related to variation in cannabinoid and terpene content of Cannabis. The expanding 
Cannabis industry needs to provide consistent products to the ever-increasing customer 
base in both the recreational and medical marketplaces. Sources of variation are 
numerous and genetic variation has been found where there should be little to none, 
especially when striving for consistency. Moreover, there are currently no widely 
practiced standard growing or harvesting protocols to minimize variation among growing 
facilities. Variation in growing conditions, harvest time, curing and storage conditions 
can affect Cannabis chemotypes, but to what extent is largely a mystery. We conducted a 
small investigation with 15 samples from four strains. Using 10 microsatellite markers, 
we identified genetically cohesive samples of “Durban Poison” (n=3), “Blue Dream” 
(n=4), “Mob Boss” (n=2), and “OG Kush” (n=3). We also identified one genetic outlier 
for “Blue Dream”, “Mob Boss”, and “OG Kush”. We compared the chemotypes of the 
genetic outliers to the genetic consensus samples to investigate whether genotypic 
differences are reflected as chemotypic differences. A panel of nine cannabinoids and 21 
terpenes were analyzed using HPLC-DAD and GC-MS, respectively. An additional three 
strains were added to the terpene analysis to examine terpene variation among strains. 
The results from this study show that cannabinoids and terpenes are highly variable 
among samples independent of their genetic similarity, as well as among strains. The 
relationship between genetic assignment and cannabinoid profile is less pronounced than 
the terpene profile, where genetic outliers differed substantially from the consensus 
samples in  > 50% of the 21 terpenes analyzed. Although the sampling in this study was 
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not extensive and include a relatively small number of cannabinoids and terpenes, the 
results clearly demonstrate both are quantitatively and qualitatively inconsistent among 
samples, and, therefore, using chemotype to identify Cannabis strains is not 
recommended. 
Introduction 
Overview 
 
Human driven dispersal across the globe along with cultivation for thousands of 
years have resulted in many different varieties of Cannabis, which have been selected for 
a multitude of desirable characters, the most notorious of which are the 
phytocannabinoids. Although research on the chemical constituent differences among 
Cannabis strains is abundant (e.g., Pacifico et al. 2006), there are few studies examining 
the genetic contribution to chemotypic variation within strains (de Meijer and Hammond 
2005; Lynch et al. 2016; Sawler et al. 2015).  
Cannabis varietals are preferably propagated through cloning techniques to 
ensure minimal phenotypic variation among plants within strains. For some strains, stable 
seeds are available, but there is a lack of information for many of these seeds, and it is not 
clear how much variation there is within seed lots from many sources. Recent research 
has shown substantial genetic variation within strains from different sources (Schwabe 
and McGlaughlin 2018) as well as within seeds of the same varietal (Soler et al. 2017).  
Medical and recreational drug type Cannabis breeders aim to produce a consistent 
product and maximize yield by using all female clones from a single mother plant. Given 
that desirable Cannabis strains are grown from clones or from a single parent seed, 
strains should be similar regardless of where the product was purchased. An organism’s 
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physical appearance (phenotype) is a product of both environmental factors and genetic 
makeup (genotype). Likewise, the chemical profile (chemotype) of Cannabis is 
determined by a combination of both genotype and environmental factors. While the 
chemical profile is inherited from the parents, the expression levels of the various 
chemicals within each plant can vary under different growing conditions (Cervantes 
2006; Fischedick et. al 2010; Elzinga 2015; Jikomes and Zoorob 2018). To what extent 
the environment contributes to variation in the chemotype of Cannabis strains is largely 
unknown. Even when grown in controlled conditions, small but significant variation in 
mean THC/CBD ratios have previously been found among offspring of the same inbred 
line (de Meijer et al. 2002; de Meijer and Hammond 2005). As more people look to 
Cannabis for medical and recreational purposes, it is important to determine if there are 
inconsistencies observed in the chemotype within Cannabis strains.  
Chemical Constituents of Cannabis 
The number of isolated chemical constituents from Cannabis has increased from 
423 in 1980 (Turner et al. 1980) to 490 in 2005 (ElSohly and Slade 2005), and there are 
currently more than 560 described chemical constituents (ElSohly et al. 2017). Chemical 
constituents found in Cannabis include approximately 120 phytocannabinoids, 
approximately 140 terpenes and an additional approximately 305 non-cannabinoids 
which include fatty acids, amino acids, carbohydrates and other chemical constituents 
(ElSohly et al. 2017). While terpenes are abundant in the plant kingdom, 
phytocannabinoids are rarely found outside the Cannabaceae, and are largely unique to 
Cannabis sativa (Small 2015b). Phytocannabinoids are a unique set of chemicals, which 
mimic compounds in the endocannabinoid system of many animals, excluding insects 
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(McPartland et al. 2001; Small 2015a). Glandular trichomes on the flowers of female 
plants are the main production site of phytocannabinoids and terpenes (Figure 5.1).  
 
Figure 5.1. The glandular trichomes of the female flower of Cannabis sativa 
magnified 4X. 
Cannabinoids. Anandamide (N-arachidonylethanolamine) is a neurotransmitter 
of the endocannabinoid system in humans. Anandamide binds to neuromodulatory CB1 
receptors in the central nervous system and the immunomodulatory CB2 receptors in the 
peripheral nervous system (Small 2015a). The cannabinoids THC (Δ9-
tetrahydrocannabinol) and CBD (cannabidiol) mimic anandamide and 2-
arachidonoylglycerol by binding to the CB1 and CB2 receptors (Mechoulam et al. 1995; 
Pertwee 2008). THC functions as an agonist by binding to and activating the receptor, 
while CBD is an agonist that binds to but does not activate the receptor. However, THC 
and CBD are not naturally produced in the Cannabis plant. Rather, Cannabis produces 
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THCA (Δ9-tetrahydrocannabinolic acid) and CBDA (cannabidiolic acid), which are non-
bioactive precursors to THC and CBD. Both THCA and CBDA can be converted to the 
bioactive forms through decarboxylation methods, which is often achieved through 
heating the flower material. Consumers are generally most interested in the effects of the 
active cannabinoid forms, and therefore Cannabis products that are not prepared for 
smoking or vaporizing have been processed prior to sale. Smoking and vaporizing are 
accomplished by applying a flame or heat to the Cannabis product and inhaling the 
smoke or vapors. Cannabinoids are fat soluble and infusing fat or oil allows the 
compounds to be more biologically available and absorbed more readily. ‘Edibles’ can be 
prepared using butter, oils, or sprays that have been infused with THC and/or CBD by 
heating flower material in oil or butter slowly over time. The four most widely 
recognized cannabinoids (THCA, CBDA, THC and CBD) are often reported separately 
or as a total calculated amount (see Methods Cannabinoids) on the labels of retail 
products as a percent of dry weight. Other cannabinoids and compounds, however, are 
produced in varying levels in Cannabis, and are only sometimes included on retail labels.  
Medical and retail marijuana laws in Colorado as of January 2018 are mandated 
by the Colorado Department of Revenue Marijuana Enforcement Division. Testing 
protocols are published in the Colorado Department of Public Health and Environment’s 
reference library. Retail Marijuana Cultivation Licensees are required to test two harvest 
batches for microbial contaminants every 30 days and potency once per quarter 
(Colorado Department of Revenue 2017). Cannabinoids are required to be listed as a 
percentage which represents an average of the results from all batch test samples 
(Colorado Department of Revenue 2017). Colorado requires analysis of five compounds 
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(THC, THCA, CBD, CBDA and cannabinol (CBN)) (Colorado Department of Revenue 
2017).  
Chemical analysis in Cannabis is generally conducted using gas chromatography 
(GC), high performance liquid chromatography (HPLC), mass spectroscopy (MS), or 
some variation of these assays such as HPLC- Diode Array Detector (HPLC-DAD) or 
High-Speed Liquid Chromatography (HSLC) (DeBacker et al. 2009, Hazecamp & 
Fischedick 2012, de Cássia Mariotti et al. 2015, Aizpurua-Olaizola et al. 2014, Chan 
2014, Elzinga et al. 2015, Gul et al. 2015). Cannabinoids commonly analyzed include 
THCA, THC, CBDA, CBD, CBN, cannabigerolic acid (CBGA), cannabigerol (CBG), 
tetrahydrocannabivarin (THCV), and Δ9-trans- cannabichromene (CBC), (Gul et al. 
2015). Gas chromatography is less expensive than HPLC, but GC uses high temperatures 
and therefore is not an accurate way to measure levels of THCA and CBDA since those 
compounds are converted to THC and CBD when heated. Chemical analysis for 
commercial Cannabis in Colorado can be conducted by any licensed testing facility that 
adheres to state-mandated protocols, but variation in sample storage, testing equipment, 
and technicians may introduce variation.  
Terpenes. Terpenes are a large group of chemicals that contribute to 
characteristics found in many herbal plants and essential oils. Terpenes are also partially 
responsible for some of the pharmacological properties of Cannabis. The terms terpene 
and terpenoid are often used interchangeably, although terpenes are basic hydrocarbons, 
while terpenoids contain additional functional groups. There are more than 120 identified 
terpenes found in Cannabis that are categorized as primary or secondary terpenes based 
on abundance. It is thought that terpenes work in concert with cannabinoids, and the 
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various levels and combinations of each in different varieties are responsible for the suite 
of pharmacological benefits reported for medicinal marijuana. This synergistic 
mechanism of action has been termed “the entourage effect” (Ben-Shabat et al. 1998). 
Terpenes are classified according to the number of repeating units of 5-carbon building 
blocks (isoprene units). The molecular structure of monoterpenes has 10 carbons, 
sesquiterpenes have 15 carbons, and triterpenes have 30 carbons. Yield and distribution 
of phytochemicals are the result of genetics, environmental conditions, and plant maturity 
(Meier and Mediavilla 1998). Monoterpenes dominate the volatile terpene profile of 
Cannabis, but there are a few common, sesquiterpenes. Research on Cannabis 
phytochemicals has traditionally focused on terpene and cannabinoid levels, because it is 
these phytochemicals that give the psychoactive effects, therapeutic benefits, and unique 
aromas associated with Cannabis.  
Monoterpenes. Monoterpenes are the most common terpenes found in Cannabis 
(ElSohly 2007). -Pinene (Figure 5.2A) is the most abundant terpene in the plant 
kingdom and is found in conifers, pines, sage, parsley, dill and basil (PCRlabs 2019). The 
therapeutics of -pinene are anti-inflammatory, anti-osteoarthritic, and anti-nociception 
properties (PCRlabs 2019). -Myrcene (Figure 5.2B) is found in lemongrass, basil, bay 
leaves, thyme, parsley, hops and tropical fruits (PCRlabs 2019). The therapeutics of -
myrcene are anti-inflammatory, analgesic, muscle relaxation, and sedative/hypnotic 
properties (PCRlabs 2019). D-limonene (limonene) (Figure 5.2C) is the second most 
abundant terpene and is found in the rinds of citrus fruits (PCRlabs 2019). The 
therapeutics of limonene are anti-inflammatory, analgesic, anti-depressant, muscle 
relaxation and sedative properties (PCRlabs 2019). Linalool (Figure 5.2D) is found in 
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flowers and spices such as lavender, rosewood, birch, and coriander (PCRlabs 2019). The 
therapeutics of linalool are anti-inflammatory, anesthetic, analgesic, anti-convulsant, anti-
anxiety, and sedative properties (PCRlabs 2019). 
 
Figure 5.2. The chemical structures of four monoterpenes. (A) -pinene), (B) -
myrcene, (C) D-limonene, and (D) linalool. 
 
 
Sesquiterpenes. Sesquiterpenes are also found in Cannabis but are less prevalent 
(ElSohly 2007). -Caryophyllene (Figure 5.3A) is found in many spices and plants such 
as clove, cinnamon, black pepper, hops, oregano and basil (PCRlabs 2019). Therapeutics 
of -caryophyllene are anti-inflammatory and analgesic effects. -Caryophyllene 
(humulene) (Figure 5.3B) is found in spices and herbs such as clove, basil, hops, sage, 
spearmint, ginseng, as well as some fruits and vegetables (PCRlabs 2019). Therapeutics 
of -caryophyllene are anti-inflammatory and analgesic effects (PCRlabs 2019). 
 
Figure 5.3. The chemical structures of two sesquiterpenes. (A) -caryophyllene, and 
(B) -caryophyllene. 
A B C D
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Summary 
 This study aimed to investigate if genetic variation in neutral genetic markers is 
paralleled with variation in nine cannabinoids and 21 terpenes. The genotypes from four 
strains totaling 15 samples were previously assessed for genetic variation (Chapter IV). 
Samples from an additional three strains were added to the terpene analysis to examine 
terpene variation among strains. Cannabinoid profiles were analyzed using HPLC-DAD, 
and terpenes were analyzed using GC. To determine phytochemical variation in retail 
Cannabis strains, this study examined variation  (1) among samples that are genetically 
identical (2) within strains, and (3) among different strains. Variation within strains was 
compared to genetic variation to assess whether genetic variation is associated with 
cannabinoid and terpene variation.  
Methods 
 The genetic assessment (see Chapter IV) generated a set of 15 Cannabis samples 
selected from four strains: “Blue Dream” (5), “OG Kush” (4), “Mob Boss” (3), and 
“Durban Poison” (3). All three “Durban Poison” samples had identical genotypes, while 
one sample each of “Blue Dream” (3SN), “OG Kush” (1SN), and “Mob Boss” (5SN) was 
identified as having a unique genotype from the others, which were genetically cohesive 
within the strain. Samples were purchased from 11 dispensaries licensed by the state of 
Colorado for retail recreational sales located in Denver, Fort Collins, and Garden City. 
The coded, dried cannabis flower samples (1 g) from the sensory study (Table 11; 
Chapter IV) were sent to Mile High Labs (Loveland, Colorado) for blind analysis.  
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Cannabinoids 
Potency and related cannabinoid analysis of raw material were reported for nine 
cannabinoids (THC, THCA, CBD, CBDA, CBG, CBGA, THCV, CBN, and CBC). Mile 
High Labs analyzed the samples following standard protocols with a gradient HPLC 
system using a reverse-phase column and guard column with a C18 stationary phase. A 
1260 Infinity II HPLC with DAD detection at 240 nm, (bandwidth 4 nm) and reference 
360 nm (bandwidth 100 nm) was used per Colorado state compliance requirements 
(Table 5.1 - 5.3).  
Table 5.1. HPLC Method Parameters 
HPLC Information 
Column Type:  Restek Raptor ARC-18, 2.7 mm, 150 x 4.6 mm, PN 9314A65 
Guard Cartridge:  Restek Raptor ARC-18, 2.7 mm, 5 x 4.6 mm, PN 9314A0250  
Column Temperature:  35 °C  
Sample Tray 
Temperature:  Ambient 
Flow Rate:  1.5 mL/min 
Stop Time:  12 min 
Post Time:  3 min 
Method Type:  Gradient 
MP A:  0.015% formic acid in water 
MP B:  0.010% formic acid in acetonitrile 
Gradient DAD Detector Settings 
Time  
MP A 
(%) 
MP 
B 
(%) Detection:  240m nm 
0:00 30 70 Detection BW:  4 nm 
2:00 30 70 Reference:  360 nm 
8:00 5 95 Reference BW:  100 nm 
12:00 5 95 Collect UV Spectra:   190 -400 nm 
 
Peakwidth:  > 0.05 min (2.5 Hz) 
Slit Width:  4 nm 
Injector Settings 
Injection Volume 10 μL 
Needle Wash Methanol 
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Table 5.2. Injection Sequence 
Description 
# of 
Injections Parameter 
Reagent Blank NLT 1 System equilibration 
Reagent Blank 1 Contamination check and non-interference 
RL Standard 1 Reporting Limit Recovery 
Resolution Standard 1 Resolution 
Standard A 6  CBD / ISTD peak area ratio 
 Mean CBD USP Tailing Factor  
 Mean CBD USP Theoretical Plates 
Standard B 1 CBD Percent Recovery 
Samples 1 Sample analysis 
Standard A* 1 Check Standard Recovery 
*Inject standard A as a drift check at least every six samples and at the end of each sequence 
 
Table 5.3. Peak Relative Retention Time (RRT) and Relative Response Factor 
(RRF) Values 
Cannabinoids 
Approx. retention 
time 
Approx. 
RRT RRF 
tetrahydrocannabinolic acid (THCA) 7.28 1.69 0.66 
tetrahydrocannabinol (Δ9-THC) 6.38 1.48 0.89 
cannabidiolic acid (CBDA) 3.67 0.85 0.71 
cannabidiol (CBD) 4.3 1 1 
cannabigerolic acid (CBGA) 3.96 0.92 1 
cannabigerol (CBG) 4.15 0.97 1.02 
tetrahydrocannabivarin (THCV) 4.46 1.04 1 
cannabinol (CBN) 5.64 1.31 0.33 
Δ9-trans- cannabichromene (CBC) 7.07 1.64 0.32 
 
The analytical column used was a Restek Raptor ARC-18, 2.7 m, 150 x 4.6 mm, 
PN 9314A65. The guard column was a Restek Raptor ARC-18, 2.7 m, 5 x 4.6 mm, PN 
9314A0250 and Restek EXP Direct Connect Holder PN 25808. HPLC-grade acetonitrile 
(CAS# 75-050-8), methanol (CAS# 76-56-1) and water (CAS# 7732-18-5) were used, as 
well as GC grade di-n-octyl phthalate (CAS# 117-84-0), reagent grade formic acid 
(CAS# 64-18-6), Cerilliant 1 mg/mL Cannabigerol Ampoule PN C-141 (dissolved in 
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methanol), Cerilliant 1 mg/mL Cannabidiol Ampoule PN C-045 (dissolved in methanol), 
and Cerilliant © Certified Cannabinoid Standards for ID (Redrock, Texas): C-045, C-
046, C-144, T-005, C-140, C-141, T-093, C-143, C154, C171, C-150, C-152, T-032, C-
153, T-094, and C-142. A 10ul aliquot of composite cannabinoid sample was injected 
using Acq. Method TM-001 – 1260.amx and Processing method *TM-002UV.pmx with 
no manual modification (Figure 5.4, Table 5.4)
 
Figure 5.4. Composite HPLC-DAD chromatogram. 
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Table 5.4. Retention Times, Peak Height, Peak Area and Response Factor for the 
composite HPLC-DAD Analysis. 
Signal: DAD1A,Sig=240,4 Ref=360,100 
Name Tailing Plates 
RT 
(Min) 
Peak 
Height 
(mAU) 
Area 
(mAU*sec) 
Res 
(USP) 
 0.90 18093.00 1.56 0.68 1.17  
 1.00 15160.00 1.62 1.03 2.00 1.10 
 1.00 10827.00 1.73 0.80 2.24 1.90 
 1.40 4192.00 1.96 1.24 5.21 2.40 
 1.00 14444.00 2.08 1.69 4.34 1.20 
 0.80 11883.00 2.29 4.34 14.73 2.80 
 1.20 17393.00 2.42 105.22 293.92 1.60 
CBDV 1.00 16971.00 2.68 74.34 230.00 3.40 
 1.10 21209.00 3.10 0.68 2.20 5.00 
 1.40 17392.00 3.27 1.00 4.13 1.80 
CBDA 1.10 23925.00 3.58 79.60 278.90 3.20 
 1.00 34299.00 3.76 1.74 5.17 2.10 
CBGA 1.10 29880.00 3.88 86.21 291.14 1.40 
CBG 1.00 30199.00 4.04 64.32 224.49 1.80 
CBD 1.00 33788.00 4.18 62.61 212.93 1.60 
THCV 1.00 39558.00 4.34 79.61 260.05 1.70 
 2.00 63140.00 5.00 0.38 1.42 8.00 
 1.10 68243.00 5.32 0.55 1.67 4.00 
CBN 1.10 74373.00 5.51 242.42 737.08 2.30 
 1.10 90899.00 6.04 0.39 1.13 6.60 
 0.80 92846.00 6.25 95.07 264.29 2.60 
THC 1.80 38836.00 6.32 155.45 749.53 0.60 
 1.00 121577.00 6.80 125.48 367.14 4.70 
CBC 1.00 136042.00 6.94 245.48 701.31 1.90 
THCA 1.20 122548.00 7.18 87.26 273.92 3.00 
 1.50 142309.00 7.56 292.93 902.20 4.70 
 1.30 114404.00 7.67 73.85 255.63 1.40 
 1.50 27536.00 7.95 1.14 10.58 1.90 
  0.90 149960.00 8.39 0.31 1.33 3.20 
 
Mobile phase A (0.015% formic acid in water) was prepared by combining 150 
L of formic acid with 1 L of water. Mobile phase B (0.010% formic acid in acetonitrile) 
was prepared by mixing 100 L of formic acid with 1 L of acetonitrile. Stock Standard 
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solutions were stored at -80C for < 88 days, and the Internal Standard (ISTD), A/B 
Standard solutions and RL solutions were stored at -80 C for < 7 days. The Sample 
ISTD was prepared by diluting 200.00  20 mg di-n-octyl phthalate in methanol to a total 
volume of 100.0-mL. The Standard ISTD was prepared by adding methanol to 5.0 mL of 
the Sample ISTD to a final volume of 20 mL. Standard A was prepared with 100.00  10 
mg of Cannabidiol Isolate Standard to a sufficient volume of methanol in a 100-mL 
volumetric flask to just below the QS line and sonicated for 2 minutes. The solution was 
then allowed to equilibrate to room temperature and diluted to volume with methanol. In 
order to create the Standard A Preparation with a nominal concentration of 50 g/mL 
cannabidiol, 5.0 mL of the sonicated Cannabidiol Isolate Standard in methanol was 
diluted with 5.0 mL and brought to a final volume of 100.0 mL with methanol. Standard 
B was prepared with 100.00  10 mg of Cannabidiol Isolate Standard to a sufficient 
volume of methanol in a 100-mL volumetric flask to just below the QS line and sonicated 
for 2 minutes. The solution was then allowed to equilibrate to room temperature and 
diluted to volume with methanol. In order to create the Standard B Preparation with a 
nominal concentration of 50 g/mL cannabidiol, 5.0 mL of the sonicated Cannabidiol 
Isolate Standard in methanol was diluted with 5.0 mL and brought to a final volume of 
100.0 mL with methanol. Standard A/B are prepared to ensure standards were made 
correctly. If Standard B recovery fell within a 4% range of Standard A then all 
quantitation was determined to be accurate using Standard A during sample processing. 
5.0 mL of Stock Standard A was diluted to a volume of 100.0 mL with methanol to 
prepare the RL Stock Standard I Preparation with a nominal concentration of 50 g/mL 
cannabidiol. A 5.0 mL aliquot of Stock RL Standard was diluted to a volume of 100.0 
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mL with methanol to prepare the RL Stock Standard II Preparation with a nominal 
concentration of 2.5 g/mL cannabidiol. A 10.0 mL aliquot of RL Stock Standard II and 
5.0 mL of the Standard ISTD was diluted to a volume of 100.0 mL with methanol to 
prepare the RL Standard Preparation with a nominal concentration of 0.25 g/mL 
cannabidiol. The Resolution and RC Identification Standard was prepared by adding ~1.0 
mL of each Cerilliant © Certified Cannabinoid Standards (Redrock, Texas) to a 20.0 mL 
volumetric flask and diluted to volume with methanol. A 10 uL aliquot of RL standard 
was injected and Acq. Method TM-001 – 1260.amx and Processing method *TM-
002UV.pmx were used with no manual modification (Figure 5.5, Table 5.5). 
 
Figure 5.5. RL standard HPLC-DAD chromatogram. 
Table 5.5. Retention Times, Peak Height, Peak Area and Response Factor for the 
RL standard HPLC-DAD analysis. 
 
Signal: DAD1A,Sig=240,4 Ref=360,100 
Name Tailing Plates 
RT 
(Min) 
Peak Height 
(mAU) 
Area 
(mAU*sec) 
Res 
(USP) 
Blank 1.10 18713.00 2.45 0.87 2.47  
CBD 1.20 34891.00 4.19 0.30 1.02 21.60 
ISTD 0.90 271187.00 10.48 33.46 101.04 74.00 
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 Cannabis samples were prepared by weighing 200.00  10 mg of dried flower 
material and transferred to a 100 mL volumetric flask, and 5.0 mL of the Sample ISTD 
was added. To prepare a Potency and Related Cannabinoid Stock Sample Preparation 
with a nominal concentration of 2000 g/mL, a sufficient amount of methanol was added 
to bring the volume to just below the QS line and the solution was sonicated at 40 C for 
10 minutes. The solution was mixed thoroughly then brought to room temperature. The 
Stock Sample Solution was then filtered into a scintillation vial using a Pall Acrodisc 
CR13 0.2-m PTFE syringe filter. The first ~1 mL of filtrate was discarded followed by 
collection of > 5.5 mL of filtrate. The final Potency and Related Cannabinoid Sample 
Preparation with a nominal concentration of 500 g/mL was prepared by dilution 5.0 mL 
of Stock Sample Solution to 20.0 mL with methanol. A 10 uL aliquot of sample 
extraction (For example 752, OG Kush 2 Figure 5.6, Table 5.6) was injected using Acq. 
Method TM-001 – 1260.amx, Processing method *TM-002UV.pmx with no manual 
modification. 
 
Figure 5.6. Sample HPLC-DAD chromatogram for sample 752 (OG Kush 2). 
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Table 5.6. Retention Times, Peak Height, Peak Area and Response Factor for the 
sample 752 (OG Kush 2) HPLC-DAD analysis. 
Signal: DAD1A,Sig=240,4 Ref=360,100 
Name Tailing Plates 
RT 
(Min) 
Peak 
Height 
(mAU) 
Area 
(mAU*sec) 
Res 
(USP) 
 1.10 5418.00 2.29 0.88 4.32  
Blank 1.60 17959.00 2.44 1.04 3.81 1.60 
CBDA 1.50 27959.00 3.59 0.50 1.71 14.50 
CBGA 0.80 28583.00 3.89 4.61 20.09 3.30 
CBG 1.00 28834.00 4.04 1.35 5.02 1.60 
 0.80 45876.00 4.67 1.30 5.05 6.90 
 1.50 51644.00 5.32 1.48 5.25 7.20 
CBN 1.00 57983.00 5.51 0.48 1.70 2.10 
 1.10 99474.00 6.25 31.11 93.18 8.70 
THC 1.80 77805.00 6.37 2.52 9.92 1.40 
 1.40 98167.00 6.62 0.50 1.62 2.80 
 0.60 103677.00 6.87 0.58 2.26 2.90 
CBC 1.20 132966.00 6.94 1.39 3.99 0.80 
THCA 1.30 124679.00 7.16 227.63 713.80 2.90 
 1.30 131948.00 7.60 8.00 26.04 5.30 
 1.10 200307.00 8.25 0.54 1.46 8.20 
 1.30 225435.00 8.35 1.13 2.93 1.40 
 1.10 245819.00 8.77 0.73 1.90 5.90 
 1.10 223202.00 9.03 1.36 3.93 3.60 
ISTD 0.90 271602.00 10.47 30.46 91.75 18.30 
  0.80 127297.00 11.81 0.54 3.12 12.60 
 
The Reagent Blank Solution was prepared by following the steps for sample preparation 
but excluding the addition of the dried flower material (Figure 5.7, Table 5.7). Each 
sample was extracted in triplicate to ensure consistency and ensure quantitation was 
accurate.  
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Figure 5.7. HPLC-DAD chromatogram for the blank. 
Table 5.7. Retention Times, Peak Height, Peak Area and Response Factor for the 
blank HPLC-DAD analysis. 
 
Signal :DAD1A,Sig=240,4 Ref=360,100 
Name Tailing Plates 
RT 
(Min) 
Peak Height 
(mAU) 
Area 
(mAU*sec) 
Res 
(USP) 
Blank 1.00 19083.00 2.44 0.63 1.67  
 1.00 154781.00 9.40 9.66 34.88 83.60 
ISTD 1.00 270998.00 10.49 24.36 73.85 12.40 
 
 
Many of the major cannabinoids (THC, CBD, CBG, CBC, but not CBN) have the 
molecular formula C21H30O2. However, the acidic forms (THCA, CBDA, CBGA and 
CBCA) are the naturally occurring form manufactured by the trichomes in the flowers. 
The acidic forms have an additional CO2 and chemical formula C22H30O4. In order to 
calculate the THCTOTAL, a conversion factor must be used to account for the CO2 molecule 
removed during decarboxylation. The molecular weight of the acidic cannabinoids is 
358.48 and the neutral cannabinoids is 314.47, therefore 12.28% THCA is lost in the 
form of CO2(g) during the decarboxylation process. The conversion factor to account for 
this loss is 0.877 (314.47/358.48). This formula can be applied to calculate THCTOTAL, 
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CBDTOTAL, CBGTOTAL and CBCTOTAL. The conversion factor can be used to calculate the 
conversion of acidic cannabinoid forms when they lose a CO2 molecule 
(decarboxylation) and are converted to the neutral bioactive form (Equation 5.2 & 5.3).  
 
THCTOTAL (%) = % THC + (% THCA x 0.877)    Equation 5.1. 
CBDTOTAL (%) = % CBD + (% CBDA x 0.877)    Equation 5.2. 
Total Cannabinoids (%) =  individual related cannabinoids  0.05% Equation 5.3. 
  
Dispensaries may report %THC and %THCA as separate values or %THCTOTAL. The 
sample packaging used in this study did not disclose analysis methods; although we 
assume if %THC and %THCA were reported, HPLC-DAD analysis was conducted. 
Since both HPLC-DAD and GC are acceptable analyses to use to determine potency in 
retail cannabis, the %THCTOTAL can be calculated from HPLC-DAD analysis.  
The percent dry weight of nine cannabinoids in the fifteen samples were compiled 
into a table using Microsoft Excel and bar plots for the cannabinoid profiles were graphed 
in Excel. For each sample, bar plots were generated for (1) the percent dry weight for the 
full cannabinoid panel, (2) the proportions of cannabinoids within the total cannabinoid 
fraction, (3) the percent dry weight for THCA and THC, and (4) the percent dry weight 
for CBDA, CBG, CBGA, THCV, CBN, and CBC. None of the samples possessed 
measurable amounts of CBD; therefore CBD was not included in any of the subsequent 
analyses. Histograms of percentages by dry weight of the average level of THCA in the 
consensus sequences and the genetic outlier were generated in Microsoft Excel. 
Histograms of average level of the remaining cannabinoids in the consensus sequences 
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were graphed with standard deviation error bars against the cannabinoid levels of the 
genetic outlier. Microsoft Excel was also used to generate a scatter plot to determine the 
relationship between the two cannabinoids (THCA and CBDA) representing the majority 
of the variation in the data.  
 A hierarchical cluster analysis dendrogram for eight cannabinoids (CBDA, CBG, 
CBGA, CBC, CBN, THCV, THC, THCA) in 15 samples using Ward’s method and 
Euclidean distance parameters was conducted in PC-ORD (McCune and Mefford 1999). 
However, because the investigation was examining variation within strains, cannabinoid 
dendrograms for each strain were also generated to assess the relationship between the 
genetic outlier and the consensus samples. Since THCA had overwhelmingly higher 
levels than the other cannabinoids, a second clustering analysis was conducted with 
THCA and THC removed from the data set. Dendrograms were generated for the full 
samples set and for each strain. PC-ORD was also used to generate a Principal 
Components Analysis (PCA) for eight cannabinoids (CBDA, CBG, CBGA, CBC, CBN, 
THCV, THC, THCA) using Ward’s method and Euclidean distance parameters. Since 
THCA had overwhelmingly higher levels than the other cannabinoids, a second PCA was 
conducted with THCA and THC removed from the data set. 
Terpenes 
The terpene profiles for 21 Cannabis samples from seven strains were determined 
using a GC-MS. Mile High Labs analyzed the samples following standard protocols with 
reference standards to calibrate the GC-MS system. Samples were prepared by weight in 
ACS-grade methanol. Preparation concentrations were from approximately 10-15% by 
weight. All weights were obtained to within 0.1 mg. Dry sample material was crushed to 
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a fine solid, suitable for weighing and transfer. Tare weights were obtained for the crimp-
sealed vials, and then the sample was added and weighed followed by addition of 
methanol with subsequent weighing. Samples were then placed into a 50-55C sonicating 
bath for 15 minutes followed by vortexing while still warm and allowed to settle at room 
temperature. Once cooled, the liquid was decanted via pipette and syringe filtered 
through a 0.45 m filter into GC vials for analysis. An Agilent 6890 GC with a 5973 inert 
MS detector in EI mode was used for analysis. The calibration curves for components 
were created using the 21-component terpene standard from RESTEK (data not 
provided). A five- point calibration was used for standards. The column used was a 
RESTEK Rxi-624 and helium was used as the carrier gas. A computing integrator 
recorded the chromatograph and mass spectrometer analysis, and relative retention times 
of terpene peaks from the reference standards were used to identify and determine 
presence and average abundance of terpenes in samples of seven strains. Two replicates 
for each sample were analyzed. The peaks were then calculated as normalized area 
percentages of each of the terpenes present in the samples. Terpene distribution and 
relative proportions for 21 terpenes was assessed. The terpene levels were used to assess 
the relationship between genetic consensus samples and a genetic outlier within a strain, 
as well as terpene variation among different strains.  
PCA eigenvalues generated in PC-ORD for 21 terpenes using Ward’s method and 
Euclidean distance parameters were used to plot the PCA in RStudio with the ggplot 
package (R Studio Team 2015). Histograms of peak area percentages of each terpene 
present in the strain samples were generated in Microsoft Excel. The average terpene 
levels of the genetic consensus samples were graphed with standard deviation error bars 
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against the terpene levels of the genetic outlier. The five highest terpene of the genetic 
consensus samples were pooled for “Blue Dream” (12), “Mob Boss” (12), and “OG 
Kush” (10), and compared to terpene levels of the genetic outlier. Twenty-one terpenes 
levels for seven strains and the average level each terpene was reported when multiple 
samples were included. Finally, the terpenes with the highest average standard deviation 
were graphed for the seven strains in order to assess terpene variation among strains.  
Results 
Cannabinoids 
 All the samples used in this investigation had high THC concentrations (7.97 – 
22.70 % dry weight) (Table 5.8). Five samples had a detectable level of CBDA (0.04294 
– 0.06520 % dry weight), while CBD was not detected in any sample and was not 
included in the results (Table 5.8).
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Table 5.8. Percentages of eight cannabinoid levels in four strains by HPLC-DAD as percent dry weight for eight cannabinoids, and calculated 
THCTOTAL (Equation 5.1). Identification abbreviations are listed for each sample and the genetic outliers are indicated with an asterisk and highlighted in 
gray. 
Strain Identification THCA THC CBDA CBGA CBG THCV CBN CBC 
Durban Poison 1SN 12.73 0.42 0.00 0.32 0.00 0.00 0.04 0.09 
 4SN 12.28 0.04 0.00 0.76 0.09 0.00 0.00 0.02 
 5SN 17.52 0.27 0.05 0.79 0.07 0.05 0.00 0.00 
mean ± SD Consensus  14.17 ± 2.90 0.24 ± 0.19 0.02 ± 0.03 0.62 ± 0.26 0.05 ± 0.05 0.02 ± 0.03 0.01 ± 0.02 0.04 ± 0.05 
Blue Dream 1SN 14.48 0.10 0.00 0.12 0.00 0.00 0.00 0.00 
 4SN 8.85 0.21 0.00 0.14 0.00 0.00 0.00 0.00 
 5SN 12.72 0.20 0.00 0.11 0.00 0.00 0.00 0.00 
 6SN 17.11 0.25 0.04 0.13 0.00 0.00 0.00 0.00 
mean ± SD Consensus 13.29 ± 3.47 0.19 ± 0.06 0.01 ± 0.02 0.12 ± 0.01 0.00 0.00 0.00 0.00 
 3SN* 15.07 0.15 0.00 0.11 0.00 0.00 0.00 0.02 
Mob Boss 1SN 11.88 0.24 0.00 0.96 0.16 0.05 0.04 0.04 
 3SN 15.05 0.27 0.00 1.41 0.08 0.00 0.00 0.00 
 mean ± SD Consensus 13.47 ± 2.25 0.26 ± 0.02 0.00 1.19 ± 0.32 0.12 ± 0.05 0.03 ± 0.04 0.02 ± 0.03 0.02 ± 0.03 
 5SN* 11.54 0.31 0.00 0.21 0.12 0.00 0.05 0.04 
OG Kush 2SN 25.34 0.47 0.07 1.08 0.28 0.00 0.03 0.07 
 3SN 20.52 0.07 0.04 0.74 0.11 0.00 0.00 0.00 
 4SN 15.24 0.23 0.05 0.21 0.08 0.00 0.04 0.02 
mean ± SD Consensus 20.37 ± 5.05 0.26 ± 0.20 0.05 ± 0.01 0.68 ± 0.44 0.15 ± 0.11 0.00 0.02 ± 0.02 0.03 ± 0.04 
 1SN* 12.59 0.18 0.00 0.39 0.07 0.00 0.02 0.00 
1
5
5
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 To compare cannabinoid composition and quantity among samples within strains, 
histograms of eight cannabinoids were generated to show variation (Figure 5.8). The 
“Durban Poison” samples were genetically identical, and yet the cannabinoid levels 
varied among all samples. When the total cannabinoid fraction (% by dry weight) with 
relative abundance of the chemotype by proportion was graphed, THCA levels appear to 
be similar, but levels of THC, CBGA and CBC seem to be the highest contributors to the 
variation (Figure 5.9). Samples 1SN and 4SN had similar levels of THC (Table 5.6, 
Figure 5.10A) and 5SN had higher THC. Examination of the other cannabinoids showed 
1SN and 4SN differ substantially in both composition and relative levels of CBGA, CBG, 
CBC, and CBN, while 4SN and 5SN had similar levels of CBGA and CBG but differed 
in CBC, CBDA and THCV (Figure 5.11A). PCA clustering analysis using data from 
eight cannabinoids produced two large clusters, with assignment of 1SN and 4SN to one 
cluster and 5SN to the other (Figure 5.14), indicating 5SN is more distinct in 
cannabinoids than1SN and 4SN are from each other. This is supported in the clustering 
analysis containing only “Durban Poison” samples where 1SN and 4SN clustered 
together (Figure 5.15A). There is a possibility that the less prevalent minor cannabinoids 
(CBDA, CBG, CBGA, CBC, CBN, THCV) may be a better reflection of the genetic 
relationships among the samples in drug-type strains. Therefore, additional PCAs of the 
minor cannabinoids were generated (Figure 5.13 and 5.17A). Although the “Durban 
Poison” samples were still assigned to different clusters (Figure 5.16), and “Durban 
Poison” 4SN and 5SN clustered together while 1SN was the chemical deviant (Figures 
5.16 and 5.17A).  
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Figure 5.8. Percent dry weight (mg) of eight cannabinoids measured by HPLC-DAD in 15 samples of four commercially 
available strains. Arrows and asterisks indicate the genetic outlier.  
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Figure 5.9. Chemotype by proportions of detected cannabinoids within the total cannabinoid fraction (% by dry weight) 
measured by HPLC-DAD in 15 samples of four commercially available strains. Asterisks indicate genetic outlier.  
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Figure 5.10. Percent dry weight (mg) of THC and THCA (six cannabinoids 
excluded). Arrows and asterisks indicate the genetic outlier.  
 
 
 
Figure 5.11. Percent dry weight (mg) of six minor cannabinoids (THC and THCA 
excluded). Arrows and asterisks indicate the genetic outlier. Predominant minor 
cannabinoids are CBGA and CBG.  
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Figure 5.12. Average levels of THCA (total % dry weight) in the genetic consensus 
samples compared to the genetic outlier. Error bars represent the standard deviation. 
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Figure 5.13. Average levels of the minor cannabinoids (total % dry weight) in the 
genetic consensus samples compared to the levels of the genetic outlier. Error bars 
represent the standard deviation.
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Figure 5.14. Hierarchical clustering dendrogram for 15 samples of four strains based on levels of eight cannabinoids (CBDA, 
CBG, CBGA, CBC, CBN, THCV, THC, and THCA). The genetic outliers are indicated with arrows. 
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Figure 5.15. Hierarchical clustering dendrogram for 15 samples within (A) “Durban Poison”, (B) “Blue Dream”, (C) “Mob 
Boss”, and (D) “OG Kush” based on levels of eight cannabinoids (CBDA, CBG, CBGA, CBC, CBN, THCV, THC, and 
THCA). 
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Figure 5.16. Hierarchical clustering dendrogram for 15 samples of four strains based on levels of six minor cannabinoids 
(CBDA, CBG, CBGA, CBC, CBN, THCV). 
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Figure 5.17. Hierarchical clustering dendrogram for 15 samples of (A) “Durban Poison”, (B) “Blue Dream”, (C) “Mob Boss”, 
and (D) “OG Kush” based on levels of six minor cannabinoids (CBDA, CBG, CBGA, CBC, CBN, THCV). 
A 
D C 
B 
1
6
5
 
  
166 
 
The genetic consensus “Blue Dream” samples varied from one another, and the 
genetic outlier did not appear to be anomalous compared to the consensus samples. When 
the total cannabinoid fraction (% by dry weight) with relative abundance of the 
chemotype by proportion was graphed, levels of THCA, THC and CBGA seem to be the 
highest contributors to the variation, although the levels of each are within 3% of the 
relative abundance of THCA, 4SN seems to be the most different (Figure 5.9). Among 
“Blue Dream”, most samples are similar in THCA (Table 5.4) although 4SN is noticeably 
lower (Figure 5.10B). Examination of the minor cannabinoids in “Blue Dream” are low, 
but have comparable levels of CBGA, and differing in only CBC and CBDA in 3SN and 
6SN, respectively (Figure 5.11B). No other cannabinoids were detected in the “Blue 
Dream” samples. Hierarchical clustering analysis using data from eight cannabinoids 
produced two large clusters, with assignment of 1SN, 3SN* and 6SN to one cluster, 
while 4SN and 5SN were assigned to the other (Figure 5.14). Clustering analysis 
containing only “Blue Dream” samples clustered 1SN and 3SN together, while 4SN, 5SN 
and 6SN are assigned to the other cluster (Figure 5.15B). Hierarchical clustering analysis 
of the minor cannabinoids assigned all five “Blue Dream” samples to one cluster 
indicating none of the samples substantially differed in the less prominent cannabinoids 
(Figure 5.16). However, when “Blue Dream” samples were examined together, 1SN and 
3SN* formed a cluster, while the remaining samples were assigned to a second cluster 
(Figure 5.17B). 
The genetic consensus “Mob Boss” samples varied from one another, although 
the genetic outlier did not appear to be anomalous compared to the consensus samples 
and had a similar level of THCA to 1SN (Figure 5.8). When the total cannabinoid 
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fraction (% by dry weight) with relative abundance of the chemotype by proportion was 
graphed, levels of THCA and CBGA seem to be the highest contributors to the variation, 
although levels of THCA, THC and CBGA in the genetic outlier is markedly different 
(Figure 5.9). Among “Mob Boss”, the outlier shares a similar THC profile with 1SN 
(Figure 5.10C). Examination of the minor cannabinoids reveals the “Mob Boss” samples 
are vastly different in CBGA content, and differ in CBN, CBC and THCV (Figure 
5.11C). Only CBG and CBGA were detected in 3SN, while CBN and CBC were detected 
in 5SN* and 1SN, and THCV in 1SN. Hierarchical clustering analysis using data from 
eight cannabinoids produced two large clusters, with assignment of the genetic outlier 
and one consensus sample to one cluster, while the other consensus sample was assigned 
to the other cluster (Figure 5.14). Clustering analysis containing only “Mob Boss” 
samples clustered 1SN and 3SN together, while the outlier was assigned to the other 
cluster (Figure 5.15C). Hierarchical clustering analysis of the minor cannabinoids 
assigned all genetic consensus “Mob Boss” samples to one cluster and the genetic outlier 
to the other, indicating the genetic outlier differed in the less prominent cannabinoids 
(Figure 5.16). Clustering analysis of “Mob Boss” samples supported the difference in less 
prominent cannabinoids in the genetic outlier (Figure 5.17C). 
The genetic consensus “OG Kush” samples varied, and the genetic outlier 
appeared to be most similar to 4SN in cannabinoid levels (Figure 5.8). When the total 
cannabinoid fraction (% by dry weight) with relative abundance of the chemotype by 
proportion was graphed, levels of THCA, THC and CBGA seem to be the highest 
contributors to the variation, although levels of THCA are similar in 1SN*, 3SN and 4SN 
(Figure 5.9). THC in 3SN differs from the other samples, and 1SN* is the only sample 
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with no CBDA detected. All samples contained CBG and CBGA, although 4SN 
contained far less CBGA. CBC and CBN were detected at low levels in 2SN and 4SN.  
Among “OG Kush”, the outlier shares a similar THC profile with 4SN (Figure 5.10D). 
Examination of the minor cannabinoids reveals the “OG Kush” samples are vastly 
different in CBGA content, and CBG is higher in 2SN (Figure 5.11D). Only CBG, 
CBGA, and CBN were detected in 1SN*, while CBD was detected in the three consensus 
samples. 2SN and 4SN both contained CBN and CBC. Hierarchical clustering analysis 
using data from eight cannabinoids produced two large clusters, with assignment of the 
genetic outlier to one cluster, while the consensus sample were assigned to the other 
cluster (Figure 5.14). Clustering analysis containing only “OG Kush” samples placed the 
genetic outlier with two consensus samples and assigned 2SN to the other cluster (Figure 
5.15D). Hierarchical clustering analysis of the minor cannabinoids assigned 4SN, and 
3SN and 2SN were assigned to the other cluster (Figure 5.16). Clustering analysis of “OG 
Kush” assigned 1SN*, 4SN and 3SN to one cluster and 2SN to the other (Figure 5.17D). 
Principal Components Analysis generated plots for eight cannabinoids which 
represented 99.9% of the variation in the data and is explained almost entirely by THCA 
concentrations. The PCA scaled by THCA (Axis 1; 99.002 % of variation; r = 1.00, tau = 
0.981) (Figure 5.18) confirms that THCA is the overwhelming source of variation. A 
PCA was conducted on the minor cannabinoids (CBDA, CBG, CBGA, CBC, CBN, 
THCV) to determine if any minor cannabinoids are driving variation (Figure 5.19). The 
PCA scaled by CBGA (Axis 1, 99.2% of variation; r = -1.00, tau = -1.00) confirms that 
CBGA is the overwhelming source of variation.  
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Figure 5.18. Principal Components Analysis of scaled by THCA on Axis 1 (99.002% of variation) and remaining variation on 
Axes 2 and 3 (0.900% and 0.079% of variation).  
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Figure 5.19. Principal Components Analysis of scaled by CBGA on Axis 1 (99.925% of variation) and the remaining variation 
on Axis 2 (0.075% of variation). 
PCA of CBGA 
1
7
0
 
  
171 
 
 Given that THCA and CBGA were found to be driving variation, a linear 
regression analysis of THCA and CBGA was conducted to determine if there is a 
relationship between these two cannabinoids (Figure 5.20). There is a weak positive 
correlation (R2 = 0.1749) between THCA and CBGA, and samples within strains do not 
cluster, although all ‘Blue Dream’ samples were low in CBGA.   
 
 
Figure 5.20. Linear regression analysis of THCA level (% dry weight) against 
CBGA (% dry weight). Samples are color coded and labeled with the abbreviated 
identification (Table 5.4). 
 
Terpenes 
A panel of 21 terpenes were analyzed in seven strains of commercially-available 
Cannabis (Table 5.9). Nineteen cannabis samples drawn from seven strains were 
analyzed: “Durban Poison” (3), “Blue Dream” (5), “Mob Boss” (3), “OG Kush” (4), 
“White Widow” (1), “White Urkle” (2), and “Tangerine Haze” (1). The analyses included 
samples of the same strain acquired from different dispensaries, clones from the same 
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dispensary (“White Urkle”), and a single-representatives of two strains (“White Widow” 
and “Tangerine Haze.
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Table 5.9. Average terpene percent distribution by mass (mg) calculated as normalized area percentages of each of the terpenes present in the 
samples. The general molecular class is denoted as monoterpene (m) or sesquiterpene (s). 
    
-pinene  
(m) 
camphene  
(m) 
myrcene  
(m) 
-pinene 
 (m) 
3-carene  
(m) 
-terpinene  
(m) 
limonene  
(m) 
Blue Dream 1SN 11.29 (0.25) 3.66 (0.17) 9.03 (0.20) 6.66 (0.33) 3.24 (NA) 3.46 (NA) 1.80 (2.54) 
 4SN 11.87 (0.26) 4.64 (0.13) 6.93 (0.15) 6.13 (0.23) 4.60 (NA) 4.53 (0.13) 5.57 (NA) 
 5SN 11.14 (0.14) 3.34 (0.39) 7.82 (0.09) 5.68 (0.26) 3.14 (0.25) 2.96 (NA) 3.19 (NA) 
  6SN 12.65 (0.50) 3.58 (0.08) 8.65 (0.58) 6.36 (0.22) 3.51 (0.01) 3.47 (0.06) 3.29 (NA) 
  Consensus 11.71 (0.69) 3.81 (0.58) 8.11 (0.93) 6.21 (0.41) 3.67 (0.64) 3.61 (0.66) 3.46 (1.56) 
 3SN* 7.67 (0.22) 3.02 (0.11) 6.26 (0.20) 4.54 (0.04) 2.98 (0.11) 2.81 (0.11) 4.54 (1.09) 
Mob Boss 1SN 7.10 (0.34) 3.06 (0.46) 3.64 (0.44) 3.50 (0.43) 2.87 (0.32) 2.89 (0.31) 2.01 (2.84) 
 3SN 12.86 (0.61) 2.81 (0.37) 3.72 (0.39) 3.33 (0.47) 2.84 (NA) 2.14 (NA) 2.90 (NA) 
  Consensus 9.98 (4.08) 2.93 (0.17) 3.68 (0.06) 3.42 (0.12) 2.85 (0.02) 4.09 (0.53) 2.46 (0.63) 
 5SN* 7.95 (0.18) 4.50 (0.45) 7.15 (0.27) 5.26 (0.77) 0.00 4.09 (0.33) 7.42 (0.30) 
OG Kush 2SN 2.13 (0.03) 1.26 (0.02) 3.21 (0.07) 2.04 (0.02) 0.93 (0.05) 0.49 (0.69) 12.79 (0.15) 
 3SN 2.19 (0.28) 1.53 (0.24) 7.57 (0.34) 4.30 (0.01) 0.53 (0.75) 0.57 (0.80) 3.34 (1.34) 
 4SN 3.40 (0.15) 2.63 (NA) 9.89 (0.52) 6.35 (0.07) 2.63 (0.19) 2.56 (0.19) 0.00 
  Consensus 2.57 (0.72) 1.81 (0.72) 6.98 (3.39) 4.23 (2.15) 1.36 (1.11) 1.21 (1.18) 5.44 (6.74) 
 1SN* 3.05 (0.19) 2.70 (0.31) 8.32 (0.50) 5.63 (0.02) 2.89 (NA) 2.42 (NA) 2.74 (0.53) 
Durban Poison 1SN 4.64 (0.31) 3.26 (0.09) 3.94 (0.22) 3.67 (0.10) 2.96 (0.21) 2.84 (NA) 3.67 (NA) 
 4SN 5.28 (0.18) 3.47 (0.11) 3.43 (0.00) 4.68 (0.15) 4.01 (0.12) 3.81 (0.15) 0.00 
  5SN 4.61 (0.26) 2.62 (0.12) 4.78 (0.21) 3.71 (0.25) 3.52 (0.06) 3.34 (0.09) 3.46 (158) 
  Consensus 4.85 (0.38) 3.12 (0.44) 4.05 (0.68) 4.02 (0.57) 3.50 (0.52) 3.33 (0.49) 2.38 (2.06) 
White Widow WW1 5.02 (0.33) 4.33 (0.39) 9.32 (0.81) 7.68 (0.98) 0.00 4.18 (NA) 0.00 
White Urkle WE 11.42 (1.89) 1.89 (0.44) 5.78 (2.22) 3.20 (0.45) 1.68 (0.32) 1.75 (0.40) 1.15 (1.62) 
Tang. Haze TANG1 3.51 2.14 2.6 2.41 2.11 2.09 0.00 
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Table 5.9 continued       
    
p-cymene  
(m) 
ocimene  
(m) 
g-terpinene  
(m) 
terpinolene  
(m) 
linalool  
(m) 
isopulegol  
(m) 
geraniol  
(m) 
Blue Dream 1SN 0.00 3.46 (0.28) 2.94 (NA) 3.26 (0.19) 6.50 (0.10) 2.51 (0.03) 2.57 (0.16) 
 4SN 0.00 4.93 (0.02) 3.92 (NA) 0.00 4.86 (0.19) 3.23 (NA) 3.60 (0.21) 
 5SN 0.00 3.05 (0.28) 3.04 (NA) 4.18 (1.33) 3.45 (2.04) 2.20 (NA) 2.75 (NA) 
  6SN 0.00 3.47 (0.03) 3.02 (NA) 3.30 (0.06) 6.94 (0.12) 2.46 (0.15) 2.54 (NA) 
  Consensus 0.00 3.59 (0.57) 3.23 (0.46) 2.68 (1.84) 5.44 (1.60) 2.60 (0.44) 2.87 (0.50) 
 3SN* 0.00 3.47 (0.02) 2.58 (0.17) 4.91 (0.06) 5.02 (0.10) 1.97 (0.01) 2.25 (0.00) 
Mob Boss 1SN 0.00 3.09 (0.40) 1.15 (1.62) 2.74 (0.21) 4.11 (0.26) 2.74 (0.20) 2.52 (0.25) 
 3SN 0.00 3.02 (0.34) 2.18 (0.47) 2.64 (0.36) 3.71 (0.30) 1.88 (0.05) 1.90 (0.35) 
  Consensus 0.00 3.06 (0.05) 1.67 (0.73) 2.69 (0.07) 3.91 (0.28) 2.17 (0.42) 2.21 (0.44) 
 5SN* 0.00 3.82 (0.30) 3.54 (0.20) 3.72 (0.06) 5.45 (0.29) 2.92 (0.17) 3.45 (0.67) 
OG Kush 2SN 0.00 0.94 (0.10) 0.80 (0.04) 1.16 (0.09) 9.73 (0.34) 1.13 (0.02) 0.91 (0.01) 
 3SN 0.00 1.20 (0.09) 0.57 (0.81) 1.38 (0.14) 10.18 (0.45) 1.15 (0.07) 1.13 (0.17) 
 4SN 0.00 2.81 (0.11) 2.33 (NA) 2.69 (0.20) 6.57 (0.15) 1.84 (0.19) 2.13 (0.03) 
  Consensus 0.00 1.65 (1.01) 1.23 (0.96) 1.75 (0.83) 8.83 (1.97) 1.37 (0.41) 1.39 (0.65) 
 1SN* 0.00 3.05 (0.11) 2.48 (NA) 2.78 (0.19) 6.19 (0.04) 1.79 (0.22) 2.09 (0.06) 
Durban Poison 1SN 0.00 3.11 (0.34) 2.59 (NA) 2.81 (0.11) 6.08 (0.09) 2.33 (0.34) 2.42 (0.13) 
 4SN 4.39 (0.18) 6.95 (0.19) 3.66 (0.21) 12.37 (0.19) 3.95 (0.06) 2.38 (0.06) 2.94 (0.37) 
  5SN 1.53 (2.17) 8.08 (0.16) 3.04 (0.03) 16.89 (0.97) 2.65 (0.15) 1.92 (0.01) 2.49 (0.02) 
  Consensus 1.97 (2.23) 6.05 (2.60) 3.09 (0.54) 10.69 (7.19) 4.23 (1.73) 2.21 (0.25) 2.62 (0.28) 
White Widow WW1 6.12 (0.83) 3.59 (0.33) 3.47 (0.41) 1.60 (2.26) 4.48 (0.52) 2.77 (0.24) 2.94 (0.38) 
White Urkle WE 1.24 (1.75) 3.23 (1.02) 1.44 (0.24) 0.69 (0.97) 1.51 (0.34) 1.19 (0.22) 1.30 (0.34) 
Tang. Haze TANG1 3.26 2.28 1.81 1.89 4.83 1.81 1.55 
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Table 5.9 continued         
    
-caryophyllene 
(s) 
-caryophyllene  
(s) 
nerolidol-1  
(s) 
-gurjunene  
(s) 
nerolidol-2 
(s) 
guaiol  
(s) 
-bisabolol  
(s) 
Blue Dream 1SN 16.03 (0.99) 7.08 (0.33) 4.21 (0.30) 4.82 (0.46) 4.87 (0.36) 2.50 (0.09) 4.85 (0.17) 
 4SN 16.67 (2.07) 7.62 (0.33) 4.10 (NA) 5.18 (0.06) 4.60 (0.32) 3.10 (0.01) 4.45 (0.23) 
 5SN 19.07 (NA) 6.67 (2.32) 5.84 (NA) 6.39 (1.62) 4.20 (2.78) 4.57 (2.98) 5.01 (NA) 
  6SN 14.98 (0.75) 6.80 (0.38) 2.50 (1.63) 4.74 (0.02) 5.02 (0.19) 2.68 (0.14) 4.48 (0.68) 
  Consensus 16.69 (1.73) 7.04 (0.42) 4.16 (1.36) 5.28 (0.76) 4.67 (0.36) 3.21 (0.94) 4.70 (0.28) 
 3SN* 14.00 (0.18) 5.91 (0.00) 3.46 (0.03) 3.90 (0.07) 5.75 (0.07) 8.73 (0.11) 7.47 (0.01) 
Mob Boss 1SN 15.01 (0.04) 7.12 (0.08 6.12 (0.03) 6.28 (0.33) 13.35 (0.18) 2.30 (0.23) 8.86 (0.37) 
 3SN 18.90 (0.05) 8.46 (0.29) 3.94 (3.39) 6.15 (0.32) 12.71 (0.08) 1.83 (0.40) 6.02 (0.25) 
  Consensus 16.95 (2.75 7.79 (0.95) 5.03 (1.54) 6.21 (0.10) 13.03 (0.45) 2.07 (0.33) 7.35 (1.89) 
 5SN* 10.01 (0.97) 6.18 (0.08) 1.31 (0.09) 6.00 (0.09) 9.87 (0.68) 3.04 (0.37) 4.33 (0.05) 
OG Kush 2SN 15.81 (0.03) 7.83 (0.04) 2.43 (0.12) 10.54 (0.10) 24.10 (0.10) 0.67 (0.07) 0.92 (0.37) 
 3SN 27.77 (0.09) 10.04 (0.14) 2.86 (2.55) 5.40 (0.09) 10.80 (0.22) 7.49 (0.12) 0.00 
 4SN 22.63 (0.27) 7.57 (0.09) 0.95 (0.08) 5.04 (0.15) 7.94 (0.16) 6.88 (0.09) 5.54 (0.16) 
  Consensus 22.07 (6.00) 8.51 (1.32) 2.08 (1.00) 6.99 (3.08) 14.28 (8.62) 5.01 (3.77) 2.15 (2.97) 
 1SN* 23.13 (1.42) 8.05 (0.39) 1.00 (0.01) 4.95 (0.09) 7.88 (0.65) 7.22 (0.56) 5.54 (0.18) 
Durban Poison 1SN 13.13 (0.32) 5.63 (0.05) 4.60 (NA) 5.18 (0.03) 10.77 (0.54) 10.44 (0.21) 12.19 (0.38) 
 4SN 11.53 (0.54) 4.39 (1.43) 5.11 (2.63) 4.73 (0.07) 7.49 (0.62) 5.42 (0.09) 0.00 
  5SN 9.21 (1.18) 4.26 (0.41) 8.36 (1.56) 3.63 (0.34) 5.84 (1.02) 4.97 (0.47) 1.08 (1.53) 
 Consensus 11.29 (1.97) 4.76 (0.75) 6.02 (2.04) 4.51 (0.80) 8.04 (2.51) 6.94 (3.03) 4.43 (6.75) 
White Widow WW1 16.84 (NA) 6.64 (2.68) 10.01 (1.66) 4.80 (0.57) 7.03 (1.09) 6.61 (1.12) 0.00 
White Urkle WE 34.12 (0.98) 699 (6.10) 6.29 (0.96) 4.20 (4.20) 4.72 (5.04) 1.26 (0.37) 4.95 (4.07) 
Tang. Haze TANG1 28.31 2.49 5.14 4.35 9.21 6.78 11.43 
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 Histograms of 21 terpenes were generated to compare terpene composition among 
samples within strains (Figure 5.21). The level of terpenes varied within strains as well as 
across the four strains. “Durban Poison” samples were genetically identical, and yet the 
terpene levels varied among the samples (Figure 5.21A). Although many terpenes were 
similar among the samples, limonene, p-cymene, ocimene, terpinolene, nerolidol-1, 
nerolidol-2, guialol and -bisabolol had at least one sample that was markedly different. 
In the PCA of terpenes “Durban Poison” showed a wide distribution across Coordinate 1 
(Figure 5.23).  
Four “Blue Dream” samples were genetically identical (1SN, 4SN, 5SN and 6SN) 
and 3SN* was a genetic outlier. Although many of the terpenes had similar levels, -
pinene, terpinolene, nerolidol-1, guialol, and -bisabolol had at least one sample that was 
markedly different (Figure 5.21B). Seventeen of 21 terpene levels in the genetic outlier 
fell outside the standard deviation of the genetic consensus (Figure 5.22A). Of the five 
highest levels of terpenes pooled within each strain, eight of 12 terpenes in the genetic 
outlier fell outside the standard deviation of the genetic consensus average (Figure 
5.23A). In the PCA of terpenes “Blue Dream” samples cluster, indicating shared terpene 
characteristics (Figure 5.24).
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Figure 5.21. cont. next page  
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Figure 5.21. Terpene variation within each accession of four strains (% distribution) for (A) “Durban Poison”, (B) “Blue 
Dream”, (C) “Mob Boss”, and (D) “OG Kush”. The genetic outlier is indicated with an asterisk.
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Figure 5.22. Twenty-one terpenes (A) “Blue Dream”, (B) “Mob Boss”, and (C) “OG 
Kush”, with the average for the genetic consensus samples and the genetic outlier. 
Error bars represent the standard deviation.
A 
B 
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Two “Mob Boss” samples were genetically identical (1SN and 3SN) and 5SN* 
was a genetic outlier. Although terpenes such as ocimene, terpinolene, isopulegol, and -
gurjunene had similar levels, almost all terpenes had at least one sample that was 
markedly different, and in many cases the sample with the different level was the genetic 
outlier 5SN* (Figure 5.21C). Nineteen of 21 terpene levels in the genetic outlier fell 
outside the standard deviation of the genetic consensus (Figure 5.22B). Of the five 
highest levels of terpenes pooled within each strain, 10 of 12 terpene levels in the genetic 
outlier fell outside the standard deviation of the genetic consensus (Figure 5.23B). In the 
PCA of terpenes “Mob Boss” samples cluster, indicating shared terpene characteristics 
(Figure 5.24). 
Three “OG Kush” samples were genetically similar (2SN, 3SN and 4SN) and 
1SN* was a genetic outlier. Although terpenes such as isopulegol, and geraniol had 
similar levels, almost all terpenes had at least one sample that was markedly different, 
although there does not seem to be a sample that is consistently different across terpenes 
(Figure 5.21D). However, samples 1SN* and 4SN have highly similar levels in almost 
every terpene. This was supported in the average terpene level of the genetic consensus 
samples compared to the genetic outlier, where only thirteen of 21 terpenes fell outside 
the standard deviation of the genetic consensus (Figure 5.22C). Of the five highest levels 
of terpenes pooled within each strain, and only one of 10 terpene levels in the genetic 
outlier fell outside the standard deviation of the genetic consensus average (Figure 
5.23C). The PCA of “OG Kush” samples do not form a tight cluster, indicating minimal 
shared terpene characteristics (Figure 5.24). 
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Figure 5.23. Top five terpenes with the highest levels pooled for (A) “Blue Dream”, 
(B) “Mob Boss”, and (C) “OG Kush”, with the average for the genetic consensus 
samples and the genetic outlier. Error bars represent the standard deviation. 
 
Histograms of the average terpene levels for seven strains was generated to 
examine terpene variation of different strains to explore the possibility that strains may 
have unique terpene composition (Figure 5.24). From this analysis, it is clear that strains 
have varying terpene profiles. For example, “White Widow” had no detectable levels of 
A 
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-bisabolol and “Durban Poison” has a much higher level of terpinolene than the other 
strains.  
 
 
Figure 5.24. PCA clustering analysis. Genetic outlier labels are underlined.  
 
In order to determine if specific terpenes contribute to variation among strains, 
standard deviations across all samples were calculated and terpenes with the highest 
deviation were graphed by strain (Figure 5.25). “OG Kush” has relatively high levels of 
-caryophyllene and neridiol-2 compared to -pinene, -bisabolol and terpinolene. 
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Figure 5.25. Average terpene levels in seven strains (% distribution by terpene). “Blue Dream”, “Mob Boss” and “OG Kush” 
averages only include the genetic consensus samples. The molecular structure for each terpene is displayed above the graph. 
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Figure 5.26 Terpene profiles for seven strains. These five terpenes had the five highest average % distributions across samples and 
are arranged by highest average terpene level. “Blue Dream”, “Mob Boss” and “OG Kush” averages only include the genetic 
consensus samples. 
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Discussion 
Cannabis diversity is reflected in a wide range of phenotypes. Over the last 
several decades of prohibition, underground breeders have created new strains with 
variable and unique characters that are desirable to consumers. Now that Cannabis is a 
growing legal market in the majority of the United States, variation is problematic as 
medical and recreational consumers and industry look for consistency in products. 
Consumers accept slight variation in plants of the same variety, but there is also an 
expected level of consistency when looking for a particular product. A ‘Granny Smith’ 
apple is not an acceptable substitute for a ‘Honey Crisp’ apple, while there may be some 
variability within either type sourced from different producers or regions. Variation in 
any plant variety (including Cannabis) can come from several sources, such as growth 
conditions (soil, light, temperature, water, air flow, etc.), harvest time (early, mid or late), 
storage conditions, and shelf life (time until deterioration), but no matter the 
environmental variation affecting the quality of the harvest, the genetic integrity is 
maintained. Moreover, cannabinoid concentrations can differ significantly not only at 
different times during flower maturation, but also in flowers from different locations 
(high or low) on the same plant (Aizpurua-Olaizola et al. 2016; Richins et al. 2018). 
Previous work has uncovered genetic variation within Cannabis strains (Chapter II), 
which we consider in some cases to be an initial source of variation; if there is genetic 
variation within a strain, the potential to grow a consistent product among facilities is 
more difficult.  
Public interest in Cannabis is increasing, and breeders continue to produce strains 
with unique chemical compositions. Interest in medical applications of Cannabis is 
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expanding, and clinicians are seeking information on the benefits of particular 
phytochemical constituents, or combinations thereof, that contribute to alleviating certain 
symptoms of a variety of medical conditions. Evidence suggests Cannabis 
phytochemicals work synergistically (Ben-Shabat et al. 1998), and the unique 
combination of cannabinoids and terpenes in different strains is a centerpiece of interest 
in the industry. Recently, the potential of using a chemical fingerprint to identify specific 
strains and provide consistent products to consumers has been suggested (Hazekamp and 
Fischedick 2012; Hillig and Mahlberg 2004; Jikomes and Zoorob 2018).  
The purpose of this study was to determine if genetic differences are mirrored as 
differences in chemical profiles within the same strain. Four strains, three of which 
included samples that were genotyped as identical (“Durban Poison”, “Blue Dream” and 
“Mob Boss”), and one which had samples differing at only one locus (“OG Kush”), were 
analyzed. Three of the strains included a previously determined genetic outlier (“Blue 
Dream”, “Mob Boss” and “OG Kush” (Chapter IV). Cannabinoid and terpene levels of 
genetic consensus samples were compared to levels in the genetic outlier to determine if 
phytochemicals vary (1) among samples that are genetically identical (2) within strains, 
and (3) among different strains. Cannabis research has shown some strains have limited 
variability and may be distinguishable by chemotype (Hazekamp and Fischedick 2012; 
Jikomes and Zoorob 2018). However, data are limited describing chemical composition 
and quality within strains resulting from variation in the genotype and/or varying 
environmental conditions (Richins et al. 2018).  
Cannabinoids produced in the trichomes of the female flower are phytochemicals 
that elicit physiological effects and are known to vary in potency due to environmental 
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and genetic differences. Our cannabinoid analyses demonstrate that not only is there 
variation in levels of phytochemicals, but also in the relative ratios of cannabinoids 
(THC, CBD, and CBG) among plants with identical genotypes (Figure 5.9). THCA/THC 
varied among samples within the four strains (Figure 5.14), and the levels in the genetic 
outlier fell within one standard deviation for “Blue Dream” and “Mob Boss”, but not for 
“OG Kush”. Given that THCA is one of the main phenotypic traits breeders are selecting, 
it is possible that the minor cannabinoids paint a more accurate picture of how genetic 
differences are reflected in chemotype. The minor cannabinoids varied among samples 
within the four strains (Figure 5.13). Genetic outliers varied in cannabinoid levels in 
“Blue Dream” (CBC) “Mob Boss” (THCV and CBN), and “OG Kush” (CBDA). 
Clustering analysis scaled to THCA and CBGA indicated these two cannabinoids are 
driving variation in all samples (Figures 5.18 and 5.19). 
Terpenes produced in the trichomes of the female flower are phytochemicals that 
contribute to aromas and flavors in Cannabis and are known to vary in potency due to 
environmental and genetic differences. Our terpene analyses demonstrate there is 
variation among plants with identical genotypes (5.21). Terpenes varied among samples 
within the four strains (Figure 5.21), and the levels in the genetic outlier fell within one 
standard deviation for four of 21 terpenes for “Blue Dream”, two of 21 terpenes for “Mob 
Boss”, and eight of 21 terpenes for “OG Kush” (Figure 5.18). Therefore the terpenes 
measured in the genetic outlier of “Blue Dream” differed by 80%, “Mob Boss” differed 
by 90%, “OG Kush” differed by 61%. Although variation in terpenes is expected due to 
differences in cultivation and storage practices, these results suggest that the genetic 
outlier is not only genetically different, but also chemotypically different. This analysis 
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gives more evidence to mislabeling and also indicate the need for further examination of 
genetic differences in strains and how they may be driving variability in chemotypes. 
The variation assessment of cannabinoids among strains show THCA, THC, and 
CBGA are the largest constituents in the profile with variable levels within strains 
(Figure 5.10 and 5.11). In the light of recent work highlighting genetic variation within 
strains (Schwabe and McGlaughlin 2018), it is possible that genetic variability would 
result in deviations from chemotype expectations. Fischedick et al. (2010) collected 
samples of “White Widow” and “Amnesia” from 10 coffee shops in the Netherlands and 
found chemical deviants in both strains, which coincidently aligned with the chemotype 
of the alternate strain, possibly indicating a mix-up at the coffee shop or the supplier. 
However, without examining the genetic identity of the samples, it is unclear if the 
chemical deviation from the other samples in the set were due to genetic differences, or 
differences in flower maturity, or post-harvest processing and storage. As there are no 
standard growing or harvesting protocols, variation in abundance of phytochemicals is 
expected among facilities.  Previous work has shown chemical composition and 
THCTOTAL can be highly variable within strains and has suggested that strain names are 
an unreliable indicator of potency, and therefore strain names should be eliminated and 
Cannabis types should be based on chemotype (Hazekamp and Fischedick 2012; Elzinga 
et. al 2015). However, strain names are not potency specific, but rather a name given to a 
cultivar with a unique profile of hundreds of compounds. Although, accurate reporting of 
a wider scope of phytochemicals in products would be beneficial, the unique cultivars 
and varieties should have names as they allow consumers and growers to communicate 
and identify characteristics associated with a certain cultivar. Consistency in cultivars is 
  
189 
 
achievable through genotyping, stabilizing genetic lines, and standardizing protocols in 
the Cannabis industry. Without standard conditions, and a confirmed genotype, variation 
is not only expected but will continue to proliferate. 
Chemotypes of “Blue Dream” and “OG Kush” were previously analyzed in a 
large study which included 35 strains with > seven samples in each (N = 494) (Elzinga et 
al. 2015). It was found that most replicates within strains did not cluster and showed 
highly variable chemotypes, but some strains, including “Blue Dream”, formed clear 
clusters indicating a distinct chemical profile. In the current study, we also found that 
“Blue Dream” forms a distinct cluster, even with the genetic outlier (Figures 5.19 and 
5.24). Fischedick et al. (2010) found that Cannabis clones of several strains could be 
distinguished from one another based on their cannabinoid and terpene content. Cannabis 
varieties are generally divided into three chemotype groups based on THC:CBD ratios 
(Hazekamp and Fischedick 2012; Hillig and Mahlberg 2004; Jikomes and Zoorob 2018). 
Most drug-type, and all the strains included in this study, are included in the chemotype I 
group, which is categorized as high THC and low CBD (Jikomes and Zoorob 2018). 
Given that there has been a relationship found between THC/CBD in different 
chemotypes, we thought perhaps there might also be a relationship between CBGA and 
THCA. Linear regression on the samples here indicate there is a weak relationship (R2 = 
0.174) between CBGA and THCA (Figure 5.20), but because there is so much variation, 
more sampling is needed to examine this further.  Elzinga et al. (2015) proposed that 
strains with distinct chemical profiles might be more easily identified by their smell due 
to relatively high concentrations of specific terpenes. However, our analysis indicates 
“Blue Dream” does not have relatively high levels of any specific measured terpenes. The 
  
190 
 
highest terpene found in “Blue Dream” samples was -caryophyllene, but levels were 
much higher in “OG Kush”, “White Urkle” and “Tangerine Haze” (Figure 5.25 & 5.26). 
The most abundant terpene in the seven strains we examined was -caryophyllene, 
(Figure 5.25) although other terpene studies have found myrcene to be the most abundant 
terpene in Cannabis (Casano et al. 2011). It is not clear why there would be such a clear 
descrepancy between these two studies. Strain names were not  provided in the Casano et 
al. (2011) study, but they categorized their samples as ‘mostly indica’ or ‘mostly sativa’, 
and the ‘mostly sativa’ had much lower levels of myrcene than the ‘mostly indica’ 
samples. All of the strains in our data set are Hybrid types with the exception of “Durban 
Poison”, which is a Sativa type strain.  
Since this was an investigation of sources of variation within Cannabis, we 
thought it would be interesting to compare THC levels reported on the dispensary 
packaging to the total THC equivalent levels measured at Mile High Labs. Jikomes and 
Zoorob (2018) analyzed Washington state’s seed-to-sale tracabililty data set and found 
principle cannabinoid variation among state-certified testing laboratories. The 15 samples 
we used for this study had striking discrepancies in the reported levels of major 
cannabinoids (THCA and THC) between dispensary packaging labels and levels 
measured by Mile High Labs (Table 5.10). Every sample tested had lower THCTOTAL 
content than was reported on packaging labels, with reported levels of THCTOTAL by 
dispensaries being 23.5% – 61.48%. higher than what was measure at Mile High Labs. 
This discrepancy could be the result of several variables such as lab testing protocols, 
storage conditions, or age, but there is not enough information provided by distributors to 
determine the source of the discrepancy. However, this should be considered a major 
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issue in the industry, since the high potency strains that have been receiving attention in 
that last few years may not actually have the THC levels reported by the testing lab and 
claimed on the packaging. For example, “Mob Boss” 5SN had one of the highest reported 
THC levels (25.2 – 28.9 %), but tested at 10.42% at Mile High Labs, an average 
difference of 61.48%. The highest total THC equivalent measured at Mile High Labs was 
“OG Kush” 2SN, and although the packaging report was over-represented, this sample 
had the least discrepancy of only 23.5% more total THC equivalent than was determined 
by Mile High Labs. 
Table 5.10. THCTOTAL determined by mile high labs compared to THC reported 
on retail packaging. Fifteen samples from four strains with the THCTOTAL (total % dry 
weight) measured by Mile High Labs (MHL). The THC levels reported by the 
dispensary, the discrepancy difference in average reported THC and the THC (total) 
measured by MHL, and the % of THC that was over-reported by the dispensary label 
vs. what MHL measured.  
Strain Sample ID 
MHL 
THC 
(TOTAL) 
Reported 
Range  
Reported 
Average 
THC 
Discrepancy 
% THC 
overreporte
d 
Durban Poison DuPo 1SN 11.58 NA 17.40 5.82 33.45 
 DuPo 4SN 10.81 NA 20.14 9.33 46.33 
  DuPo 5SN 15.63 NA 21.50 5.87 27.30 
Blue Dream BlDr 1SN 12.80 NA 17.33 4.53 26.14 
 BlDr 3SN 13.37 NA 17.87 4.50 25.18 
 BlDr 4SN 7.970 14.41-25.18 19.80 11.82 59.74 
 BlDr 5SN 11.35 NA 16.64 5.29 31.79 
  BlDr 6SN 15.26 NA NA NA NA 
Mob Boss MoBo1SN 10.66 19.00-31.00 25.00* 14.34 57.36 
 MoBo 3SN 13.47 22.12-24.87 23.50* 10.02 42.67 
  MoBo 5SN 10.42 25.20-28.90 27.05* 16.63 61.48 
OG Kush OGKu 1SN 11.23 15.20-26.14 20.67* 9.44 45.67 
 OGKu 2SN 22.70 28.07-31.28 29.68* 6.98 23.50 
 OGKu 3SN 18.06 NA 24.10 6.04 25.06 
  OGKu 4SN 13.60 NA 25.93 12.33   47.55 
Asterisk indicates samples identified as the same grow facility and batch 
*Average calculated based on the THC% range reported on the packaging  
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 Although these results show variation among genetically identical samples, 
challenges and limitations need to be addressed. The samples were purchased three 
months prior to chemotype testing and had been moved in and out of -2 C storage during 
the sensory study (Chapter IV). During this process, care was taken to limit the 
degradation of phytochemicals by storing at low temperatures (-2 C) in amber glass jars 
with screw-top lids. Moreover, CBN, the degradation product of THCA, was not present 
in levels indicative of incorrect storage. It is possible, however, that phytochemical levels 
were affected. There may also be differences in lab testing protocols. Although there are 
standard protocols for testing in Colorado, labs are not restricted to either HPLC or GC, 
and it is possible these two tests may produce different results. Dispensaries and 
consumers often choose products with higher THC content, and for this reason, some labs 
may have protocols maximizing THC measures. Mile High Labs is traditionally a facility 
that caters to the Hemp industry and therefore not looking to maximize the measurement 
of THCA. Mile High Labs has a duty to accurately measure THCA and CBDA content 
following the same protocols as the DEA and USDA, as Hemp is defined by THCTOTAL < 
0.3%, and crops that measure over that threshold are destroyed. However, because Mile 
High Labs is a Hemp testing facility, the protocol may not be calibrated to measure high 
amounts of THC, which we recognize as a limitation and therefore further investigation 
of the discrepancy is needed.  
This study demonstrated significant variation in cannabinoids and terpenes even 
when samples are genetically identical, which could be annoying for recreational 
consumers expecting certain effects but is more problematic for those consuming to 
alleviate medical symptoms. This study included a relatively small sampling of Cannabis 
  
193 
 
strains, but nevertheless demonstrated genotype is not necessarily reflected as a 
predictable chemotype. In order to determine what is a reasonable amount of variation in 
chemotypes, more in-depth studies examining other environmental factors known to 
influence cannabinoid and terpene production such as growing conditions, harvest time, 
curing procedure and storage conditions, are needed.  
Conclusion 
The purpose of this study was to determine if genetic differences are mirrored as 
differences in chemical profiles of cannabinoids and terpenes within the same Cannabis 
strain. Based on these results, cannabinoids and terpene levels vary (1) among samples 
that are genetically identical, (2) within strains, and (3) among strains. The samples used 
in this study had variable chemotypes, but the variation did not seem to be linked to 
genetic identity. Given that chemotype is a phenotypic expression, and phenotype is the 
result of genotype and environment, the variation observed in cannabinoids and terpenes 
are most certainly the result of a combination of several variables. The Cannabis industry 
should aim to produce consistent products, especially for medicinal patients. There have 
been suggestions that focusing on chemotyping rather than using strain names for 
consistency would be a viable option. Minimizing phenotypic variation, including 
chemotype, would require standard growing conditions, harvesting protocols, curing 
techniques and storage conditions. However, the Cannabis industry currently has no such 
accepted standards for growing facilities and/or dispensaries, and therefore 
phytochemical variation within strains is inevitable, even if plants are genetically 
identical. Chemotyping for identity would be relatively easy if it were able to accurately 
identify and distinguish strains from one another. These results suggest that this is not the 
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case. Before chemotyping for identity can be utilized, it is crucial that industry standards 
are set and adhered to by every grower and producer. Until that happens, the only way to 
accurately identify Cannabis strains is through genotyping.  
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CHAPTER VI 
CONCLUSION 
Conclusion 
 Cannabis sativa is a highly versatile plant with variable phenotypes in fiber 
production, flower production, and phytochemical production (Clarke and Merlin 2013, 
2016; Small 2015a; Small 2016). Artificial selection for desirable phenotypic characters 
throughout the history of the human relationship with Cannabis has led to genetic 
divergence between hemp and drug-types (Dufresnes et al. 2017; Henry 2015; Houston et 
al. 2017; Lynch et al. 2016; Sawler et al. 2015; Soler et al. 2017). Cannabis has largely 
been prohibited in the U.S. since the 1930’s, but recent legalization in many states 
following growing public acceptance has led to a wave of new legislation allowing 
medical and adult recreational marijuana as well as hemp production. The Cannabis 
industry is growing at an unprecedented rate, but due to a tumultuous history, basic 
scientific knowledge and research on the plant is lacking. Not only that, but protections 
afforded to other plant varietals are not applicable to Cannabis and therefore stable 
genetic lines are relatively rare. Without taking the time and resources to stabilize the 
genetics through inbreeding, cloning is the preferred method for many growers to 
reproduce plants with desirable phenotypes. However, variation among plants that should 
be essentially identical has been identified as a problem (Chapter 2; Schwabe and 
McGlaughlin 2018) for the industry as they seek to provide customers with the quality 
and consistency they deserve. Variation within strains is of particular concern as 
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practitioners worldwide turn to Cannabis to treat a growing number of medical 
conditions.    
The genetic, olfactory, and phytochemical research presented in this dissertation 
provides considerable evidence of both genotypic and phenotypic variation in Cannabis 
sativa (Chapters II-V). This investigation found variation is not limited to one source, but 
rather several possible sources. Potential origins for the genetic variation observed are 
numerous, but within strain variation was greater than expected (Chapter II), which is of 
particular concern for medical marijuana patients. Additionally, genotypic variation was 
not necessarily reflected in phenotypic variation, and genotypic cohesiveness among 
samples did not result in a consistent phenotype (Chapters IV and V). Although these 
studies were conducted using relatively small sample sizes, the results clearly 
demonstrate the need for regulatory systems.  
Cannabis can be subdivided into two main categories: Hemp (<0.3% THC) and 
drug-types (>0.3% THC). The drug-type categories are further sub-divided into the 
commonly referenced Sativa, Indica, and Hybrid types, as well as the High CBD type 
which has lower THC levels but has >0.3% THC and is therefore assigned to the drug-
type category. The commonly referenced Sativa, Indica and Hybrid types used to 
describe differences in psychoactive effects were not clearly resolved using genetic 
analysis (Chapter II and III), and this is probably due to extensive hybridizing of strains 
to create novel combinations with characteristics of both Sativa and Indica types. The 
genetic investigation had representative samples ranging from 100% Sativa to 100% 
Indica (Chapter II and III). However, the phytochemical portion of the study only 
included hybrids (“Blue Dream” 50:50, “Mob Boss” 50:50, “OG Kush” 55:45, “White 
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Widow” 60:40, “Tangerine Haze” 60:40, and “White Urkle” 50:50) and “Durban 
Poison”, which is 100% Sativa. Therefore, investigating category assignment based on 
scent profile or phytochemical content was not possible in this study (Chapter IV and V). 
Hemp is genetically divergent from drug-types, although there are some drug-types that 
share a high degree of ancestry with Hemp types (Chapter III). The High CBD samples 
bridge the genetic division between Hemp and drug-types (Chapter III). One of the most 
important discoveries was that “research grade marijuana” supplied for medical studies in 
the U.S. is substantially different from drug-type samples purchased through the legal 
market (Chapter III). This has serious implications because medical studies researching 
medical applications using federally supplied marijuana are inherently flawed as medical 
patients do not have access to and are not consuming similar products.  
Cannabis phytochemicals are abundant and 120 terpenes to date have been 
identified (ElSohly et al. 2017) which contribute to the diverse aromas found in 
Cannabis. The discovery of genetic inconsistencies within strains led us to investigate if 
genetic differences were expressed through detectable aromatic differences (Chapter IV). 
We purposefully chose four strains based on availability and previously determined 
unique aromatic profiles (Gilbert and DiVerdi 2018). There was considerable variation in 
the aromatic profiles within samples of the same strain and with identical genotypes but 
purchased from different locations (Chapter IV). However, analyses revealed the 
aromatic profile of the genetic outliers not only differed substantially from those with the 
same genotype, but also the aromatic profile of the outliers were uncharacteristic of 
previously described profiles (Gilbert and DiVerdi 2018; Leafly 2018b). Detectable 
differences in aromatic profiles of a genetic imposter suggest that genetic inconsistencies 
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observed within strains may not be simply a case of mistaken identity, but perhaps an 
indication of mislabeling or relabeling.  
In addition to terpenes, Cannabis also has 120 known cannabinoids (ElSohly et al. 
2017) which are responsible for physiological and psychoactive effects (Andre et al. 
2016). Laws on potency testing for several cannabinoids vary from state to state, but 
THCA/THC and CBDA/CBD are a standard requirement (e.g.: Colorado Department of 
Revenue 2017). In order to further examine the relationship between genetic variation 
and chemotype, we analyzed eight cannabinoids and found variation in levels of 
phytochemicals, as well as the relative ratios of cannabinoids among plants with identical 
genotypes (Chapter V). Also, it appears that two cannabinoids, THCA and CBGA are the 
contributing to the majority of the variation (Chapter V). Variation in cannabinoids did 
not appear to align with genetic variation (or lack of variation). These results indicate that 
cannabinoid levels are likely substantially influenced by environmental conditions that 
vary among different growing facilities.  
Sensory perception of the various aromas found in Cannabis is attributed to levels 
and combinations of terpenes produced in the flower trichomes. Olfaction and 
perceptions of smell are personal and subjective, and the subjects who participated in this 
research were not sensory experts. However, additional scientific examination was 
possible by analyzing the terpene profiles of the samples in the olfactory study. A 
pairwise analysis between sensory perception and terpene levels found 33 significant 
correlations (Table 6.1). This analysis shows perceived scents produced by the terpenes 
can be categorized: a-caryophyllene and b-caryophyllene are contributing to “Earthy” 
smells including soil, buttery, nutty or roasted aromas; guaiol and isopulegol contribute to 
  
199 
 
the “Spicy” including spices and dried leafy scents; neridiol-1, ocimene, p-cymene and 
terpinolene contribute to “Floral” scents such as fresh plants/flowers; neridiol-2 is the 
main contributor to “Pungent” scents including diesel, ammonia and chemical smells.  
Table 6.1. Significant pairwise Pearson correlation coefficients (R2) between 
terpene levels (Chapter V) and scents detected in the olfactory study (Chapter 
IV). 
Smell Terpene R2 P 
Butter a-caryophyllene 0.648 0.0226 
Cheese a-caryophyllene 0.632 0.0274 
Coffee a-caryophyllene 0.623 0.0304 
Earthy a-caryophyllene 0.623 0.0304 
Menthol a-gurjunene 0.584 0.0461 
Butter b-caryophyllene 0.741 0.0059 
Coffee b-caryophyllene 0.638 0.0257 
Nutty b-caryophyllene 0.583 0.0468 
Sage guaiol 0.740 0.0059 
Pepper isopulegol 0.582 0.0472 
Menthol limonene 0.584 0.0460 
Coffee linalool 0.794 0.0021 
Butter myrcene 0.673 0.0165 
Flowery nerolidol-1 0.632 0.0304 
Mint nerolidol-1 0.678 0.0154 
Rose nerolidol-1 0.721 0.0082 
Sweet nerolidol-1 0.607 0.0363 
Violet nerolidol-1 0.735 0.0065 
Ammonia nerolidol-2 0.694 0.0123 
Chemical nerolidol-2 0.640 0.0250 
Diesel nerolidol-2 0.620 0.0316 
Pungent nerolidol-2 0.602 0.0385 
Flowery ocimene 0.617 0.0326 
Mint ocimene 0.925 < 0.0001 
Flowery p-cymene 0.732 0.0068 
Lemon p-cymene 0.629 0.0285 
Mint p-cymene 0.848 0.0005 
Tropical fruit p-cymene 0.600 0.0392 
Flowery terpinolene 0.753 0.0047 
Mint terpinolene 0.821 0.0011 
Rose terpinolene 0.721 0.0082 
Tropical fruit terpinolene 0.641 0.0247 
Violet terpinolene 0.605 0.0373 
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The abundance of phytochemicals present in Cannabis is impressive and are one 
of the main drivers of the artificial selection process for desirable aromas and 
physiological effects. There is an expected amount of variation among organisms of the 
same genetic lineage, as phenotypic variation is the product of genotype and 
environment. Therefore, individuals with identical genotypes are expected to have highly 
similar phenotypes. However, the extent to which environmental variation impacts 
phenotype is largely unknown. Analyses of both terpene and cannabinoid profiles among 
individuals with identical genotypes acquired from different sources indicate 
environmental variation has a substantial impact on phenotype in Cannabis. Considering 
these results, medical marijuana patients are unlikely to have access to consistent 
products, even if the genotype has been verified. Not only are potency levels variable, but 
variation in phytochemical constituents detected in the samples is evident.   
The Cannabis industry needs a system to verify products to ensure consumers are 
provided the product as indicated by the name provided. There have been suggestions 
that due to strain name unreliability, describing products based on chemotype may be a 
solution. However, I would caution against this approach as there are 560 chemical 
constituents in Cannabis and analytical labs only test a small portion of cannabinoids and 
terpenes, ignoring the vast majority of the micro-chemotype which likely contribute to 
differences in aromatic profiles and effects (Amirault and Boyar 2019). Additionally, the 
variation in samples with identical genotypes indicates varying environmental conditions 
are influencing chemical profiles. Cannabis consumers, practitioners, breeders, and 
growers need to be able to communicate about varietals, and the most familiar method to 
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do this is to give varietals a name. It would be counter intuitive and incredibly difficult to 
discuss Cannabis flowers based on a partial chemotype that changes over time. 
Future Directions 
The Cannabis industry exists to produce products for a variety of markets. The 
industrial hemp industry grows crops for fiber, oils, and seeds which can be transformed 
into thousands of products. Because many industrial hemp products are produced from 
processed plant material, consistency among plants is not imperative. The marijuana 
Cannabis industry grows plants for human consumption, some of which are processed, 
such as isolates, tinctures and edibles. However, there is a large proportion of products on 
dispensary shelves that are sold under specific names and are non-processed flowers. 
These products are intended to be smoked and will have some effect on the consumer. 
Recreational adult use is associated with the psychotropic responses to partaking in 
smoking marijuana. Medicinal use may include psychotropic responses, but more 
importantly, the medical consumer is seeking to alleviate symptoms related to particular 
medical conditions. Medicine needs to be reliable and consistent, and current Cannabis 
products sampled in this study are not reliable or consistent. Producers strive to produce a 
consistent phenotype through cloning, but it is apparent that environmental influences 
have a large effect. A standard genotyping procedure is needed to confirm identity in 
addition to the chemotype tests currently in place that determine potency. Also, a set of 
standard growing conditions needs to be established, as well as standard harvesting and 
curing procedures.  
Studies have shown that environmental stresses can lead to phenotypic changes in 
plants. I am unaware of any published work investigating how environmental stress 
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effects the epigenome and the phenotypic consequences of those changes in clonal plants. 
It is possible that the stress of the cloning process, on both the plant from which clones 
are cut as well as the resulting progeny, will result in phenotypic changes due to 
epigenetic changes. This is certainly a possible source for variation in Cannabis and 
warrants investigation. Additionally, a system to protect intellectual property of breeders 
who develop genetically stable lines (varietals) would limit variation from cloning and 
allow desirable lineages to persist into the future. 
The results of these studies suggest the industry should implement regulatory 
checks in the form of genetic testing in order to provide consistency, especially for 
medical applications. Current required testing includes pesticide and potency analysis and 
reporting, and genetic tests could be implemented to verify products. In order to provide 
consumers consistent products, it is imperative to understand sources of variation. 
Phenotypic variation is unavoidable when genotype has not been verified. Following 
genotypic confirmation, it is possible to create phenotypic consistency if standard 
growing conditions can be established. This would not stifle the ability for growers to 
develop alternative conditions to produce different desirable characters such as larger 
flowers or higher terpene content, but it would allow for the production of consistent 
products if standard conditions are met. Following verification and established standards 
in protocols, deviations resulting in phenotypic changes should be disclosed to consumers 
so they are aware that there may be deviations from expected effects. Consumers deserve 
to be provided with quality consistent products as the industry continues to thrive on a 
global scale. 
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